Publications, Projects & Awards

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr; OlympiA Clinical Trial Steering Committee and Investigators. N Engl J Med. 2021 Jun 24;384(25):2394-2405. IF: 91.253.

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Oyervides Juárez VM, Hsieh JJ, Basso U, Shah AY, Suárez C, Hamzaj A, Goh JC, Barrios C, Richardet M, Porta C, Kowalyszyn R, Feregrino JP, Żołnierek J, Pook D, Kessler ER, Tomita Y, Mizuno R, Bedke J, Zhang J, Maurer MA, Simsek B, Ejzykowicz F, Schwab GM, Apolo AB, Motzer RJ; CheckMate 9ER Investigators. N Engl J Med. 2021 Mar 4;384(9):829-841. IF: 91.253.

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, O’Shaughnessy J, Diéras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS; ASCENT Clinical Trial Investigators. N Engl J Med. 2021 Apr 22;384(16):1529-1541. IF: 91.253.

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Felip E, Altorki N, Zhou C, Csőszi T, Vynnychenko I, Goloborodko O, Luft A, Akopov A, Martinez-Marti A, Kenmotsu H, Chen YM, Chella A, Sugawara S, Voong D, Wu F, Yi J, Deng Y, McCleland M, Bennett E, Gitlitz B, Wakelee H; IMpower010 Investigators. Lancet. 2021 Oct 9;398(10308):1344-1357. IF: 79.323.

Enhancing anti-tumour efficacy with immunotherapy combinations. Meric-Bernstam F, Larkin J, Tabernero J, Bonini C. Lancet. 2021 Mar 13;397(10278):1010-1022. IF: 79.323.

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, Kojima T, Metges JP, Li Z, Kim SB, Cho BC, Mansoor W, Li SH, Sunpaweravong P, Maqueda MA, Goekkurt E, Hara H, Antunes L, Fountzilas C, Tsuji A, Oliden VC, Liu Q, Shah S, Bhagia P, Kato K; KEYNOTE-590 Investigators. Lancet. 2021 Aug 28;398(10302):759-771. IF: 79.323.

Precision oncology in metastatic colorectal cancer - from biology to medicine. Di Nicolantonio F, Vitiello PP, Marsoni S, Siena S, Tabernero J, Trusolino L, Bernards R, Bardelli A. Nat Rev Clin Oncol. 2021 Aug;18(8):506-525. IF: 66.675.

An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer. Powles T, Carroll D, Chowdhury S, Gravis G, Joly F, Carles J, Fléchon A, Maroto P, Petrylak D, Rolland F, Cook N, Balar AV, Sridhar SS, Galsky MD, Grivas P, Ravaud A, Jones R, Cosaert J, Hodgson D, Kozarewa I, Mather R, McEwen R, Mercier F, Landers D. Nat Med. 2021 May;27(5):793-801. IF: 53.440.

CDK4/6 inhibitors in breast cancer: spotting the difference. Perez-Garcia JM, Cortes J, Llombart-Cussac A. Nat Med. 2021 Nov;27(11):1868-1869. IF: 53.440.

Endometrial cancer. Makker V, MacKay H, Ray-Coquard I, Levine DA, Westin SN, Aoki D,Oaknin A. Nat Rev Dis Primers 7, 88 (2021). IF: 52.329.

The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Janjigian YY, Kawazoe A, Yañez P, Li N, Lonardi S, Kolesnik O, Barajas O, Bai Y, Shen L, Tang Y, Wyrwicz LS, Xu J, Shitara K, Qin S, Van Cutsem E, Tabernero J, Li L, Shah S, Bhagia P, Chung HC. Nature. 2021 Dec;600(7890):727-730. IF: 49.962.

Anthracyclines for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Are We Ready to Let Them Go? Tarantino P, Tolaney SM, Harbeck N, Cortes J, Curigliano G. J Clin Oncol. 2021 Nov 10;39(32):3541-3545. IF: 44.544.

Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. Pal SK, McGregor B, Suárez C, Tsao CK, Kelly W, Vaishampayan U, Pagliaro L, Maughan BL, Loriot Y, Castellano D, Srinivas S, McKay RR, Dreicer R, Hutson T, Dubey S, Werneke S, Panneerselvam A, Curran D, Scheffold C, Choueiri TK, Agarwal N. J Clin Oncol. 2021 Nov 20;39(33):3725-3736. IF:44.544.

Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Elez E, Gollerkeri A, Maharry K, Christy-Bittel J, Kopetz S. J Clin Oncol. 2021 Feb 1;39(4):273-284. IF: 44.544.

First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors. Baird RD, Linossi C, Middleton M, Lord S, Harris A, Rodón J, Zitt C, Fiedler U, Dawson KM, Leupin N, Stumpp MT, Harstrick A, Azaro A, Fischer S, Omlin A. J Clin Oncol. 2021 Jan 10;39(2):145-154. IF: 44.544.

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. Borghaei H, Gettinger S, Vokes EE, Chow LQM, Burgio MA, de Castro Carpeno J, Pluzanski A, Arrieta O, Frontera OA, Chiari R, Butts C, Wójcik-Tomaszewska J, Coudert B, Garassino MC, Ready N, Felip E, García MA, Waterhouse D, Domine M, Barlesi F, Antonia S, Wohlleber M, Gerber DE, Czyzewicz G, Spigel DR, Crino L, Eberhardt WEE, Li A, Marimuthu S, Brahmer J. J Clin Oncol. 2021 Mar 1;39(7):723-733. IF: 44.544.

Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. Hutchings M, Morschhauser F, Iacoboni G, Carlo-Stella C, Offner FC, Sureda A, Salles G, Martínez-Lopez J, Crump M, Thomas DN, Morcos PN, Ferlini C, Bröske AE, Belousov A, Bacac M, Dimier N, Carlile DJ, Lundberg L, Perez-Callejo D, Umaña P, Moore T, Weisser M, Dickinson MJ. J Clin Oncol. 2021 Jun 20;39(18):1959-1970. IF: 44.544.

Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509). Capdevila J, Fazio N, Lopez C, Teulé A, Valle JW, Tafuto S, Custodio A, Reed N, Raderer M, Grande E, Garcia-Carbonero R, Jimenez-Fonseca P, Hernando J, Bongiovanni A, Spada F, Alonso V, Antonuzzo L, Spallanzani A, Berruti A, La Casta A, Sevilla I, Kump P, Giuffrida D, Merino X, Trejo L, Gajate P, Matos I, Lamarca A, Ibrahim T. J Clin Oncol. 2021 Jul 10;39(20):2304-2312. IF: 44.544.

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451. Owonikoko TK, Park K, Govindan R, Ready N, Reck M, Peters S, Dakhil SR, Navarro A, Rodríguez-Cid J, Schenker M, Lee JS, Gutierrez V, Percent I, Morgensztern D, Barrios CH, Greillier L, Baka S, Patel M, Lin WH, Selvaggi G, Baudelet C, Baden J, Pandya D, Doshi P, Kim HR. J Clin Oncol. 2021 Apr 20;39(12):1349-1359. IF: 44.544.

Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma. McDermott DF, Lee JL, Ziobro M, Suarez C, Langiewicz P, Matveev VB, Wiechno P, Gafanov RA, Tomczak P, Pouliot F, Donskov F, Alekseev BY, Shin SJ, Bjarnason GA, Castellano D, Silverman RK, Perini RF, Schloss C, Atkins MB. J Clin Oncol. 2021 Mar 20;39(9):1029-1039. IF: 44.544.

Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes. Garcia-Manero G, Santini V, Almeida A, Platzbecker U, Jonasova A, Silverman LR, Falantes J, Reda G, Buccisano F, Fenaux P, Buckstein R, Diez Campelo M, Larsen S, Valcarcel D, Vyas P, Giai V, Olíva EN, Shortt J, Niederwieser D, Mittelman M, Fianchi L, La Torre I, Zhong J, Laille E, Lopes de Menezes D, Skikne B, Beach CL, Giagounidis A. J Clin Oncol. 2021 May 1;39(13):1426-1436. IF: 44.544.

Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis. Lambertini M, Blondeaux E, Bruzzone M, Perachino M, Anderson RA, de Azambuja E, Poorvu PD, Kim HJ, Villarreal-Garza C, Pistilli B, Vaz-Luis I, Saura C, Ruddy KJ, Franzoi MA, Sertoli C, Ceppi M, Azim HA Jr, Amant F, Demeestere I, Del Mastro L, Partridge AH, Pagani O, Peccatori FA. J Clin Oncol. 2021 Oct 10;39(29):3293-3305. IF: 44.544.

Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA). Hecht JR, Lonardi S, Bendell J, Sim HW, Macarulla T, Lopez CD, Van Cutsem E, Muñoz Martin AJ, Park JO, Greil R, Wang H, Hozak RR, Gueorguieva I, Lin Y, Rao S, Ryoo BY. J Clin Oncol. 2021 Apr 1;39(10):1108-1118. IF: 44.544.

Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations. Ho AL, Brana I, Haddad R, Bauman J, Bible K, Oosting S, Wong DJ, Ahn MJ, Boni V, Even C, Fayette J, Flor MJ, Harrington K, Kim SB, Licitra L, Nixon I, Saba NF, Hackenberg S, Specenier P, Worden F, Balsara B, Leoni M, Martell B, Scholz C, Gualberto A. J Clin Oncol. 2021 Jun 10;39(17):1856-1864. IF: 44.544.

Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. Brose MS, Robinson B, Sherman SI, Krajewska J, Lin CC, Vaisman F, Hoff AO, Hitre E, Bowles DW, Hernando J, Faoro L, Banerjee K, Oliver JW, Keam B, Capdevila J. Lancet Oncol. 2021 Aug;22(8):1126-1138. IF: 41.316.

Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial. Pérez-García JM, Gebhart G, Ruiz Borrego M, Stradella A, Bermejo B, Schmid P, Marmé F, Escrivá-de-Romani S, Calvo L, Ribelles N, Martinez N, Albacar C, Prat A, Dalenc F, Kerrou K, Colleoni M, Afonso N, Di Cosimo S, Sampayo-Cordero M, Malfettone A, Cortés J, Llombart-Cussac A; PHERGain steering committee and trial investigators. Lancet Oncol. 2021 Jun;22(6):858-871. IF: 41.316.

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O, Alexandru A, Sakai H, Lingua A, Salman P, Souquet PJ, De Marchi P, Martin C, Pérol M, Scherpereel A, Lu S, John T, Carbone DP, Meadows-Shropshire S, Agrawal S, Oukessou A, Yan J, Reck M. Lancet Oncol. 2021 Feb;22(2):198-211. IF: 41.316.

Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. Andre T, Amonkar M, Norquist JM, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt CJA, Smith D, Garcia-Carbonero R, Sevilla I, De La Fouchardiere C, Rivera F, Elez E, Diaz LA Jr, Yoshino T, Van Cutsem E, Yang P, Farooqui M, Le DT. Lancet Oncol. 2021 May;22(5):665-677. IF: 41.316.

Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Banerjee S, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Oza A, González-Martín A, Aghajanian C, Bradley WH, Holmes E, Lowe ES, DiSilvestro P. Lancet Oncol. 2021 Dec;22(12):1721-1731. IF: 41.316.

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Mayer EL, Dueck AC, Martin M, Rubovszky G, Burstein HJ, Bellet-Ezquerra M, Miller KD, Zdenkowski N, Winer EP, Pfeiler G, Goetz M, Ruiz-Borrego M, Anderson D, Nowecki Z, Loibl S, Moulder S, Ring A, Fitzal F, Traina T, Chan A, Rugo HS, Lemieux J, Henao F, Lyss A, Antolin Novoa S, Wolff AC, Vetter M, Egle D, Morris PG, Mamounas EP, Gil-Gil MJ, Prat A, Fohler H, Metzger Filho O, Schwarz M, DuFrane C, Fumagalli D, Theall KP, Lu DR, Bartlett CH, Koehler M, Fesl C, DeMichele A, Gnant M. Lancet Oncol. 2021 Feb;22(2):212-222. IF: 41.316.

Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial. Friedlander M, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, Lisyanskaya A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley WH, Liu J, Mathews C, Selle F, Lortholary A, Lowe ES, Hettle R, Flood E, Parkhomenko E, DiSilvestro P. Lancet Oncol. 2021 May;22(5):632-642. IF: 41,316.

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Morales Barrera R, Fléchon A, Gunduz S, Loriot Y, Rodriguez-Vida A, Mamtani R, Yu EY, Nam K, Imai K, Homet Moreno B, Alva A; KEYNOTE-361 Investigators. Lancet Oncol. 2021 Jul;22(7):931-945. IF: 41.316.

Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Winer EP, Lipatov O, Im SA, Goncalves A, Muñoz-Couselo E, Lee KS, Schmid P, Tamura K, Testa L, Witzel I, Ohtani S, Turner N, Zambelli S, Harbeck N, Andre F, Dent R, Zhou X, Karantza V, Mejia J, Cortes J; KEYNOTE-119 investigators. Lancet Oncol. 2021 Apr;22(4):499-511. IF: 41.316.

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Gainor JF, Curigliano G, Kim DW, Lee DH, Besse B, Baik CS, Doebele RC, Cassier PA, Lopes G, Tan DSW, Garralda E, Paz-Ares LG, Cho BC, Gadgeel SM, Thomas M, Liu SV, Taylor MH, Mansfield AS, Zhu VW, Clifford C, Zhang H, Palmer M, Green J, Turner CD, Subbiah V. Lancet Oncol. 2021 Jul;22(7):959-969. IF: 41.316.

Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. Pinato DJ, Tabernero J, Bower M, Scotti L, Patel M, Colomba E, Dolly S, Loizidou A, Chester J, Mukherjee U, Zambelli A, Dalla Pria A, Aguilar-Company J, Ottaviani D, Chowdhury A, Merry E, Salazar R, Bertuzzi A, Brunet J, Lambertini M, Tagliamento M, Pous A, Sita-Lumsden A, Srikandarajah K, Colomba J, Pommeret F, Seguí E, Generali D, Grisanti S, Pedrazzoli P, Rizzo G, Libertini M, Moss C, Evans JS, Russell B, Harbeck N, Vincenzi B, Biello F, Bertulli R, Liñan R, Rossi S, Carmona-García MC, Tondini C, Fox L, Baggi A, Fotia V, Parisi A, Porzio G, Saponara M, Cruz CA, García-Illescas D, Felip E, Roqué Lloveras A, Sharkey R, Roldán E, Reyes R, Earnshaw I, Ferrante D, Marco-Hernández J, Ruiz-Camps I, Gaidano G, Patriarca A, Bruna R, Sureda A, Martinez-Vila C, Sanchez de Torre A, Cantini L, Filetti M, Rimassa L, Chiudinelli L, Franchi M, Krengli M, Santoro A, Prat A, Van Hemelrijck M, Diamantis N, Newsom-Davis T, Gennari A, Cortellini A; OnCovid study group. Lancet Oncol. 2021 Dec;22(12):1669-1680. IF: 41.316.

SARS-CoV-2 vaccination and phase 1 cancer clinical trials. Yap TA, Siu LL, Calvo E, Lolkema MP, LoRusso PM, Soria JC, Plummer R, de Bono JS, Tabernero J, Banerji U. Lancet Oncol. 2021 Mar;22(3):298-301. IF: 41.316.

Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg EM, Roodvoets AGH, Nagtegaal ID, Beets-Tan RGH, Blomqvist LK, Fokstuen T, Ten Tije AJ, Capdevila J, Hendriks MP, Edhemovic I, Cervantes A, Nilsson PJ, Glimelius B, van de Velde CJH, Hospers GAP; RAPIDO collaborative investigators. Lancet Oncol. 2021 Jan;22(1):29-42. IF: 41.316.

Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Siena S, Di Bartolomeo M, Raghav K, Masuishi T, Loupakis F, Kawakami H, Yamaguchi K, Nishina T, Fakih M, Elez E, Rodriguez J, Ciardiello F, Komatsu Y, Esaki T, Chung K, Wainberg Z, Sartore-Bianchi A, Saxena K, Yamamoto E, Bako E, Okuda Y, Shahidi J, Grothey A, Yoshino T; DESTINY-CRC01 investigators. Lancet Oncol. 2021 Jun;22(6):779-789. IF: 41.316.

Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial. Carreira S, Porta N, Arce-Gallego S, Seed G, Llop-Guevara A, Bianchini D, Rescigno P, Paschalis A, Bertan C, Baker C, Goodall J, Miranda S, Riisnaes R, Figueiredo I, Ferreira A, Pereira R, Crespo M, Gurel B, Nava Rodrigues D, Pettitt SJ, Yuan W, Serra V, Rekowski J, Lord CJ, Hall E, Mateo J, de Bono JS. Cancer Discov. 2021 Nov;11(11):2812-2827. IF: 39.397.

Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. Aftimos P, Oliveira M, Irrthum A, Fumagalli D, Sotiriou C, Gal-Yam EN, Robson ME, Ndozeng J, Di Leo A, Ciruelos EM, de Azambuja E, Viale G, Scheepers ED, Curigliano G, Bliss JM, Reis-Filho JS, Colleoni M, Balic M, Cardoso F, Albanell J, Duhem C, Marreaud S, Romagnoli D, Rojas B, Gombos A, Wildiers H, Guerrero-Zotano A, Hall P, Bonetti A, Larsson KF, Degiorgis M, Khodaverdi S, Greil R, Sverrisdóttir Á, Paoli M, Seyll E, Loibl S, Linderholm B, Zoppoli G, Davidson NE, Johannsson OT, Bedard PL, Loi S, Knox S, Cameron DA, Harbeck N, Montoya ML, Brandão M, Vingiani A, Caballero C, Hilbers FS, Yates LR, Benelli M, Venet D, Piccart MJ. Cancer Discov. 2021 Nov;11(11):2796-2811. IF: 39.397.

José “Pepe” Baselga, MD, PhD: In Memoriam (1959-2021). Tabernero J, Hyman DM, Soria JC. Cancer Discov. 2021 Jul;11(7):1614-1616. IF: 39.397.

Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Woo XY, Giordano J, Srivastava A, Zhao ZM, Lloyd MW, de Bruijn R, Suh YS, Patidar R, Chen L, Scherer S, Bailey MH, Yang CH, Cortes-Sanchez E, Xi Y, Wang J, Wickramasinghe J, Kossenkov AV, Rebecca VW, Sun H, Mashl RJ, Davies SR, Jeon R, Frech C, Randjelovic J, Rosains J, Galimi F, Bertotti A, Lafferty A, O’Farrell AC, Modave E, Lambrechts D, Ter Brugge P, Serra V, Marangoni E, El Botty R, Kim H, Kim JI, Yang HK, Lee C, Dean DA 2nd, Davis-Dusenbery B, Evrard YA, Doroshow JH, Welm AL, Welm BE, Lewis MT, Fang B, Roth JA, Meric-Bernstam F, Herlyn M, Davies MA, Ding L, Li S, Govindan R, Isella C, Moscow JA, Trusolino L, Byrne AT, Jonkers J, Bult CJ, Medico E, Chuang JH; PDXNET Consortium; EurOPDX Consortium: Bailey MH, Rebecca VW, Davies MA, Robinson PN, Sanderson BJ, Neuhauser SB, Dobrolecki LE, Zheng X, Majidi M, Zhang R, Zhang X, Akcakanat A, Evans KW, Yap TA, Li D,Yucan E, Lanier CD, Saridogan T, Kirby BP, Ha MJ, Chen H, Kopetz S, Menter DG, Zhang J, Westin SN, Kim MP, Dai B, Gibbons DL, Tapia C, Jensen VB, Boning G, Minna JD, Park H, Timmons BC, Girard L, Fingerman D, Liu Q, Somasundaram R, Xiao M, Yennu VG, Tetzlaff MT, Xu X, Nathanson KL, Cao S, Chen F, DiPersio JF, Lim KH, Ma CX, Rodriguez FM, Van BA, Wang A, Wendl MC, Wu Y, Wyczalkowski MA, Yao L, Jayasinghe R, Aft RL, Fields RC, Luo J, Fuh KC, Chin V, DiGiovanna J, Grover J, Koc S, Seepo S, Wallace T, Pan CX, Chen Jr. MS, Carvajal LG, Kirane AR, Cho M, Gandara DR, Riess JW, Le T, deVere RW, Tepper CG, Zhang H, Coggins NB, Lott P, Estrada A, Toal T, Arana AM, Polanco G, Rocha S, Ma AH, Mitsiades N, Kaochar S, O’Malley BW, Ellis MJ, Hilsenbeck SG, Ittmann M, de Bruijn R, Ter P, Corso S, Fiori A, Giordano S, van de Ven M, Peeper DS, Miller I, Bernadó C, Morancho B, Ramírez L, Arribas J, Palmer HG, Piris A, Soucek L, et al. Nat Genet. 2021 Jan;53(1):86-99. IF: 38.330.

Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial. Llop-Guevara A, Loibl S, Villacampa G, Vladimirova V, Schneeweiss A, Karn T, Zahm DM, Herencia-Ropero A, Jank P, van Mackelenbergh M, Fasching PA, Marmé F, Stickeler E, Schem C, Dienstmann R, Florian S, Nekljudova V, Balmaña J, Hahnen E, Denkert C, Serra V. Ann Oncol. 2021 Dec;32(12):1590-1596. IF: 32.976.

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Harbeck N, Rastogi P, Martin M, Tolaney SM, Shao ZM, Fasching PA, Huang CS, Jaliffe GG, Tryakin A, Goetz MP, Rugo HS, Senkus E, Testa L, Andersson M, Tamura K, Del Mastro L, Steger GG, Kreipe H, Hegg R, Sohn J, Guarneri V, Cortés J, Hamilton E, André V, Wei R, Barriga S, Sherwood S, Forrester T, Munoz M, Shahir A, San Antonio B, Nabinger SC, Toi M, Johnston SRD, O’Shaughnessy J; monarchE Committee Members. Ann Oncol. 2021 Dec;32(12):1571-1581. IF: 32.976.

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Bardia A, Tolaney SM, Punie K, Loirat D, Oliveira M, Kalinsky K, Zelnak A, Aftimos P, Dalenc F, Sardesai S, Hamilton E, Sharma P, Recalde S, Gil EC, Traina T, O’Shaughnessy J, Cortes J, Tsai M, Vahdat L, Diéras V, Carey LA, Rugo HS, Goldenberg DM, Hong Q, Olivo M, Itri LM, Hurvitz SA. Ann Oncol. 2021 Sep;32(9):1148-1156. IF: 32.976.

Building bridges between drug development and cancer science: a tribute to José Baselga’s legacy. Hyman DM, Soria JC, Tabernero J. Ann Oncol. 2021 Jul;32(7):825-828. IF: 32.976.

Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer. Schoenfeld AJ, Antonia SJ, Awad MM, Felip E, Gainor J, Gettinger SN, Hodi FS, Johnson ML, Leighl NB, Lovly CM, Mok T, Perol M, Reck M, Solomon B, Soria JC, Tan DSW, Peters S, Hellmann MD. Ann Oncol. 2021 Dec;32(12):1597-1607. IF: 32.976.

EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. Le Rhun E, Guckenberger M, Smits M, Dummer R, Bachelot T, Sahm F, Galldiks N, de Azambuja E, Berghoff AS, Metellus P, Peters S, Hong YK, Winkler F, Schadendorf D, van den Bent M, Seoane J, Stahel R, Minniti G, Wesseling P, Weller M, Preusser M; EANO Executive Board and ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Ann Oncol. 2021 Nov;32(11):1332-1347. IF: 32.976.

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A, Dent R, Fenlon D, Gligorov J, Hurvitz SA, Im SA, Krug D, Kunz WG, Loi S, Penault-Llorca F, Ricke J, Robson M, Rugo HS, Saura C, Schmid P, Singer CF, Spanic T, Tolaney SM, Turner NC, Curigliano G, Loibl S, Paluch-Shimon S, Harbeck N; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Ann Oncol. 2021 Dec;32(12):1475-1495. IF: 32.976.

ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. Powles T, Albiges L, Bex A, Grünwald V, Porta C, Procopio G, Schmidinger M, Suárez C, de Velasco G; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Ann Oncol. 2021 Dec;32(12):1511-1519. IF: 32.976.

ESMO pays tribute to Professor José Baselga. Peters S, Tabernero J, Cervantes A, Banerjee S, Giuliani R, Lordick F. Ann Oncol. 2021 Jul;32(7):823-824. IF: 32.976.

Genomic testing for targeted oncology drugs: hopes against hype. Dienstmann R, Tamborero D. Ann Oncol. 2021 Jul;32(7):837-838. IF: 32.976.

Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study. Tempero M, Oh DY, Tabernero J, Reni M, Van Cutsem E, Hendifar A, Waldschmidt DT, Starling N, Bachet JB, Chang HM, Maurel J, Garcia-Carbonero R, Lonardi S, Coussens LM, Fong L, Tsao LC, Cole G Jr, James D, Macarulla T. Ann Oncol. 2021 May;32(5):600-608. IF: 32.976.

Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. Felip E, Shaw AT, Bearz A, Camidge DR, Solomon BJ, Bauman JR, Bauer TM, Peters S, Toffalorio F, Abbattista A, Thurm H, Peltz G, Wiltshire R, Besse B. Ann Oncol. 2021 May;32(5):620-630. IF: 32.976.

Longitudinal whole-exome sequencing of cell-free DNA for tracking the co-evolutionary tumor and immune evasion dynamics: longitudinal data from a single patient. Hastings RK, Openshaw MR, Vazquez M, Moreno-Cardenas AB, Fernandez-Garcia D, Martinson L, Kulbicki K, Primrose L, Guttery DS, Page K, Toghill B, Richards C, Thomas A, Tabernero J, Coombes RC, Ahmed S, Toledo RA, Shaw JA. Ann Oncol. 2021 May;32(5):681-684. IF: 32.976.

Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines. Grothey A, Fakih M, Tabernero J. Ann Oncol. 2021 Aug;32(8):959-967. IF: 32.976.

Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. Eikesdal HP, Yndestad S, Elzawahry A, Llop-Guevara A, Gilje B, Blix ES, Espelid H, Lundgren S, Geisler J, Vagstad G, Venizelos A, Minsaas L, Leirvaag B, Gudlaugsson EG, Vintermyr OK, Aase HS, Aas T, Balmaña J, Serra V, Janssen EAM, Knappskog S, Lønning PE. Ann Oncol. 2021 Feb;32(2):240-249. IF: 32.976.

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. Yoshino T, Argilés G, Oki E, Martinelli E, Taniguchi H, Arnold D, Mishima S, Li Y, Smruti BK, Ahn JB, Faud I, Chee CE, Yeh KH, Lin PC, Chua C, Hasbullah HH, Lee MA, Sharma A, Sun Y, Curigliano G, Bando H, Lordick F, Yamanaka T, Tabernero J, Baba E, Cervantes A, Ohtsu A, Peters S, Ishioka C, Pentheroudakis G. Ann Oncol. 2021 Dec;32(12):1496-1510. IF: 32.976.

Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial. Hughes BGM, Munoz-Couselo E, Mortier L, Bratland Å, Gutzmer R, Roshdy O, González Mendoza R, Schachter J, Arance A, Grange F, Meyer N, Joshi A, Billan S, Zhang P, Gumuscu B, Swaby RF, Grob JJ. Ann Oncol. 2021 Oct;32(10):1276-1285. IF: 32.976.

Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Rodríguez-Abreu D, Powell SF, Hochmair MJ, Gadgeel S, Esteban E, Felip E, Speranza G, De Angelis F, Dómine M, Cheng SY, Bischoff HG, Peled N, Reck M, Hui R, Garon EB, Boyer M, Kurata T, Yang J, Pietanza MC, Souza F, Garassino MC. Ann Oncol. 2021 Jul;32(7):881-895. IF: 32.976.

Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial. Dent S, Cortés J, Im YH, Diéras V, Harbeck N, Krop IE, Wilson TR, Cui N, Schimmoller F, Hsu JY, He J, De Laurentiis M, Sousa S, Drullinsky P, Jacot W. Ann Oncol. 2021 Feb;32(2):197-207. IF: 32.976.

Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Moore KN, Oza AM, Colombo N, Oaknin A, Scambia G, Lorusso D, Konecny GE, Banerjee S, Murphy CG, Tanyi JL, Hirte H, Konner JA, Lim PC, Prasad-Hayes M, Monk BJ, Pautier P, Wang J, Berkenblit A, Vergote I, Birrer MJ. Ann Oncol. 2021 Jun;32(6):757-765. IF: 32.976.

Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331. Spigel DR, Vicente D, Ciuleanu TE, Gettinger S, Peters S, Horn L, Audigier-Valette C, Pardo Aranda N, Juan-Vidal O, Cheng Y, Zhang H, Shi M, Luft A, Wolf J, Antonia S, Nakagawa K, Fairchild J, Baudelet C, Pandya D, Doshi P, Chang H, Reck M. Ann Oncol. 2021 May;32(5):631-641. IF: 32.976.

Therapeutic cancer vaccines revamping: technology advancements and pitfalls. Antonarelli G, Corti C, Tarantino P, Ascione L, Cortes J, Romero P, Mittendorf EA, Disis ML, Curigliano G. Ann Oncol. 2021 Dec;32(12):1537-1551. IF: 32.976.

VP2-2021: Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small cell lung cancer (Nsq-NSCLC) with high PD-L1 expression using real-world data. Peters S, Dafni U, Perol M, Felip E, Polito L, Pal N, Ton TGN, Merritt D, Morris S, Stahel RA. Ann Oncol. 2021. 32(5): 687-688. IF: 32.976.

VP4-2021: EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs. investigator’s choice (IC) chemotherapy (chemo) in recurrent/metastatic (R/M) cervical carcinoma. Tewari KS, Monk BJ, Vergote I, Miller A, de Melo AC, Kim HS, Kim YM, Lisyanskaya A, Samouelian V, Lorusso D, Damian F, Chang C-L, Gotovkin EA, Takahashi S, Ramone D, Pikiel J, Li J, Mathias M, Fury MG, Oaknin A. Ann Oncol. 2021. 32(7):940-941. IF: 32.976.

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Subbiah V, Hu MI, Wirth LJ, Schuler M, Mansfield AS, Curigliano G, Brose MS, Zhu VW, Leboulleux S, Bowles DW, Baik CS, Adkins D, Keam B, Matos I, Garralda E, Gainor JF, Lopes G, Lin CC, Godbert Y, Sarker D, Miller SG, Clifford C, Zhang H, Turner CD, Taylor MH. Lancet Diabetes Endocrinol. 2021 Aug;9(8):491-501. IF: 32.069.

Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. Chao J, Fuchs CS, Shitara K, Tabernero J, Muro K, Van Cutsem E, Bang YJ, De Vita F, Landers G, Yen CJ, Chau I, Elme A, Lee J, Özgüroglu M, Catenacci D, Yoon HH, Chen E, Adelberg D, Shih CS, Shah S, Bhagia P, Wainberg ZA. JAMA Oncol. 2021 Jun 1;7(6):895-902. IF: 31.777.

Clarification of Definitions of Hyperprogressive Disease During Immunotherapy. Matos I, Garralda E. JAMA Oncol. 2021 Jan 1;7(1):136-137. IF: 31.777.

Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial. Rugo HS, Im SA, Cardoso F, Cortés J, Curigliano G, Musolino A, Pegram MD, Wright GS, Saura C, Escrivá-de-Romaní S, De Laurentiis M, Levy C, Brown-Glaberman U, Ferrero JM, de Boer M, Kim SB, Petráková K, Yardley DA, Freedman O, Jakobsen EH, Kaufman B, Yerushalmi R, Fasching PA, Nordstrom JL, Bonvini E, Koenig S, Edlich S, Hong S, Rock EP, Gradishar WJ; SOPHIA Study Group. JAMA Oncol. 2021 Apr 1;7(4):573-584. IF: 31.777.

Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial. Zhu AX, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DVT, Borad MJ, Bridgewater JA, Harris WP, Murphy AG, Oh DY, Whisenant JR, Lowery MA, Goyal L, Shroff RT, El-Khoueiry AB, Chamberlain CX, Aguado-Fraile E, Choe S, Wu B, Liu H, Gliser C, Pandya SS, Valle JW, Abou-Alfa GK. JAMA Oncol. 2021 Nov 1;7(11):1669-1677. IF: 31.777.

Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial. Llombart-Cussac A, Pérez-García JM, Bellet M, Dalenc F, Gil-Gil M, Ruíz-Borrego M, Gavilá J, Sampayo-Cordero M, Aguirre E, Schmid P, Marmé F, Di Cosimo S, Gligorov J, Schneeweiss A, Albanell J, Zamora P, Wheatley D, Martínez-de Dueñas E, Amillano K, Malfettone A, Cortés J; PARSIFAL Steering Committee and Trial Investigators. JAMA Oncol. 2021 Dec 1;7(12):1791-1799. IF: 31.777.

Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A Review. Tarantino P, Modi S, Tolaney SM, Cortés J, Hamilton EP, Kim SB, Toi M, Andrè F, Curigliano G. JAMA Oncol. 2021 Dec 1;7(12):1873-1881. IF: 31.777.

Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib. Kwan TT, Oza AM, Tinker AV, Ray-Coquard I, Oaknin A, Aghajanian C, Lorusso D, Colombo N, Dean A, Weberpals J, Severson E, Vo LT, Goble S, Maloney L, Harding T, Kaufmann SH, Ledermann JA, Coleman RL, McNeish IA, Lin KK, Swisher EM. JAMA Oncol. 2021 Dec 1;7(12):1772-1781. IF: 31,777.

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial. Zhou C, Ramalingam SS, Kim TM, Kim SW, Yang JC, Riely GJ, Mekhail T, Nguyen D, Garcia Campelo MR, Felip E, Vincent S, Jin S, Griffin C, Bunn V, Lin J, Lin HM, Mehta M, Jänne PA. JAMA Oncol. 2021 Dec 1;7(12):e214761. IF: 31.777.

Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial. Jabbour SK, Lee KH, Frost N, Breder V, Kowalski DM, Pollock T, Levchenko E, Reguart N, Martinez-Marti A, Houghton B, Paoli JB, Safina S, Park K, Komiya T, Sanford A, Boolell V, Liu H, Samkari A, Keller SM, Reck M. JAMA Oncol. 2021 Jun 4;7(9):1–9. IF: 31.777.

I-SPY2 platform: New lessons from the olaparib and durvalumab combination in breast cancer treatment. Perez-Garcia J, Gion M, Cortes J. Cancer Cell. 2021 Jul 12;39(7):902-904. IF: 31.743.

Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. Yap TA, Nakagawa K, Fujimoto N, Kuribayashi K, Guren TK, Calabrò L, Shapira-Frommer R, Gao B, Kao S, Matos I, Planchard D, Chatterjee A, Jin F, Norwood K, Kindler HL. Lancet Respir Med. 2021 Jun;9(6):613-621. IF: 30.700.

B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide. Fürstenau M, Fink AM, Schilhabel A, Weiss J, Robrecht S, Eckert R, de la Serna J, Crespo M, Coscia M, Vitale C, Böttcher S, Weppner G, Ritgen M, Stilgenbauer S, Tausch E, Fischer K, Hallek M, Eichhorst B, Brüggemann M, Herling CD. Blood. 2021 Apr 22;137(16):2267-2271. IF: 23.629.

Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia. Ribera JM, Morgades M, Ciudad J, Montesinos P, Esteve J, Genescà E, Barba P, Ribera J, García-Cadenas I, Moreno MJ, Martínez-Carballeira D, Torrent A, Martínez-Sánchez P, Monsalvo S, Gil C, Tormo M, Artola MT, Cervera M, González-Campos J, Rodríguez C, Bermúdez A, Novo A, Soria B, Coll R, Amigo ML, López-Martínez A, Fernández-Martín R, Serrano J, Mercadal S, Cladera A, Giménez-Conca A, Peñarrubia MJ, Abella E, Vall-Llovera F, Hernández-Rivas JM, Garcia-Guiñon A, Bergua JM, de Rueda B, Sánchez-Sánchez MJ, Serrano A, Calbacho M, Alonso N, Méndez-Sánchez JÁ, García-Boyero R, Olivares M, Barrena S, Zamora L, Granada I, Lhermitte L, Feliu E, Orfao A. Blood. 2021 Apr 8;137(14):1879-1894. IF: 23.629.

Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era. Bobillo S, Joffe E, Lavery JA, Sermer D, Ghione P, Noy A, Caron PC, Hamilton A, Hamlin PA, Horwitz SM, Kumar A, Matasar MJ, Moskowitz A, Owens CN, Palomba ML, Batlevi CL, Straus D, von Keudell G, Zelenetz AD, Yahalom J, Dogan A, Seshan VE, Younes A. Blood. 2021 Jan 7;137(1):39-48. IF: 23.629.

Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study. Horwitz ME, Stiff PJ, Cutler C, Brunstein C, Hanna R, Maziarz RT, Rezvani AR, Karris NA, McGuirk J, Valcarcel D, Schiller GJ, Lindemans CA, Hwang WYK, Koh LP, Keating A, Khaled Y, Hamerschlak N, Frankfurt O, Peled T, Segalovich I, Blackwell B, Wease S, Freedman LS, Galamidi-Cohen E, Sanz G. Blood. 2021 Oct 21;138(16):1429-1440. IF: 23.629.

Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development. Alameda D, Goicoechea I, Vicari M, Arriazu E, Nevone A, Rodriguez S, Lasa M, Puig N, Cedena MT, Alignani D, Garate S, Lara-Astiaso D, Vilas-Zornoza A, Sarvide S, Ocio EM, Lecumberri R, Garcia de Coca A, Labrador J, Gonzalez ME, Palomera L, Gironella M, Cabañas V, Casanova M, Oriol A, Krsnik I, Perez-Montaña A, de la Rubia J, de la Puerta JE, de Arriba F, Fazio VM, Martinez-Lopez J, Lahuerta JJ, Mateos MV, Odero MD, Prosper F, Weiner A, Amit I, Nuvolone M, San Miguel JF, Paiva B. Blood. 2021 Oct 28;138(17):1583-1589. IF: 23.629.

Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. Powles T, Atkins MB, Escudier B, Motzer RJ, Rini BI, Fong L, Joseph RW, Pal SK, Sznol M, Hainsworth J, Stadler WM, Hutson TE, Ravaud A, Bracarda S, Suarez C, Choueiri TK, Reeves J, Cohn A, Ding B, Leng N, Hashimoto K, Huseni M, Schiff C, McDermott DF. Eur Urol. 2021 May;79(5):665-673. IF: 20.096.

Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study. Sternberg CN, Castellano D, de Bono J, Fizazi K, Tombal B, Wülfing C, Kramer G, Eymard JC, Bamias A, Carles J, Iacovelli R, Melichar B, Sverrisdóttir Á, Theodore C, Feyerabend S, Helissey C, Poole EM, Ozatilgan A, Geffriaud-Ricouard C, de Wit R. Eur Urol. 2021 Oct;80(4):497-506. IF: 20.096.

Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA. Sumanasuriya S, Seed G, Parr H, Christova R, Pope L, Bertan C, Bianchini D, Rescigno P, Figueiredo I, Goodall J, Fowler G, Flohr P, Mehra N, Neeb A, Rekowski J, Eisenberger M, Sartor O, Oudard S, Geffriaud-Ricouard C, Ozatilgan A, Chadjaa M, Macé S, Lord C, Baxter J, Pettitt S, Lambros M, Sharp A, Mateo J, Carreira S, Yuan W, de Bono JS. Eur Urol. 2021 Aug;80(2):243-253. IF: 20.096.

Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians. Merseburger AS, Waldron N, Ribal MJ, Heidenreich A, Perner S, Fizazi K, Sternberg CN, Mateo J, Wirth MP, Castro E, Olmos D, Petrylak DP, Chowdhury S. Eur Urol. 2021 Apr;79(4):519-529. IF: 20.096.

Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer. Casanova-Salas I, Athie A, Boutros PC, Del Re M, Miyamoto DT, Pienta KJ, Posadas EM, Sowalsky AG, Stenzl A, Wyatt AW, Mateo J. Eur Urol. 2021 Jun;79(6):762-771. IF: 20.096.

Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study. Pleyer L, Leisch M, Kourakli A, Padron E, Maciejewski JP, Xicoy Cirici B, Kaivers J, Ungerstedt J, Heibl S, Patiou P, Hunter AM, Mora E, Geissler K, Dimou M, Jimenez Lorenzo MJ, Melchardt T, Egle A, Viniou AN, Patel BJ, Arnan M, Valent P, Roubakis C, Bernal Del Castillo T, Galanopoulos A, Calabuig Muñoz M, Bonadies N, Medina de Almeida A, Cermak J, Jerez A, Montoro MJ, Cortés A, Avendaño Pita A, Lopez Andrade B, Hellstroem-Lindberg E, Germing U, Sekeres MA, List AF, Symeonidis A, Sanz GF, Larcher-Senn J, Greil R. Lancet Haematol. 2021 Feb;8(2):e135-e148. IF: 18.959.

Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study. Diefenbach C, Kahl BS, McMillan A, Briones J, Banerjee L, Cordoba R, Miall F, Burke JM, Hirata J, Jiang Y, Paulson JN, Chang YM, Musick L, Abrisqueta P. Lancet Haematol. 2021 Dec;8(12):e891-e901. IF: 18.959.

Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Javle M, Roychowdhury S, Kelley RK, Sadeghi S, Macarulla T, Weiss KH, Waldschmidt DT, Goyal L, Borbath I, El-Khoueiry A, Borad MJ, Yong WP, Philip PA, Bitzer M, Tanasanvimon S, Li A, Pande A, Soifer HS, Shepherd SP, Moran S, Zhu AX, Bekaii-Saab TS, Abou-Alfa GK. Lancet Gastroenterol Hepatol. 2021 Oct;6(10):803-815. IF: 18.486.

DNA hypomethylating agents increase activation and cytolytic activity of CD8+ T cells. Loo Yau H, Bell E, Ettayebi I, de Almeida FC, Boukhaled GM, Shen SY, Allard D, Morancho B, Marhon SA, Ishak CA, Gonzaga IM, da Silva Medina T, Singhania R, Chakravarthy A, Chen R, Mehdipour P, Pommey S, Klein C, Amarante-Mendes GP, Roulois D, Arribas J, Stagg J, Brooks DG, De Carvalho DD. Mol Cell. 2021 Apr 1;81(7):1469-1483. IF: 17.970.

COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). Pagano L, Salmanton-García J, Marchesi F, Busca A, Corradini P, Hoenigl M, Klimko N, Koehler P, Pagliuca A, Passamonti F, Verga L, Víšek B, Ilhan O, Nadali G, Weinbergerová B, Córdoba-Mascuñano R, Marchetti M, Collins GP, Farina F, Cattaneo C, Cabirta A, Gomes-Silva M, Itri F, van Doesum J, Ledoux MP, Čerňan M, Jakšić O, Duarte RF, Magliano G, Omrani AS, Fracchiolla NS, Kulasekararaj A, Valković T, Poulsen CB, Machado M, Glenthøj A, Stoma I, Ráčil Z, Piukovics K, Navrátil M, Emarah Z, Sili U, Maertens J, Blennow O, Bergantim R, García-Vidal C, Prezioso L, Guidetti A, Del Principe MI, Popova M, de Jonge N, Ormazabal-Vélez I, Fernández N, Falces-Romero I, Cuccaro A, Meers S, Buquicchio C, Antić D, Al-Khabori M, García-Sanz R, Biernat MM, Tisi MC, Sal E, Rahimli L, Čolović N, Schönlein M, Calbacho M, Tascini C, Miranda-Castillo C, Khanna N, Méndez GA, Petzer V, Novák J, Besson C, Duléry R, Lamure S, Nucci M, Zambrotta G, Žák P, Seval GC, Bonuomo V, Mayer J, López-García A, Sacchi MV, Booth S, Ciceri F, Oberti M, Salvini M, Izuzquiza M, Nunes-Rodrigues R, Ammatuna E, Obr A, Herbrecht R, Núñez-Martín-Buitrago L, Mancini V, Shwaylia H, Sciumè M, Essame J, Nygaard M, Batinić J, Gonzaga Y, Regalado-Artamendi I, Karlsson LK, Shapetska M, Hanakova M, El-Ashwah S, Borbényi Z, Çolak GM, Nordlander A, Dragonetti G, Maraglino AME, Rinaldi A, De Ramón-Sánchez C, Cornely OA; EPICOVIDEHA working group. J Hematol Oncol. 2021 Oct 14;14(1):168. IF: 17.388.

Variable interplay of UV-induced DNA damage and repair at transcription factor binding sites. Frigola J, Sabarinathan R, Gonzalez-Perez A, Lopez-Bigas N. Nucleic Acids Res. 2021 Jan 25;49(2):891-901. IF: 16.971.

Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, Lee KH, Delmonte A, Garcia Campelo MR, Kim DW, Griesinger F, Felip E, Califano R, Spira AI, Gettinger SN, Tiseo M, Lin HM, Liu Y, Vranceanu F, Niu H, Zhang P, Popat S. J Thorac Oncol. 2021 Dec;16(12):2091-2108. IF: 15.609.

Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14). Peters S, Felip E, Dafni U, Tufman A, Guckenberger M, Álvarez R, Nadal E, Becker A, Vees H, Pless M, Martinez-Marti A, Lambrecht M, Andratschke N, Tsourti Z, Piguet AC, Roschitzki-Voser H, Gasca-Ruchti A, Vansteenkiste J, Stahel RA, De Ruysscher D. J Thorac Oncol. 2021 Feb;16(2):278-288. IF: 15.609.

Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC. Jassem J, de Marinis F, Giaccone G, Vergnenegre A, Barrios CH, Morise M, Felip E, Oprean C, Kim YC, Andric Z, Mocci S, Enquist I, Komatsubara K, McCleland M, Kuriki H, Villalobos M, Phan S, Spigel DR, Herbst RS. J Thorac Oncol. 2021 Nov;16(11):1872-1882. IF: 15.609.

A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Coignard J, Lush M, Beesley J, O’Mara TA, Dennis J, Tyrer JP, Barnes DR, McGuffog L, Leslie G, Bolla MK, Adank MA, Agata S, Ahearn T, Aittomäki K, Andrulis IL, Anton-Culver H, Arndt V, Arnold N, Aronson KJ, Arun BK, Augustinsson A, Azzollini J, Barrowdale D, Baynes C, Becher H, Bermisheva M, Bernstein L, Białkowska K, Blomqvist C, Bojesen SE, Bonanni B, Borg A, Brauch H, Brenner H, Burwinkel B, Buys SS, Caldés T, Caligo MA, Campa D, Carter BD, Castelao JE, Chang-Claude J, Chanock SJ, Chung WK, Claes KBM, Clarke CL; GEMO Study Collaborators; EMBRACE Collaborators, Collée JM, Conroy DM, Czene K, Daly MB, Devilee P, Diez O, Ding YC, Domchek SM, Dörk T, Dos-Santos-Silva I, Dunning AM, Dwek M, Eccles DM, Eliassen AH, Engel C, Eriksson M, Evans DG, Fasching PA, Flyger H, Fostira F, Friedman E, Fritschi L, Frost D, Gago-Dominguez M, Gapstur SM, Garber J, Garcia-Barberan V, García-Closas M, García-Sáenz JA, Gaudet MM, Gayther SA, Gehrig A, Georgoulias V, Giles GG, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Greene MH, Guénel P, Haeberle L, Hahnen E, Haiman CA, Håkansson N, Hall P, Hamann U, Harrington PA, Hart SN, He W, Hogervorst FBL, Hollestelle A, Hopper JL, Horcasitas DJ, Hulick PJ, Hunter DJ, Imyanitov EN; KConFab Investigators; HEBON Investigators; ABCTB Investigators, Jager A, Jakubowska A, James PA, Jensen UB, John EM, Jones ME, Kaaks R, Kapoor PM, Karlan BY, Keeman R, Khusnutdinova E, Kiiski JI, Ko YD, Kosma VM, Kraft P, Kurian AW, Laitman Y, Lambrechts D, Le Marchand L, Lester J, Lesueur F, Lindstrom T, Lopez-Fernández A, et al. Nat Commun. 2021 Feb 17;12(1):1078. IF: 14.919.

Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation. Arenas EJ, Martínez-Sabadell A, Rius Ruiz I, Román Alonso M, Escorihuela M, Luque A, Fajardo CA, Gros A, Klein C, Arribas J. Nat Commun. 2021 Feb 23;12(1):1237. IF: 14.919.

Dynamics of genome architecture and chromatin function during human B cell differentiation and neoplastic transformation. Vilarrasa-Blasi R, Soler-Vila P, Verdaguer-Dot N, Russiñol N, Di Stefano M, Chapaprieta V, Clot G, Farabella I, Cuscó P, Kulis M, Agirre X, Prosper F, Beekman R, Beà S, Colomer D, Stunnenberg HG, Gut I, Campo E, Marti-Renom MA, Martin-Subero JI. Nat Commun. 2021 Jan 28;12(1):651. IF: 14.919.

HER2+breast cancers evade anti-HER2 therapy via a switch in driver pathway. Smith AE, Ferraro E, Safonov A, Morales CB, Lahuerta EJA, Li Q, Kulick A, Ross D, Solit DB, de Stanchina E, Reis-Filho J, Rosen N, Arribas J, Razavi P, Chandarlapaty S. HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway. Nat Commun. 2021. Nov18; 12(1):6667. IF: 14.919.

Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment. Rubio-Perez C, Planas-Rigol E, Trincado JL, Bonfill-Teixidor E, Arias A, Marchese D, Moutinho C, Serna G, Pedrosa L, Iurlaro R, Martínez-Ricarte F, Escudero L, Cordero E, Cicuendez M, Ruiz S, Parra G, Nuciforo P, Gonzalez J, Pineda E, Sahuquillo J, Tabernero J, Heyn H, Seoane J. Nat Commun. 2021 Mar 8;12(1):1503. IF: 14.919.

Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial. Gonzalez-Cao M, Mayo de Las Casas C, Oramas J, Berciano-Guerrero MA, de la Cruz L, Cerezuela P, Arance A, Muñoz-Couselo E, Espinosa E, Puertolas T, Diaz Beveridge R, Ochenduszko S, Villanueva MJ, Basterretxea L, Bellido L, Rodriguez D, Campos B, Montagut C, Drozdowskyj A, Molina MA, Lopez-Martin JA, Berrocal A. Nat Commun. 2021 Dec 1;12(1):7008. IF: 14.919.

Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response. Georgopoulou D, Callari M, Rueda OM, Shea A, Martin A, Giovannetti A, Qosaj F, Dariush A, Chin SF, Carnevalli LS, Provenzano E, Greenwood W, Lerda G, Esmaeilishirazifard E, O’Reilly M, Serra V, Bressan D; IMAXT Consortium, Mills GB, Ali HR, Cosulich SS, Hannon GJ, Bruna A, Caldas C. IMAXT Consortium: H R Ali, M Al Sa’d, S Alon, S Aparicio, G Battistoni, S Balasubramanian, R Becker, B Bodenmiller, E S Boyden, D Bressan, A Bruna, Marcel Burger, C Caldas, M Callari, I G Cannell, H Casbolt, N Chornay, Y Cui, A Dariush, K Dinh, A Emenari, Y Eyal-Lubling, J Fan, A Fatemi, E Fisher, E A González-Solares, C González-Fernández, D Goodwin, W Greenwood, F Grimaldi, G J Hannon, O Harris, S Harris, C Jauset, J A Joyce, E D Karagiannis, T Kovačević, L Kuett, R Kunes, Yoldaş A Küpcü, D Lai, E Laks, H Lee, M Lee, G Lerda, Y Li, A McPherson, N Millar, C M Mulvey, F Nugent, C H O’Flanagan, M Paez-Ribes, I Pearsall, F Qosaj, A J Roth, O M Rueda, T Ruiz, K Sawicka, L A Sepúlveda, S P Shah, A Shea, A Sinha, A Smith, S Tavaré, S Tietscher, I Vázquez-García, S L Vogl, N A Walton, A T Wassie, S S Watson, J Weselak, S A Wild, E Williams, J Windhager, T Whitmarsh, C Xia, P Zheng, X Zhuang. Nat Commun. 2021 Mar 31;12(1):1998. IF: 14.919.

Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). Swisher EM, Kwan TT, Oza AM, Tinker AV, Ray-Coquard I, Oaknin A, Coleman RL, Aghajanian C, Konecny GE, O’Malley DM, Leary A, Provencher D, Welch S, Chen LM, Wahner Hendrickson AE, Ma L, Ghatage P, Kristeleit RS, Dorigo O, Musafer A, Kaufmann SH, Elvin JA, Lin DI, Chambers SK, Dominy E, Vo LT, Goble S, Maloney L, Giordano H, Harding T, Dobrovic A, Scott CL, Lin KK, McNeish IA. Nat Commun. 2021 May 3;12(1):2487. IF: 14.919.

Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma. Frontzek F, Staiger AM, Zapukhlyak M, Xu W, Bonzheim I, Borgmann V, Sander P, Baptista MJ, Heming JN, Berning P, Wullenkord R, Erdmann T, Lutz M, Veratti P, Ehrenfeld S, Wienand K, Horn H, Goodlad JR, Wilson MR, Anagnostopoulos I, Lamping M, Gonzalez-Barca E, Climent F, Salar A, Castellvi J, Abrisqueta P, Menarguez J, Aldamiz T, Richter J, Klapper W, Tzankov A, Dirnhofer S, Rosenwald A, Mate JL, Tapia G, Lenz P, Miething C, Hartmann W, Chapuy B, Fend F, Ott G, Navarro JT, Grau M, Lenz G. Nat Commun. 2021 Aug 31;12(1):5183. IF: 14.919.

SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade. Romero OA, Vilarrubi A, Alburquerque-Bejar JJ, Gomez A, Andrades A, Trastulli D, Pros E, Setien F, Verdura S, Farré L, Martín-Tejera JF, Llabata P, Oaknin A, Saigi M, Piulats JM, Matias-Guiu X, Medina PP, Vidal A, Villanueva A, Sanchez-Cespedes M. Nat Commun. 2021 Jul 14;12(1):4319. IF: 14.919.

Severe SARS-CoV-2 placenta infection can impact neonatal outcome in the absence of vertical transmission. Cribiù FM, Erra R, Pugni L, Rubio-Perez C, Alonso L, Simonetti S, Croci GA, Serna G, Ronchi A, Pietrasanta C, Lunghi G, Fagnani AM, Piñana M, Matter M, Tzankov A, Terracciano L, Anton A, Ferrazzi E, Ferrero S, Iurlaro E, Seoane J, Nuciforo P. J Clin Invest. 2021 Mar 15;131(6):e145427. IF: 14.808.

Acute kidney injury in patients treated with immune checkpoint inhibitors. Gupta S, Short SAP, Sise ME, Prosek JM, Madhavan SM, Soler MJ, Ostermann M, Herrmann SM, Abudayyeh A, Anand S, Glezerman I, Motwani SS, Murakami N, Wanchoo R, Ortiz-Melo DI, Rashidi A, Sprangers B, Aggarwal V, Malik AB, Loew S, Carlos CA, Chang WT, Beckerman P, Mithani Z, Shah CV, Renaghan AD, Seigneux S, Campedel L, Kitchlu A, Shin DS, Rangarajan S, Deshpande P, Coppock G, Eijgelsheim M, Seethapathy H, Lee MD, Strohbehn IA, Owen DH, Husain M, Garcia-Carro C, Bermejo S, Lumlertgul N, Seylanova N, Flanders L, Isik B, Mamlouk O, Lin JS, Garcia P, Kaghazchi A, Khanin Y, Kansal SK, Wauters E, Chandra S, Schmidt-Ott KM, Hsu RK, Tio MC, Sarvode Mothi S, Singh H, Schrag D, Jhaveri KD, Reynolds KL, Cortazar FB, Leaf DE; ICPi-AKI Consortium Investigators. ICPi-AKI Consortium Investigators; Campedel L, Salem JE, Bagnis CI, Gupta S, Leaf DE, Singh H, Motwani SS, Murakami N, Tio MC, Rahma OE, Mothi SS, Selamet U, Schrag D, Loew S, Schmidt KM, Chang W, Jhaveri KD, Wanchoo R, Khanin Y, Hirsch JS, Sakhiya V, Stalbow D, Wu S, Ortiz DI, Ostermann M, Lumlertgul N, Seylanova N, Flanders L, Cennamo A, Papa S, Rigg A, Shaunak N, Kibbelaar ZA, Benesova K, Deshpande P, Sise ME, Reynolds KL, Seethapathy HS, Lee M, Strohbhen IA, Herrmann SM, Isik B, Glezerman IG, Cortazar FB, Aggarwal V, Chandra S, Prosek JM, Madhavan SM, Owen DH, Husain M, Beckerman P, Mini S, Anand S, Garcia P, Kaghazchi A, Rangarajan S, Shin DS, Cherry G, Carlos CA, Hsu RK, Kisel A, Rashidi A, Kansal SK, Albert N, Carter K, Donley V, Young T, Cigoi H, Seigneux S, Koessler T, Ben EW, Shah CV, Eijgelsheim M, Mithani Z, Pagan JA, Coppock G, Hogan JJ, Abudayyeh A, Mamlouk O, Lin JS, Page V, Kitchlu A, Short SA, Renaghan AD, Gaughan EM, Bilal A, Soler MJ, García C, Bermejo S, Felip E, Muñoz E, Carreras MJ. J Immunother Cancer. 2021 Oct;9(10):e003467. IF: 13.751.

Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM). Gonzalez-Cao M, Puertolas T, Riveiro M, Muñoz-Couselo E, Ortiz C, Paredes R, Podzamczer D, Manzano JL, Molto J, Revollo B, Carrera C, Mateu L, Fancelli S, Espinosa E, Clotet B, Martinez-Picado J, Cerezuela P, Soria A, Marquez I, Mandala M, Berrocal A; Spanish Melanoma Group (GEM). J Immunother Cancer. 2021 Mar;9(3):e001664. IF: 13.751.

Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial. Sierra-Rodero B, Cruz-Bermúdez A, Nadal E, Garitaonaindía Y, Insa A, Mosquera J, Casal-Rubio J, Dómine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, De Castro Carpeño J, Cobo M, López Vivanco G, Del Barco E, Bernabé Caro R, Viñolas N, Barneto Aranda I, Viteri S, Massuti B, Laza-Briviesca R, Casarrubios M, García-Grande A, Romero A, Franco F, Provencio M. J Immunother Cancer. 2021 Aug;9(8):e002804. IF: 13.751.

First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas. Piha-Paul SA, Geva R, Tan TJ, Lim DW, Hierro C, Doi T, Rahma O, Lesokhin A, Luke JJ, Otero J, Nardi L, Singh A, Xyrafas A, Chen X, Mataraza J, Bedard PL. J Immunother Cancer. 2021 Aug;9(8):e002863. IF: 13.751.

Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. Pietrantonio F, Lonardi S, Corti F, Infante G, Elez ME, Fakih M, Jayachandran P, Shah AT, Salati M, Fenocchio E, Salvatore L, Curigliano G, Cremolini C, Ambrosini M, Ros J, Intini R, Nappo F, Damian S, Morano F, Fucà G, Overman M, Miceli R. J Immunother Cancer. 2021 Aug;9(8):e003370. IF: 13.751.

Safety and activity of the TGFß receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer. Melisi D, Oh DY, Hollebecque A, Calvo E, Varghese A, Borazanci E, Macarulla T, Merz V, Zecchetto C, Zhao Y, Gueorguieva I, Man M, Gandhi L, Estrem ST, Benhadji KA, Lanasa MC, Avsar E, Guba SC, Garcia-Carbonero R. J Immunother Cancer. 2021 Mar;9(3):e002068. IF: 13.751.

Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score. Dettorre GM, Dolly S, Loizidou A, Chester J, Jackson A, Mukherjee U, Zambelli A, Aguilar-Company J, Bower M, Sng CCT, Salazar R, Bertuzzi A, Brunet J, Mesia R, Sita-Lumsden A, Seguí E, Biello F, Generali D, Grisanti S, Seeva P, Rizzo G, Libertini M, Maconi A, Moss C, Russell B, Harbeck N, Vincenzi B, Bertulli R, Ottaviani D, Liñan R, Marrari A, Carmona-García MC, Chopra N, Tondini CA, Mirallas O, Tovazzi V, Fotia V, Cruz CA, Saoudi-Gonzalez N, Felip E, Roqué A, Lee AJX, Newsom-Davis T, García-Illescas D, Reyes R, Wong YNS, Ferrante D, Scotti L, Marco-Hernández J, Ruiz-Camps I, Patriarca A, Rimassa L, Chiudinelli L, Franchi M, Santoro A, Prat A, Gennari A, Van Hemelrijck M, Tabernero J, Diamantis N, Pinato DJ; OnCovid study group. J Immunother Cancer. 2021 Mar;9(3):e002277. IF: 13.751.

Association of Obesity with Breast Cancer Outcome in Relation to Cancer Subtypes: A Meta-Analysis. Lohmann AE, Soldera SV, Pimentel I, Ribnikar D, Ennis M, Amir E, Goodwin PJ. J Natl Cancer Inst. 2021 Nov 2;113(11):1465-1475. IF: 13.506.

EGFR Amplification in Metastatic Colorectal Cancer. Randon G, Yaeger R, Hechtman JF, Manca P, Fucà G, Walch H, Lee J, Élez E, Seligmann J, Mussolin B, Pagani F, Germani MM, Ambrosini M, Rossini D, Ratti M, Salvà F, Richman SD, Wood H, Nanjangud G, Gloghini A, Milione M, Bardelli A, de Braud F, Morano F, Cremolini C, Pietrantonio F. J Natl Cancer Inst. 2021 Nov 2;113(11):1561-1569. IF: 13.506.

The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32. Pimentel I, Chen BE, Lohmann AE, Ennis M, Ligibel J, Shepherd L, Hershman DL, Whelan T, Stambolic V, Mayer I, Hobday T, Lemieux J, Thompson A, Rastogi P, Gelmon K, Rea D, Rabaglio M, Ellard S, Mates M, Bedard P, Pitre L, Vandenberg T, Dowling RJO, Parulekar W, Goodwin PJ. J Natl Cancer Inst. 2021 Feb 1;113(2):192-198. IF: 13.506.

The Global Landscape of Treatment Standards for Breast Cancer. Trapani D, Douillard JY, Winer EP, Burstein H, Carey LA, Cortes J, Lopes G, Gralow JR, Gradishar WJ, Magrini N, Curigliano G, Ilbawi AM. The Global Landscape of Treatment Standards for Breast Cancer. J Natl Cancer Inst. 2021 Sep 4;113(9):1143-1155. IF: 13.506.

The Transcription Factor SLUG Uncouples Pancreatic Cancer Progression from the RAF-MEK1/2-ERK1/2 Pathway. Bilal F, Arenas EJ, Pedersen K, Martínez-Sabadell A, Nabet B, Guruceaga E, Vicent S, Tabernero J, Macarulla T, Arribas J. Cancer Res. 2021 Jul 15;81(14):3849-3861. IF: 12.701.

Widespread Repression of Gene Expression in Cancer by a Wnt/ß-Catenin/MAPK Pathway. Harmston N, Lim JYS, Arqués O, Palmer HG, Petretto E, Virshup DM, Madan B. Cancer Res. 2021 Jan 15;81(2):464-475. IF: 12.701.

Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer. Vathiotis IA, Moutafi MK, Divakar P, Aung TN, Qing T, Fernandez A, Yaghoobi V, El-Abed S, Wang Y, Guillaume S, Nuciforo P, Huober J, Di Cosimo S, Kim SB, Harbeck N, Gomez H, Shafi S, Syrigos KN, Fountzilas G, Sotiriou C, Pusztai L, Warren S, Rimm DL. Clin Cancer Res. 2021 Nov 15;27(22):6156-6163. IF: 12.531.

Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non-Hodgkin Lymphoma. Ribeiro ML, Reyes-Garau D, Vinyoles M, Profitós Pelejà N, Santos JC, Armengol M, Fernández-Serrano M, Sedó Mor A, Bech-Serra JJ, Blecua P, Musulen E, De La Torre C, Miskin H, Esteller M, Bosch F, Menéndez P, Normant E, Roué G. Clin Cancer Res. 2021 Dec 1;27(23):6591-6601. IF: 12.531.

Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer. Saura C, Matito J, Oliveira M, Wildiers H, Brufksy AM, Waters SH, Hurvitz SA, Moy B, Kim SB, Gradishar WJ, Queiroz GS, Cronemberger E, Wallweber GJ, Bebchuk J, Keyvanjah K, Lalani AS, Bryce R, Vivancos A, Eli LD, Delaloge S. Clin Cancer Res. 2021 Nov 1;27(21):5818-5827. IF: 12.531.

Characterizing CDK12-Mutated Prostate Cancers. Rescigno P, Gurel B, Pereira R, Crespo M, Rekowski J, Rediti M, Barrero M, Mateo J, Bianchini D, Messina C, Fenor de la Maza MD, Chandran K, Carmichael J, Guo C, Paschalis A, Sharp A, Seed G, Figueiredo I, Lambros M, Miranda S, Ferreira A, Bertan C, Riisnaes R, Porta N, Yuan W, Carreira S, de Bono JS. Clin Cancer Res. 2021 Jan 15;27(2):566-574. IF: 12.531.

Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study. Bauer S, Heinrich MC, George S, Zalcberg JR, Serrano C, Gelderblom H, Jones RL, Attia S, D’Amato G, Chi P, Reichardt P, Meade J, Su Y, Ruiz-Soto R, Blay JY, von Mehren M, Schöffski P. Clin Cancer Res. 2021 Dec 1;27(23):6333-6342. IF: 12.531.

Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD1402 Trial. Vidal J, Casadevall D, Bellosillo B, Pericay C, Garcia-Carbonero R, Losa F, Layos L, Alonso V, Capdevila J, Gallego J, Vera R, Salud A, Martin-Richard M, Nogué M, Cillán E, Maurel J, Faull I, Raymond V, Fernández-Martos C, Montagut C. Clin Cancer Res. 2021 May 15;27(10):2890-2898. IF: 12.531.

Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for RAS Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study. Kagawa Y, Elez E, García-Foncillas J, Bando H, Taniguchi H, Vivancos A, Akagi K, García A, Denda T, Ros J, Nishina T, Baraibar I, Komatsu Y, Ciardiello D, Oki E, Kudo T, Kato T, Yamanaka T, Tabernero J, Yoshino T. Clin Cancer Res. 2021 May 1;27(9):2515-2522. IF: 12.531.

Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial. Venet D, Rediti M, Maetens M, Fumagalli D, Brown DN, Majjaj S, Salgado R, Pusztai L, Harbeck N, El-Abed S, Wang Y, Saura C, Gomez H, Semiglazov VF, de Azambuja E, Huober J, Nuciforo P, Di Cosimo S, Piccart M, Loi S, Rothé F, Sotiriou C. Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial. Clin Cancer Res. 2021 Oct 15;27(20):5607-5618. IF: 12.531.

Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10. Wainberg ZA, Fuchs CS, Tabernero J, Shitara K, Muro K, Van Cutsem E, Bang YJ, Chung HC, Yamaguchi K, Varga E, Chen JS, Hochhauser D, Thuss-Patience P, Al-Batran SE, Garrido M, Kher U, Shih CS, Shah S, Bhagia P, Chao J. Clin Cancer Res. 2021 Apr 1;27(7):1923-1931. IF: 12.531.

In Memoriam: José Baselga’s Journey in Cancer Medicine. Kumar R, Hortobagy GN, Albanell J, Arribas J, Norton L. Clin Cancer Res. 2021 Jun 15;27(12):3499-3502. IF: 12.531.

Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy. Pascual T, Fernandez-Martinez A, Tanioka M, Dieci MV, Pernas S, Gavila J, Guarnieri V, Cortes J, Villagrasa P, Chic N, Vidal M, Adamo B, Muñoz M, Griguolo G, Llombart A, Conte P, Oliveira M, Conte B, Paré L, Galvan P, Carey LA, Perou CM, Prat A. Clin Cancer Res. 2021 Jun 1;27(11):3116-3125. IF: 12.531.

Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis. Pizzamiglio S, Ciniselli CM, Triulzi T, Gargiuli C, De Cecco L, de Azambuja E, Fumagalli D, Sotiriou C, Harbeck N, Izquierdo M, Nuciforo P, Huober J, Cappelletti V, Cinieri S, Piccart M, Daidone MG, Pruneri G, Colombo MP, Tagliabue E, Verderio P, Di Cosimo S. Clin Cancer Res. 2021 Dec 1;27(23):6307-6313. IF: 12.531.

Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma. Kiyokawa J, Kawamura Y, Ghouse SM, Acar S, Barçın E, Martínez-Quintanilla J, Martuza RL, Alemany R, Rabkin SD, Shah K, Wakimoto H. Clin Cancer Res. 2021 Feb 1;27(3):889-902. IF: 12.531.

Molecular Subtyping Combined with Biological Pathway Analyses to Study Regorafenib Response in Clinically Relevant Mouse Models of Colorectal Cancer. Lafferty A, O’Farrell AC, Migliardi G, Khemka N, Lindner AU, Sassi F, Zanella ER, Salvucci M, Vanderheyden E, Modave E, Boeckx B, Halang L, Betge J, Ebert MPA, Dicker P, Argilés G, Tabernero J, Dienstmann R, Medico E, Lambrechts D, Bertotti A, Isella C, Trusolino L, Prehn JHM, Byrne AT. Clin Cancer Res. 2021 Nov 1;27(21):5979-5992. IF: 12.531.

Motixafortide and pembrolizumab combined to nanoliposomal irinotecan, fluorouracil, and folinic acid in metastatic pancreatic cancer: The COMBAT/ KEYNOTE-202 trial. Bockorny B, Macarulla T, Semenisty V, Borazanci E, Feliu J, Ponz-Sarvise M, Abad DG, Oberstein P, Alistar A, Muñoz A, Geva R, Guillén-Ponce C, Fernandez MS, Peled A, Chaney M, Gliko-Kabir I, Shemesh-Darvish L, Ickowicz D, Sorani E, Kadosh S, Vainstein-Haras A, Hidalgo M. Clin Cancer Res. 2021 Sep 15;27(18):5020-5027. IF: 12.531.

Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study. Turner NC, Balmaña J, Poncet C, Goulioti T, Tryfonidis K, Honkoop AH, Zoppoli G, Razis E, Johannsson OT, Colleoni M, Tutt AN, Audeh W, Ignatiadis M, Mailliez A, Trédan O, Musolino A, Vuylsteke P, Juan-Fita MJ, Macpherson IRJ, Kaufman B, Manso L, Goldstein LJ, Ellard SL, Láng I, Jen KY, Adam V, Litière S, Erban J, Cameron DA; BRAVO Steering Committee and the BRAVO investigators. Clin Cancer Res. 2021 Oct 15;27(20):5482-5491. IF: 12.531.

OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors. Gutierrez M, Moreno V, Heinhuis KM, Olszanski AJ, Spreafico A, Ong M, Chu Q, Carvajal RD, Trigo J, Ochoa de Olza M, Provencio M, De Vos FY, De Braud F, Leong S, Lathers D, Wang R, Ravindran P, Feng Y, Aanur P, Melero I. Clin Cancer Res. 2021 Jan 15;27(2):460-472. IF: 12.531.

Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers. Jhaveri K, Chang MT, Juric D, Saura C, Gambardella V, Melnyk A, Patel MR, Ribrag V, Ma CX, Aljumaily R, Bedard PL, Sachdev JC, Dunn L, Won H, Bond J, Jones S, Savage HM, Scaltriti M, Wilson TR, Wei MC, Hyman DM. Clin Cancer Res. 2021 Jan 15;27(2):447-459. IF: 12.531.

Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma. Hollebecque A, Salvagni S, Plummer R, Isambert N, Niccoli P, Capdevila J, Curigliano G, Moreno V, Martin-Romano P, Baudin E, Arias M, Mora S, de Alvaro J, Di Martino J, Parra-Palau JL, Sánchez-Pérez T, Aronchik I, Filvaroff EH, Lamba M, Nikolova Z, de Bono JS. Clin Cancer Res. 2021 Jan 15;27(2):438-446. IF: 12.531.

Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer. Guardia C, Bianchini G, Arpí-LLucià O, Menendez S, Casadevall D, Galbardi B, Dugo M, Servitja S, Montero JC, Soria-Jiménez L, Sabbaghi M, Peña R, Madoz-Gúrpide J, Lloveras B, Lluch A, Eroles P, Arribas J, Pandiella A, Gianni L, Rojo F, Rovira A, Albanell J. Clin Cancer Res. 2021 Sep 15;27(18):5096-5108. IF: 12.531.

Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy. Casarrubios M, Cruz-Bermúdez A, Nadal E, Insa A, García Campelo MDR, Lázaro M, Dómine M, Majem M, Rodríguez-Abreu D, Martínez-Martí A, de Castro-Carpeño J, Cobo M, López-Vivanco G, Del Barco E, Bernabé Caro R, Viñolas N, Barneto Aranda I, Viteri S, Massuti B, Barquín M, Laza-Briviesca R, Sierra-Rodero B, Parra ER, Sanchez-Espiridion B, Rocha P, Kadara H, Wistuba II, Romero A, Calvo V, Provencio M. Clin Cancer Res. 2021 Nov 1;27(21):5878-5890. IF: 12.531.

Unmasking New Promises: Expanding the Antigen Landscape For Antibody-Drug Conjugates. Oberoi HK, Garralda E. Clin Cancer Res. 2021 Aug 15;27(16):4459-4461. IF: 12.531.

WORLD CANCER RESEARCH DAY: A Call to Action for a Coordinated International Research Effort to Prevent, Diagnose, and Treat Cancer. Puyol M, Seoane J, Aguilar E, Vozza LB, Orbe I, Crawford KH, Fernández A, Bray F, Johnson SE, Gopal S. Clin Cancer Res. 2021 Feb 15;27(4):963-966. IF: 12.531.

Neuron type-specific increase in lamin B1 contributes to nuclear dysfunction in Huntington’s disease. Alcalá-Vida R, Garcia-Forn M, Castany-Pladevall C, Creus-Muncunill J, Ito Y, Blanco E, Golbano A, Crespí-Vázquez K, Parry A, Slater G, Samarajiwa S, Peiró S, Di Croce L, Narita M, Pérez-Navarro E. EMBO Mol Med. 2021 Feb 5;13(2):e12105. IF: 12.137.

Checkpoint inhibitors in metastatic papillary renal cell carcinoma. de Vries-Brilland M, McDermott DF, Suárez C, Powles T, Gross-Goupil M, Ravaud A, Flippot R, Escudier B, Albigès L. Cancer Treat Rev. 2021 Sep;99:102228. IF: 12.111.

PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations. Vanacker H, Harter P, Labidi-Galy SI, Banerjee S, Oaknin A, Lorusso D, Ray-Coquard I. Cancer Treat Rev. 2021 Sep;99:102255. IF: 12.111.

Integrated requirement of non-specific and sequence-specific DNA binding in Myc-driven transcription. Pellanda P, Dalsass M, Filipuzzi M, Loffreda A, Verrecchia A, Castillo Cano V, Thabussot H, Doni M, Morelli MJ, Soucek L, Kress T, Mazza D, Mapelli M, Beaulieu ME, Amati B, Sabò A. EMBO J. 2021 May 17;40(10):e105464. IF: 11.598.

COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. Ljungman P, de la Camara R, Mikulska M, Tridello G, Aguado B, Zahrani MA, Apperley J, Berceanu A, Bofarull RM, Calbacho M, Ciceri F, Lopez-Corral L, Crippa C, Fox ML, Grassi A, Jimenez MJ, Demir SK, Kwon M, Llamas CV, Lorenzo JLL, Mielke S, Orchard K, Porras RP, Vallisa D, Xhaard A, Knelange NS, Cedillo A, Kröger N, Piñana JL, Styczynski J. Leukemia. 2021 Oct;35(10):2885-2894. IF: 11.528.

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Barbui T, Vannucchi AM, Alvarez-Larran A, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Ferrari A, Rossi G, Elli E, Andrade-Campos MM, Kabat MG, Kiladjian JJ, Palandri F, Benevolo G, Garcia-Gutierrez V, Fox ML, Foncillas MA, Morcillo CM, Rumi E, Osorio S, Papadopoulos P, Bonifacio M, Cervantes KSQ, Serrano MS, Carreno-Tarragona G, Sobas MA, Lunghi F, Patriarca A, Elorza BN, Angona A, Mazo EM, Koschmieder S, Ruggeri M, Cuevas B, Hernandez-Boluda JC, Abadia EL, Cirici BX, Guglielmelli P, Garrote M, Cattaneo D, Daffini R, Cavalca F, Bellosillo B, Benajiba L, Curto-Garcia N, Bellini M, Betti S, De Stefano V, Harrison C, Rambaldi A. Leukemia. 2021 Feb;35(2):485-493. IF: 11.528.

Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis. Cuenca I, Alameda D, Sanchez-Vega B, Gomez-Sanchez D, Alignani D, Lasa M, Onecha E, Lecumberri R, Prosper F, Ocio EM, González ME, García de Coca A, De La Rubia J, Gironella M, Palomera L, Oriol A, Casanova M, Cabañas V, Taboada F, Pérez-Montaña A, De Arriba F, Puig N, Carreño-Tarragona G, Barrio S, Enrique de la Puerta J, Ramirez-Payer A, Krsnik I, Bargay JJ, Lahuerta JJ, Mateos MV, San-Miguel JF, Paiva B, Martinez-Lopez J. Leukemia. 2021 Jan;35(1):245-249. IF: 11.528.

Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study. Visco C, Di Rocco A, Evangelista A, Quaglia FM, Tisi MC, Morello L, Zilioli VR, Rusconi C, Hohaus S, Sciarra R, Re A, Tecchio C, Chiappella A, Marin-Niebla A, McCulloch R, Gini G, Perrone T, Nassi L, Pennese E, Stefani PM, Cox MC, Bozzoli V, Fabbri A, Polli V, Ferrero S, Celis MIA, Sica A, Petrucci L, Arcaini L, Rule S, Krampera M, Vitolo U, Balzarotti M. Leukemia. 2021 Mar;35(3):787-795. IF: 11.528.

Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group. Spanjaart AM, Ljungman P, de La Camara R, Tridello G, Ortiz-Maldonado V, Urbano-Ispizua A, Barba P, Kwon M, Caballero D, Sesques P, Bachy E, Di Blasi R, Thieblemont C, Calkoen F, Mutsaers P, Maertens J, Giannoni L, Nicholson E, Collin M, Vaz CP, Metafuni E, Martinez-Lopez J, Dignan FL, Ribera JM, Nagler A, Folber F, Sanderson R, Bloor A, Ciceri F, Knelange N, Ayuk F, Kroger N, Kersten MJ, Mielke S. Leukemia. 2021 Dec;35(12):3585-3588. IF: 11.528.

Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. Wieduwilt MJ, Stock W, Advani A, Luger S, Larson RA, Tallman M, Appelbaum F, Zhang MJ, Bo-Subait K, Wang HL, Bhatt VR, Dholaria B, Eapen M, Hamadani M, Jamy O, Prestidge T, Pulsipher M, Ritchie D, Rizzieri D, Sharma A, Barba P, Sandmaier BM, de Lima M, Kebriaei P, Litzow M, Saber W, Weisdorf D. Leukemia. 2021 Jul;35(7):2076-2085. IF: 11.528.

COVID-19 in melanoma patients: Results of the Spanish Melanoma Group Registry, GRAVID study. Gonzalez-Cao M, Carrera C, Rodriguez Moreno JF, Rodríguez-Jiménez P, Basa MA, Ochoa RF, Puertolas T, Muñoz-Couselo E, Manzano JL, Marquez-Rodas I, Martín-Liberal J, Soria A, Criado PL, Garcia-Castaño A, Boada A, Ayala de Miguel P, Puig S, Crespo G, Fra PL, Zamora CA, Rodríguez MF, Valles L, Drozdowskyj A, Maldonado-Seral C, Gardeazabal J, Villalobos L, Rosell R, Fernandez-Morales LA, Rodrigo A, Viteri S, Provencio M, Berrocal A; Spanish Melanoma Group (GEM). J Am Acad Dermatol. 2021 May;84(5):1412-1415. IF: 11.527.

Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial. Laza-Briviesca R, Cruz-Bermúdez A, Nadal E, Insa A, García-Campelo MDR, Huidobro G, Dómine M, Majem M, Rodríguez-Abreu D, Martínez-Martí A, De Castro Carpeño J, Cobo M, López Vivanco G, Del Barco E, Bernabé Caro R, Viñolas N, Barneto Aranda I, Viteri S, Massuti B, Casarrubios M, Sierra-Rodero B, Tarín C, García-Grande A, Haymaker C, Wistuba II, Romero A, Franco F, Provencio M. Clin Transl Med. 2021 Jul;11(7):e491. IF: 11.492.

A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. Ligero M, Garcia-Ruiz A, Viaplana C, Villacampa G, Raciti MV, Landa J, Matos I, Martin-Liberal J, Ochoa-de-Olza M, Hierro C, Mateo J, Gonzalez M, Morales-Barrera R, Suarez C, Rodon J, Elez E, Braña I, Muñoz-Couselo E, Oaknin A, Fasani R, Nuciforo P, Gil D, Rubio-Perez C, Seoane J, Felip E, Escobar M, Tabernero J, Carles J, Dienstmann R, Garralda E, Perez-Lopez R. Radiology. 2021 Apr;299(1):109-119. IF: 11.105.

Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19. Barbui T, De Stefano V, Alvarez-Larran A, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Ferrari A, Cancelli V, Elli EM, Andrade-Campos MM, Kabat MG, Kiladjian JJ, Palandri F, Benevolo G, Garcia-Gutierrez V, Fox ML, Foncillas MA, Morcillo CM, Rumi E, Osorio S, Papadopoulos P, Bonifacio M, Cervantes KSQ, Serrano MS, Carreno-Tarragona G, Sobas MA, Lunghi F, Patriarca A, Elorza BN, Angona A, Mazo EM, Koschmieder S, Carli G, Cuevas B, Hernandez-Boluda JC, Abadia EL, Cirici BX, Guglielmelli P, Garrote M, Cattaneo D, Daffini R, Cavalca F, Bellosillo B, Benajiba L, Curto-Garcia N, Bellini M, Betti S, Harrison C, Rambaldi A, Vannucchi AM. Blood Cancer J. 2021 Feb 4;11(2):21. IF: 11.037.

Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial. Puig N, Hernández MT, Rosiñol L, González E, de Arriba F, Oriol A, González-Calle V, Escalante F, de la Rubia J, Gironella M, Ríos R, García-Sánchez R, Arguiñano JM, Alegre A, Martín J, Gutiérrez NC, Calasanz MJ, Martín ML, Couto MDC, Casanova M, Arnao M, Pérez-Persona E, Garzón S, González MS, Martín-Sánchez G, Ocio EM, Coleman M, Encinas C, Vale AM, Teruel AI, Cortés-Rodríguez M, Paiva B, Cedena MT, San-Miguel JF, Lahuerta JJ, Bladé J, Niesvizky R, Mateos MV. Blood Cancer J. 2021 May 21;11(5):101. IF: 11.037.

Long-term follow-up of recovered MPN patients with COVID-19. Barbui T, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Rossi G, Harrison C, Alvarez-Larran A, Elli EM, Kiladjian JJ, Gasior Kabat M, Marin Sanchez A, Palandri F, Andrade-Campos MM, Vannucchi AM, Carreno-Tarragona G, Papadopoulos P, Quiroz Cervantes K, Angeles Foncillas M, Fox ML, Sagues Serrano M, Rumi E, Osorio S, Benevolo G, Patriarca A, Navas Elorza B, Garcia-Gutierrez V, Magro Mazo E, Lunghi F, Bonifacio M, De Stefano V, Hernandez-Boluda JC, Lopez Abadia E, Angona A, Xicoy Cirici B, Ruggeri M, Koschmieder S, Sobas MA, Cuevas B, Cattaneo D, Daffini R, Bellini M, Curto-Garcia N, Garrote M, Cavalca F, Benajiba L, Bellosillo B, Guglielmelli P, Borsani O, Betti S, Salmoiraghi S, Rambaldi A. Blood Cancer J. 2021 Jun 16;11(6):115. IF: 11.037.

Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse. Bobillo S, Joffe E, Sermer D, Mondello P, Ghione P, Caron PC, Hamilton A, Hamlin PA, Horwitz SM, Kumar A, Matasar MJ, Batlevi CL, Moskowitz A, Noy A, Owens CN, Palomba ML, Straus D, von Keudell G, Dogan A, Zelenetz AD, Seshan VE, Younes A. Blood Cancer J. 2021 Jun 16;11(6):113. IF: 11.037.

Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora’s box. Tarantino P, Prat A, Cortes J, Cardoso F, Curigliano G. Biochim Biophys Acta Rev Cancer. 2021 Jan;1875(1):188487. IF: 10.680.

The long journey to bring a Myc inhibitor to the clinic. Whitfield JR, Soucek L. J Cell Biol. 2021 Aug 2;220(8):e202103090. IF: 10.539.

Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes. Garcia-Manero G, Diez-Campelo M, Vellenga E, Jacoby MA, Merchan B, Breems D, Cortelezzi A, Doronin V, Gomez V, Beckers M, Della Porta MG, Varsos H, Xiu L, DeAngelis N, Nnane I, Rose E, van Eygen K. Am J Hematol. 2021 Apr 1;96(4):E111-E114. IF: 10.047.

Natural gene therapy by reverse mosaicism leads to improved hematology in Fanconi anemia patients. Ramírez MJ, Pujol R, Trujillo-Quintero JP, Minguillón J, Bogliolo M, Río P, Navarro S, Casado JA, Badell I, Carrasco E, Balmaña J, Català A, Sevilla J, Beléndez C, Argilés B, López M, Díaz de Heredia C, Rao G, Nicoletti E, Schwartz JD, Bueren JA, Surrallés J. Natural gene therapy by reverse mosaicism leads to improved hematology in Fanconi anemia patients. Am J Hematol. 2021 Aug 1;96(8):989-999. IF: 10.047.

Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas. Bobillo S, Crespo M, Escudero L, Mayor R, Raheja P, Carpio C, Rubio-Perez C, Tazón-Vega B, Palacio C, Carabia J, Jiménez I, Nieto JC, Montoro J, Martínez-Ricarte F, Castellvi J, Simó M, Puigdefàbregas L, Abrisqueta P, Bosch F, Seoane J. Haematologica. 2021 Feb 1;106(2):513-521. IF: 9.941.

Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. Lazaryan A, Dolan M, Zhang MJ, Wang HL, Kharfan-Dabaja MA, Marks DI, Bejanyan N, Copelan E, Majhail NS, Waller EK, Chao N, Prestidge T, Nishihori T, Kebriaei P, Inamoto Y, Hamilton B, Hashmi SK, Kamble RT, Bacher U, Hildebrandt GC, Stiff PJ, McGuirk J, Aldoss I, Beitinjaneh AM, Muffly L, Vij R, Olsson RF, Byrne M, Schultz KR, Aljurf M, Seftel M, Savoie ML, Savani BN, Verdonck LF, Cairo MS, Hossain N, Bhatt VR, Frangoul HA, Abdel-Azim H, Al Malki M, Munker R, Rizzieri D, Khera N, Nakamura R, Ringdén O, Van der Poel M, Murthy HS, Liu H, Mori S, De Oliveira S, Bolaños-Meade J, Elsawy M, Barba P, et al. Haematologica. 2021 Aug 1;106(8):2295-2296. IF: 9.941.

Interleukin-1 receptor associated kinase 1/4 and bromodomain and extra-terminal inhibitions converge on NF-kB blockade and display synergistic antitumoral activity in activated B-cell subset of diffuse large B-cell lymphoma with MYD88 L265P mutation. Dlouhy I, Armengol M, Recasens-Zorzo C, Ribeiro ML, Pérez-Galán P, Bosch F, López-Guillermo A, Roué G. Haematologica. 2021 Oct 1;106(10):2749-2753. IF: 9.941.

Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Duell J, Maddocks KJ, González-Barca E, Jurczak W, Liberati AM, De Vos S, Nagy Z, Obr A, Gaidano G, Abrisqueta P, Kalakonda N, André M, Dreyling M, Menne T, Tournilhac O, Augustin M, Rosenwald A, Dirnberger-Hertweck M, Weirather J, Ambarkhane S, Salles G. Haematologica. 2021 Sep 1;106(9):2417-2426. IF: 9.941.

A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors. Di Giulio S, Colicchia V, Pastorino F, Pedretti F, Fabretti F, Nicolis di Robilant V, Ramponi V, Scafetta G, Moretti M, Licursi V, Belardinilli F, Peruzzi G, Infante P, Goffredo BM, Coppa A, Canettieri G, Bartolazzi A, Ponzoni M, Giannini G, Petroni M. Oncogene. 2021 Oct;40(43):6143-6152. IF: 9.867.

E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumor. García-Valverde A, Rosell J, Sayols S, Gómez-Peregrina D, Pilco-Janeta DF, Olivares-Rivas I, de Álava E, Maurel J, Rubió-Casadevall J, Esteve A, Gut M, Valverde C, Barretina J, Carles J, Demetri GD, Fletcher JA, Arribas J, Serrano C. Oncogene. 2021 Dec;40(48):6614-6626. IF: 9.867.

A first-in-human phase I/Ib dose-escalation clinical trial of the autophagy inducer ABTL0812 in patients with advanced solid tumours. Vidal L, Victoria I, Gaba L, Martín MG, Brunet M, Colom H, Cortal M, Gómez-Ferrería M, Yeste-Velasco M, Perez A, Rodon J, Sohal DPS, Lizcano JM, Domènech C, Alfón J, Gascón P. Eur J Cancer. 2021 Mar;146:87-94. IF: 9.162.

Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer. Lozano R, Salles DC, Sandhu S, Aragón IM, Thorne H, López-Campos F, Rubio-Briones J, Gutierrez-Pecharroman AM, Maldonado L, di Domenico T, Sanz A, Prieto JD, García I, Pacheco MI, Garcés T, Llacer C, Romero-Laorden N, Zambrana F, López-Casas PP, Lorente D, Mateo J, Pritchard CC, Antonarakis ES, Olmos D, Lotan TL, Castro E. Eur J Cancer. 2021 Apr;147:74-83. IF: 9.162.

Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. Jones RL, Serrano C, von Mehren M, George S, Heinrich MC, Kang YK, Schöffski P, Cassier PA, Mir O, Chawla SP, Eskens FALM, Rutkowski P, Tap WD, Zhou T, Roche M, Bauer S. Eur J Cancer. 2021 Mar;145:132-142. IF: 9.162.

Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis. Gelmon KA, Fasching PA, Couch FJ, Balmaña J, Delaloge S, Labidi-Galy I, Bennett J, McCutcheon S, Walker G, O’Shaughnessy J; Collaborating Investigators. Eur J Cancer. 2021 Jul;152:68-77. IF: 9.162.

Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Ambrosini V, Kunikowska J, Baudin E, Bodei L, Bouvier C, Capdevila J, Cremonesi M, de Herder WW, Dromain C, Falconi M, Fani M, Fanti S, Hicks RJ, Kabasakal L, Kaltsas G, Lewington V, Minozzi S, Cinquini M, Öberg K, Oyen WJG, O’Toole D, Pavel M, Ruszniewski P, Scarpa A, Strosberg J, Sundin A, Taïeb D, Virgolini I, Wild D, Herrmann K, Yao J. Eur J Cancer. 2021 Mar;146:56-73. IF: 9.162.

Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study. Fazio N, Gervaso L, Halfdanarson TR, La Salvia A, Hofland J, Hernando J, Sonbol MB, Garcia-Carbonero R, Capdevila J, de Herder WW, Koumarianou A, Kaltsas G, Rossi M, Grozinsky-Glasberg S, Oleinikov K, Boselli S, Tamayo D, Bagnardi V, Laffi A, Rubino M, Spada F. Eur J Cancer. 2021 Sep;154:246-252. IF: 9.162.

Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study. Pinato DJ, Scotti L, Gennari A, Colomba-Blameble E, Dolly S, Loizidou A, Chester J, Mukherjee U, Zambelli A, Aguilar-Company J, Bower M, Galazi M, Salazar R, Bertuzzi A, Brunet J, Mesia R, Sita-Lumsden A, Colomba J, Pommeret F, Seguí E, Biello F, Generali D, Grisanti S, Rizzo G, Libertini M, Moss C, Evans JS, Russell B, Wuerstlein R, Vincenzi B, Bertulli R, Ottaviani D, Liñan R, Marrari A, Carmona-García MC, Sng CCT, Tondini C, Mirallas O, Tovazzi V, Fotia V, Cruz CA, Saoudi-Gonzalez N, Felip E, R Lloveras A, Lee AJX, Newsom-Davis T, Sharkey R, Chung C, García-Illescas D, Reyes R, Sophia Wong YN, Ferrante D, Marco-Hernández J, Ruiz-Camps I, Gaidano G, Patriarca A, Sureda A, Martinez-Vila C, Sanchez de Torre A, Rimassa L, Chiudinelli L, Franchi M, Krengli M, Santoro A, Prat A, Tabernero J, V Hemelrijck M, Diamantis N, Cortellini A; OnCovid study group. Eur J Cancer. 2021 Jun;150:190-202. IF: 9.162.

Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results. Pavel M, Ćwikła JB, Lombard-Bohas C, Borbath I, Shah T, Pape UF, Capdevila J, Panzuto F, Truong Thanh XM, Houchard A, Ruszniewski P. Eur J Cancer. 2021 Nov;157:403-414. IF: 9.162.

EORTC-QLQ-C30 and SKINDEX-29 measurement of health-related quality of life in patients with mycosis fungoides and Sézary syndrome: real-world data in Spanish patients (MICADOS study). Del Mar Onteniente Gomis M, Matilla BN, Pujol Vallverdú RM, Escudero AC, Paz IZ, Barca EG, Montserrat CM, Andújar MM, Ferriols AP, Curto CR, de Misa Cabrera RF, Gil MH, Niebla AM, Rios Rull PJ, De la Cruz Vicente F, Izu Belloso RM, García-Sancho AM, Parera Amer ME, Mascuñano RC, Ramón Quiles MD, Carreres AS, Del Campo García R, Machan S, Ester PV, Garnelo JB, López BS, Ortiz Romero PL. Eur J Cancer. 2021 Oct;156 Suppl 1:S29-S30. IF: 9.162.

First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study. Wainberg ZA, Bekaii-Saab T, Boland PM, Dayyani F, Macarulla T, Mody K, Belanger B, Maxwell F, Moore Y, Thiagalingam A, Wang T, Zhang B, Dean A. Eur J Cancer. 2021 Jul;151:14-24. IF: 9.162.

Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer. Quintana Á, Peg V, Prat A, Moliné T, Villacampa G, Paré L, Galván P, Dientsmann R, Schmid P, Curigliano G, Muñoz-Couselo E, Perez-García J, Marti M, Blanco-Heredia J, Anjos CD, Vazquez M, De Mattos-Arruda L, Cortés J. Eur J Cancer. 2021 May;148:134-145. IF: 9.162.

Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase II trial. Pérez-García JM, Llombart-Cussac A, G Cortés M, Curigliano G, López-Miranda E, Alonso JL, Bermejo B, Calvo L, Carañana V, de la Cruz Sánchez S, M Vázquez R, Prat A, R Borrego M, Sampayo-Cordero M, Seguí-Palmer MÁ, Soberino J, Malfettone A, Schmid P, Cortés J. Eur J Cancer. 2021 May;148:382-394. IF: 9.162.

Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial. Rivera F, Izquierdo-Manuel M, García-Alfonso P, Martínez de Castro E, Gallego J, Limón ML, Alsina M, López L, Galán M, Falcó E, Manzano JL, González E, Muñoz-Unceta N, López C, Aranda E, Fernández E, Jorge M, Jiménez-Fonseca P. Eur J Cancer. 2021 Mar;145:158-167. IF: 9.162.

Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials. Matos I, Villacampa G, Hierro C, Martin-Liberal J, Berché R, Pedrola A, Braña I, Azaro A, Vieito M, Saavedra O, Gardeazabal I, Hernando-Calvo A, Alonso G, Galvao V, Ochoa de Olza M, Ros J, Viaplana C, Muñoz-Couselo E, Elez E, Rodon J, Saura C, Macarulla T, Oaknin A, Carles J, Felip E, Tabernero J, Dienstmann R, Garralda E. Eur J Cancer. 2021 Sep;155:168-178. IF: 9.162.

Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era. Rodriguez-Freixinos V, Capdevila J, Pavel M, Thawer A, Baudin E, O’Toole D, Herrmann K, Welin S, Grozinsky-Glasberg S, de Herder WW, Valle JW, Herman J, Kolarova T, Bouvier C, Falconi M, Ferone D, Singh S. Eur J Cancer. 2021 Feb;144:200-214. IF: 9.162.

Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials. Sinicrope FA, Chakrabarti S, Laurent-Puig P, Huebner L, Smyrk TC, Tabernero J, Mini E, Goldberg RM, Zaanan A, Folprecht G, Van Laethem JL, Le Malicot K, Shi Q, Alberts SR, Taieb J. Eur J Cancer. 2021 Feb;144:101-112. IF: 9.162.

Radical radiotherapy for paediatric solid tumour metastases: An overview of current European protocols and outcomes of a SIOPE multicenter survey. Huijskens SC, Kroon PS, Gaze MN, Gandola L, Bolle S, Supiot S, Abakay CD, Alexopoulou A, Bokun J, Chojnacka M, Escande A, Giralt J, Harrabi S, Maduro JH, Mandeville H, Mussano A, Napieralska A, Padovani L, Scarzello G, Timmermann B, Claude L, Seravalli E, Janssens GO. Eur J Cancer. 2021 Mar;145:121-131. IF: 9.162.

A single-cell tumor immune atlas for precision oncology. Nieto P, Elosua-Bayes M, Trincado JL, Marchese D, Massoni-Badosa R, Salvany M, Henriques A, Nieto J, Aguilar-Fernández S, Mereu E, Moutinho C, Ruiz S, Lorden P, Chin VT, Kaczorowski D, Chan CL, Gallagher R, Chou A, Planas-Rigol E, Rubio-Perez C, Gut I, Piulats JM, Seoane J, Powell JE, Batlle E, Heyn H. Genome Res. 2021 Oct;31(10):1913-1926. IF: 9.043.

Management of individuals with germline variants in PALB2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Tischkowitz M, Balmaña J, Foulkes WD, James P, Ngeow J, Schmutzler R, Voian N, Wick MJ, Stewart DR, Pal T; ACMG Professional Practice and Guidelines Committee. Genet Med. 2021 Aug;23(8):1416-1423. IF: 8.822.

Patients’ and professionals’ perspective of non-in-person visits in hereditary cancer: predictors and impact of the COVID-19 pandemic. López-Fernández A, Villacampa G, Grau E, Salinas M, Darder E, Carrasco E, Torres-Esquius S, Iglesias S, Solanes A, Gadea N, Velasco A, Urgell G, Torres M, Tuset N, Brunet J, Corbella S, Balmaña J. Genet Med. 2021 Aug;23(8):1450-1457. IF: 8.822.

The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Lakeman IMM, van den Broek AJ, Vos JAM, Barnes DR, Adlard J, Andrulis IL, Arason A, Arnold N, Arun BK, Balmaña J, Barrowdale D, Benitez J, et al. Genet Med. 2021 Sep;23(9):1726-1737. IF: 8.822.

Implications of Iron Deficiency in STEMI Patients and in a Murine Model of Myocardial Infarction. Inserte J, Barrabés JA, Aluja D, Otaegui I, Bañeras J, Castellote L, Sánchez A, Rodríguez-Palomares JF, Pineda V, Miró-Casas E, Milà L, Lidón RM, Sambola A, Valente F, Rafecas A, Ruiz-Meana M, Rodríguez-Sinovas A, Benito B, Buera I, Delgado-Tomás S, Beneítez D, Ferreira-González I. JACC Basic Transl Sci. 2021 Jul 26;6(7):567-580. IF: 8.648.

Deep learning reconstruction of digital breast tomosynthesis images for accurate breast density and patient-specific radiation dose estimation. Teuwen J, Moriakov N, Fedon C, Caballo M, Reiser I, Bakic P, García E, Diaz O, Michielsen K, Sechopoulos I. Med Image Anal. 2021 Jul;71:102061. IF: 8.545.

A Collaborative Effort to Define Classification Criteria for ATM Variants in Hereditary Cancer Patients. Feliubadaló L, Moles-Fernández A, Santamariña-Pena M, Sánchez AT, López-Novo A, Porras LM, Blanco A, Capellá G, de la Hoya M, Molina IJ, Osorio A, Pineda M, Rueda D, de la Cruz X, Diez O, Ruiz-Ponte C, Gutiérrez-Enríquez S, Vega A, Lázaro C. Clin Chem. 2021 Mar 1;67(3):518-533. IF: 8.327.

Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival. Lazar V, Magidi S, Girard N, Savignoni A, Martini JF, Massimini G, Bresson C, Berger R, Onn A, Raynaud J, Wunder F, Berindan-Neagoe I, Sekacheva M, Braña I, Tabernero J, Felip E, Porgador A, Kleinman C, Batist G, Solomon B, Tsimberidou AM, Soria JC, Rubin E, Kurzrock R, Schilsky RL. NPJ Precis Oncol. 2021 Apr 28;5(1):33. IF: 8.254.

Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer. Griguolo G, Serna G, Pascual T, Fasani R, Guardia X, Chic N, Paré L, Pernas S, Muñoz M, Oliveira M, Vidal M, Llombart-Cussac A, Cortés J, Galván P, Bermejo B, Martínez N, López R, Morales S, Garau I, Manso L, Alarcón J, Martínez E, Villagrasa P, Prat A, Nuciforo P. NPJ Precis Oncol. 2021 Mar 19;5(1):23. IF: 8.254.

BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer. Ros J, Baraibar I, Sardo E, Mulet N, Salvà F, Argilés G, Martini G, Ciardiello D, Cuadra JL, Tabernero J, Élez E. Ther Adv Med Oncol. 2021 Feb 22;13:1758835921992974. IF: 8.168.

COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry. Garrigós L, Saura C, Martinez-Vila C, Zambelli A, Bower M, Pistilli B, Lambertini M, Ottaviani D, Diamantis N, Lumsden A, Pernas S, Generali D, Seguí E, Viñas G, Felip E, Sanchez A, Rizzo G, Santoro A, Cortellini A, Perone Y, Chester J, Iglesias M, Betti M, Vincenzi B, Libertini M, Mazzoni F, Zoratto F, Berardi R, Guida A, Wuerstlein R, Loizidou A, Sharkey R, Aguilar Company J, Matas M, Saggia C, Chiudinelli L, Colomba-Blameble E, Galazi M, Mukherjee U, Van Hemelrijck M, Marin M, Strina C, Prat A, Pla H, Ciruelos EM, Bertuzzi A, Del Mastro L, Porzio G, Newsom-Davis T, Ruiz I, Delany MB, Krengli M, Fotia V, Viansone A, Chopra N, Romeo M, Salazar R, Perez I, d’Avanzo F, Franchi M, Milani M, Pommeret F, Tucci M, Pedrazzoli P, Harbeck N, Ferrante D, Pinato DJ, Gennari A. Ther Adv Med Oncol. 2021 Nov 2;13:17588359211053416. IF: 8.168.

External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry. Jimenez-Fonseca P, Carmona-Bayonas A, Martinez-Torron A, Alsina M, Custodio A, Serra O, Cacho Lavin D, Limón ML, Sauri T, López F, Visa L, Granja M, Martínez Lago N, Arrazubi V, Vidal Tocino R, Hernandez R, Aguado G, Cano JM, Martín Carnicero A, Mangas M, Pimentel P, Fernández Montes A, Macias Declara I, Longo F, Ramchandani A, Martín Richard M, Hurtado A, Azkarate A, Hernández Pérez C, Serrano R, Gallego J; AGAMENON-SEOM study group. Ther Adv Med Oncol. 2021 Jun 17;13:17588359211019672. IF: 8.168.

IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer. Hack SP, Verret W, Mulla S, Liu B, Wang Y, Macarulla T, Ren Z, El-Khoueiry AB, Zhu AX. Ther Adv Med Oncol. 2021 Jul 31;13:17588359211036544. IF: 8.168.

Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward. Lostes-Bardaji MJ, García-Illescas D, Valverde C, Serrano C. Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward. Ther Adv Med Oncol. 2021 Jan 7;13:1758835920986498. IF: 8.168.

Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective. Soosaipillai G, Wu A, Dettorre GM, Diamantis N, Chester J, Moss C, Aguilar-Company J, Bower M, Sng CC, Salazar R, Brunet J, Jones E, Mesia R, Jackson A, Mukherjee U, Sita-Lumsden A, Seguí E, Ottaviani D, Carbó A, Benafif S, Würstlein R, Carmona C, Chopra N, Cruz CA, Swallow J, Saoudi N, Felip E, Galazi M, Garcia-Fructuoso I, Lee AJX, Newsom-Davis T, Wong YNS, Sureda A, Maluquer C, Ruiz-Camps I, Cabirta A, Prat A, Loizidou A, Gennari A, Ferrante D, Tabernero J, Russell B, Van Hemelrijck M, Dolly S, Hulbert-Williams NJ, Pinato DJ. Ther Adv Med Oncol. 2021 Sep 2;13:17588359211042224. IF: 8.168.

Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospects. Gion M, Pérez-García JM, Llombart-Cussac A, Sampayo-Cordero M, Cortés J, Malfettone A. Ther Adv Med Oncol. 2021 Nov 29;13:17588359211059587. IF: 8.168.

Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy. Chic N, Schettini F, Brasó-Maristany F, Sanfeliu E, Adamo B, Vidal M, Martínez D, Galván P, González-Farré B, Cortés J, Gavilá J, Saura C, Oliveira M, Pernas S, Martínez-Sáez O, Soberino J, Ciruelos E, Carey LA, Muñoz M, Perou CM, Pascual T, Bellet M, Prat A. EBioMedicine. 2021 Jul;69:103451. IF: 8.143.

Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapies. Kast F, Klein C, Umaña P, Gros A, Gasser S. Oncoimmunology. 2021 Jan 7;10(1):1869389. IF: 8.110.

Cytomegalovirus DNAemia and risk of mortality in allogeneic hematopoietic stem cell transplantation: Analysis from the Spanish Hematopoietic Transplantation and Cell Therapy Group. Solano C, Vázquez L, Giménez E, de la Cámara R, Albert E, Rovira M, Espigado I, Calvo CM, López-Jiménez J, Suárez-Lledó M, Chinea A, Esquirol A, Pérez A, Bermúdez A, Saldaña R, Heras I, González-Huerta AJ, Torrado T, Bautista G, Batlle M, Jiménez S, Vallejo C, Barba P, Cuesta MÁ, Piñana JL, Navarro D. Am J Transplant. 2021 Jan;21(1):258-271. IF: 8.086.

Genetic evolution to tyrosine kinase inhibitory therapy in patients with EGFR-mutated non-small-cell lung cancer. Martinez-Marti A, Felip E, Mancuso FM, Caratú G, Matito J, Nuciforo P, Sansano I, Diaz-Mejia N, Cedrés S, Callejo A, Iranzo P, Pardo N, Miquel JM, Navarro A, Vivancos A, Sansó M. Br J Cancer. 2021 Nov;125(11):1561-1569. IF: 7.640.

Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group. Koessler T, Alsina M, Arnold D, Ben-Aharon I, Lutz MP, Obermannova R, Peeters M, Sclafani F, Smyth E, Valle JW, Wagner AD, Wyrwicz L, Fontana E, Moehler M. Br J Cancer. 2021 Sep;125(7):911-919. IF: 7.640.

Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours. Rodon J, Argilés G, Connolly RM, Vaishampayan U, de Jonge M, Garralda E, Giannakis M, Smith DC, Dobson JR, McLaughlin ME, Seroutou A, Ji Y, Morawiak J, Moody SE, Janku F. Br J Cancer. 2021 Jul;125(1):28-37. IF: 7.640.

PI3K activation promotes resistance to eribulin in HER2-negative breast cancer. Gris-Oliver A, Ibrahim YH, Rivas MA, García-García C, Sánchez-Guixé M, Ruiz-Pace F, Viaplana C, Pérez-García JM, Llombart-Cussac A, Grueso J, Parés M, Guzmán M, Rodríguez O, Anton P, Cozar P, Calvo MT, Bruna A, Arribas J, Caldas C, Dienstmann R, Nuciforo P, Oliveira M, Cortés J, Serra V. Br J Cancer. 2021 Apr;124(9):1581-1591. IF: 7.640.

SLFN11 informs on standard of care and novel treatments in a wide range of cancer models. Winkler C, Armenia J, Jones GN, Tobalina L, Sale MJ, Petreus T, Baird T, Serra V, Wang AT, Lau A, Garnett MJ, Jaaks P, Coker EA, Pierce AJ, O’Connor MJ, Leo E. Br J Cancer. 2021 Mar;124(5):951-962. IF: 7.640.

Epstein-Barr Virus+ B Cells in Breast Cancer Immune Response: A Case Report. Aran A, Peg V, Rabanal RM, Bernadó C, Zamora E, Molina E, Arribas YA, Arribas J, Pérez J, Roura-Mir C, Carrascal M, Cortés J, Martí M. Front Immunol. 2021 Nov 16;12:761798. IF: 7.561.

A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. Khaki AR, Li A, Diamantopoulos LN, Miller NJ, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Koshkin V, Park J, Alva A, Bilen MA, Stewart T, Santos V, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt M, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Lythgoe MP, Pinato DJ, Murgic J, Fröbe A, Joshi M, Isaacsson Velho P, Hahn N, Alonso Buznego L, Duran I, Moses M, Barata P, Galsky MD, Sonpavde G, Yu EY, Shankaran V, Lyman GH, Grivas P. Eur Urol Oncol. 2021 Jun;4(3):464-472. IF: 7.479.

Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial. Szabados B, Rodriguez-Vida A, Durán I, Crabb SJ, Van Der Heijden MS, Pous AF, Gravis G, Herranz UA, Protheroe A, Ravaud A, Maillet D, Mendez-Vidal MJ, Suárez C, Linch M, Prendergast A, Tyson C, Mousa K, Castellano D, Powles T. Eur Urol Oncol. 2021 Jun;4(3):456-463. IF: 7.479.

External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit? Jimenez-Fonseca P, Carmona-Bayonas A, Martínez de Castro E, Custodio A, Pericay Pijaume C, Hernandez R, Aguado G, Castro Unanua N, Cano JM, López F, Garrido M, Fernández Montes A, Visa L, Sánchez Cánovas M, Limón ML, Martínez Lago N, Pimentel P, Hurtado A, Azkárate A, Longo F, Diez M, Arias-Martinez A, Sauri T, Martín Carnicero A, Mangas M, Martín Richard M, Granja M, Ramchandani A, Hernández Pérez C, Cerdá P, Gil-Negrete A, Calvo M, Vidal Tocino R, Gallego J. Gastric Cancer. 2021 Mar;24(2):445-456. IF: 7.370.

Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061. Van Cutsem E, Amonkar M, Fuchs CS, Alsina M, Özgüroğlu M, Bang YJ, Chung HC, Muro K, Goekkurt E, Benson AB 3rd, Sun W, Wainberg ZA, Norquist JM, Chen X, Shih CS, Shitara K. Gastric Cancer. 2021 Nov;24(6):1330-1340. IF: 7.370.

Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry. Alvarez-Manceñido F, Jimenez-Fonseca P, Carmona-Bayonas A, Arrazubi V, Hernandez R, Cano JM, Custodio A, Pericay Pijaume C, Aguado G, Martínez Lago N, Sánchez Cánovas M, Cacho Lavin D, Visa L, Martinez-Torron A, Arias-Martinez A, López F, Limón ML, Vidal Tocino R, Fernández Montes A, Alsina M, Pimentel P, Reguera P, Martín Carnicero A, Ramchandani A, Granja M, Azkarate A, Martín Richard M, Serra O, Hernández Pérez C, Hurtado A, Gil-Negrete A, Sauri T, Morales Del Burgo P, Gallego J. Gastric Cancer. 2021 Jul;24(4):926-936. IF: 7.370.

Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study. Mansoor W, Arkenau HT, Alsina M, Shitara K, Thuss-Patience P, Cuffe S, Dvorkin M, Park D, Ando T, Van Den Eynde M, Beretta GD, Zaniboni A, Doi T, Tabernero J, Ilson DH, Makris L, Benhadji KA, Van Cutsem E. Gastric Cancer. 2021 Jul;24(4):970-977. IF: 7.370.

Clinical and pathological characteristics of peripheral T-cell lymphomas in a Spanish population: a retrospective study. Rodriguez-Pinilla SM, Domingo-Domenech E, Climent F, Sanchez J, Perez Seoane C, Lopez Jimenez J, Garcia-Cosio M, Caballero D, Blanco Muñez OJ, Carpio C, Castellvi J, Martinez Pozo A, Gonzalez Farre B, Bendaña A, Aliste C, Gonzalez AJ, Gonzalez de Villambrosia S, Piris MA, Gomez Codina J, Mayordomo-Aranda E, Navarro B, Bellas C, Rodriguez G, Borrero JJ, Ruiz-Zorrilla A, Grande M, Montoto C, Cordoba R. Br J Haematol. 2021 Jan;192(1):82-99. IF: 6.998.

Cytomegalovirus-specific T-cell immunity and DNAemia in patients with chronic lymphocytic leukaemia undergoing treatment with ibrutinib. Solano de la Asunción C, Terol MJ, Saus A, Olea B, Giménez E, Albert E, López-Jiménez J, Andreu R, García D, Fox L, Remigia MJ, Amat P, Solano C, Navarro D. Br J Haematol. 2021 Nov;195(4):637-641. IF: 6.998.

Cytoreductive treatment in patients with CALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia. Alvarez-Larrán A, Angona A, Andrade-Campos M, Soledad Noya M, Teresa Gómez-Casares M, Cuevas B, Caballero G, García-Hernández C, García-Gutiérrez V, Palomino A, Ferrer-Marín F, Isabel Mata-Vázquez M, Moretó A, Magro E, Murillo I, Manuel Alonso-Domínguez J, María Guerra J, Guerrero L, María Raya J, Pérez-Encinas M, Carreño-Tarragona G, Fox L, Pastor-Galán I, Bellosillo B, Hernández-Boluda JC; MPN Spanish Group (GEMFIN). Br J Haematol. 2021 Mar;192(6):988-996. IF: 6.998.

Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study. Stilgenbauer S, Bosch F, Ilhan O, Kisro J, Mahé B, Mikuskova E, Osmanov D, Reda G, Robinson S, Tausch E, Turgut M, Wójtowicz M, Böttcher S, Perretti T, Trask P, Van Hoef M, Leblond V, Foà R. Br J Haematol. 2021 Apr;193(2):325-338. IF: 6.998.

Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial. Filaci G, Fenoglio D, Nolè F, Zanardi E, Tomasello L, Aglietta M, Del Conte G, Carles J, Morales-Barrera R, Guglielmini P, Scagliotti G, Signori A, Parodi A, Kalli F, Astone G, Ferrera F, Altosole T, Lamperti G, Criscuolo D, Gianese F, Boccardo F. Cancer Immunol Immunother. 2021 Dec;70(12):3679-3692. IF: 6.968.

Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants. Lambertini M, Ceppi M, Hamy AS, Caron O, Poorvu PD, Carrasco E, Grinshpun A, Punie K, Rousset-Jablonski C, Ferrari A, Paluch-Shimon S, Toss A, Senechal C, Puglisi F, Pogoda K, Pérez-Fidalgo JA, De Marchis L, Ponzone R, Livraghi L, Estevez-Diz MDP, Villarreal-Garza C, Dieci MV, Clatot F, Duhoux FP, Graffeo R, Teixeira L, Córdoba O, Sonnenblick A, Ferreira AR, Partridge AH, Di Meglio A, Saule C, Peccatori FA, Bruzzone M, t’Kint de Roodenbeke MD, Ameye L, Balmaña J, Del Mastro L, Azim HA Jr. NPJ Breast Cancer. 2021 Feb 12;7(1):16. IF: 6.923.

Clinical consequences of BRCA2 hypomorphism. Castells-Roca L, Gutiérrez-Enríquez S, Bonache S, Bogliolo M, Carrasco E, Aza-Carmona M, Montalban G, Muñoz-Subirana N, Pujol R, Cruz C, Llop-Guevara A, Ramírez MJ, Saura C, Lasa A, Serra V, Diez O, Balmaña J, Surrallés J. NPJ Breast Cancer. 2021 Sep 9;7(1):117. IF: 6.923.

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. Schettini F, Chic N, Brasó-Maristany F, Paré L, Pascual T, Conte B, Martínez-Sáez O, Adamo B, Vidal M, Barnadas E, Fernández-Martinez A, González-Farre B, Sanfeliu E, Cejalvo JM, Perrone G, Sabarese G, Zalfa F, Peg V, Fasani R, Villagrasa P, Gavilá J, Barrios CH, Lluch A, Martín M, Locci M, De Placido S, Prat A. NPJ Breast Cancer. 2021 Jan 4;7(1):1. IF: 6.923.

Evaluation of the association of heterozygous germline variants in NTHL1 with breast cancer predisposition: an international multi-center study of 47,180 subjects. Li N, Zethoven M, McInerny S, Devereux L, Huang YK, Thio N, Cheasley D, Gutiérrez-Enríquez S, Moles-Fernández A, Diez O, Nguyen-Dumont T, Southey MC, Hopper JL, Simard J, Dumont M, Soucy P, Meindl A, Schmutzler R, Schmidt MK, Adank MA, Andrulis IL, Hahnen E, Engel C, Lesueur F, Girard E, Neuhausen SL, Ziv E, Allen J, Easton DF, Scott RJ, Gorringe KL, James PA, Campbell IG. NPJ Breast Cancer. 2021 May 12;7(1):52. IF: 6.923.

Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study. Vahdat LT, Schmid P, Forero-Torres A, Blackwell K, Telli ML, Melisko M, Möbus V, Cortes J, Montero AJ, Ma C, Nanda R, Wright GS, He Y, Hawthorne T, Bagley RG, Halim AB, Turner CD, Yardley DA. NPJ Breast Cancer. 2021 May 20;7(1):57. IF: 6,923.

Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial. Pascual T, Oliveira M, Villagrasa P, Ortega V, Paré L, Bermejo B, Morales S, Amillano K, López R, Galván P, Canes J, Salvador F, Nuciforo P, Rubio IT, Llombart-Cussac A, Di Cosimo S, Baselga J, Harbeck N, Prat A, Cortés J. NPJ Breast Cancer. 2021 Nov 25;7(1):145. IF: 6.923.

Nobody dares stopping clinical research, not even COVID-19. Malfettone A, Di Cosimo S, Pérez-García JM, García A, Sampayo-Cordero M, Mina L, Herrero C, Llombart-Cussac A, Cortés J. NPJ Breast Cancer. 2021 Apr 8;7(1):39. IF: 6.923.

Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition. Aziz D, Portman N, Fernandez KJ, Lee C, Alexandrou S, Llop-Guevara A, Phan Z, Yong A, Wilkinson A, Sergio CM, Ferraro D, Etemadmoghadam D, Bowtell DD; kConFab Investigators, Serra V, Waring P, Lim E, Caldon CE. NPJ Breast Cancer. 2021 Aug 31;7(1):111. IF: 6.923.

The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. El Bairi K, Haynes HR, Blackley E, Fineberg S, Shear J, Turner S, de Freitas JR, Sur D, Amendola LC, Gharib M, Kallala A, Arun I, Azmoudeh-Ardalan F, Fujimoto L, Sua LF, Liu SW, Lien HC, Kirtani P, Balancin M, El Attar H, Guleria P, Yang W, Shash E, Chen IC, Bautista V, Do Prado Moura JF, Rapoport BL, Castaneda C, Spengler E, Acosta-Haab G, Frahm I, Sanchez J, Castillo M, Bouchmaa N, Md Zin RR, Shui R, Onyuma T, Yang W, Husain Z, Willard-Gallo K, Coosemans A, Perez EA, Provenzano E, Ericsson PG, Richardet E, Mehrotra R, Sarancone S, Ehinger A, Rimm DL, Bartlett JMS, Viale G, Denkert C, Hida AI, Sotiriou C, Loibl S, Hewitt SM, Badve S, Symmans WF, Kim RS, Pruneri G, Goel S, Francis PA, Inurrigarro G, Yamaguchi R, Garcia-Rivello H, Horlings H, Afqir S, Salgado R, Adams S, Kok M, Dieci MV, Michiels S, Demaria S, Loi S; International Immuno-Oncology Biomarker Working Group: El Bairi K, Haynes HR, Blackley E, Fineberg S, Shear J, Turner S, de Freitas JR, Sur D, Amendola LC, Gharib M, Kallala A, Arun I, Azmoudeh F, Fujimoto L, Sua LF, Liu SW, Lien HC, Kirtani P, Balancin M, El Attar H, Guleria P, Yang W, Shash E, Chen IC, Bautista V, Do Prado Moura JF, Rapoport BL, Castaneda C, Spengler E, Acosta G, Frahm I, Sanchez J, Castillo M, Bouchmaa N, Zin MDRR, Shui R,Onyuma T,Yang W,Husain Z,Willard K,Coosemans A,Perez EA,Provenzano E, Ericsson PG, Richardet E, Mehrotra R, Sarancone S, Ehinger A, Rimm DL, Bartlett JMS, Viale G, Denkert C, Hida AI, Sotiriou C, Loibl S, Hewitt SM, Badve S, Symmans WF, Kim RS, Pruneri G, Goel S, Francis PA, Inurrigarro G, Yamaguchi R, Garcia H, Horlings H, Afqir S, Salgado R, Adams S, Kok M, Dieci MV, Michiels S, Demaria S, Loi S, Schelfhout V, Arbzadeh E, Bondanar A, Reyes S, Ruz JR, Kang J, Xiang L, Zimovjanova M, Togores P, Ozturk T, Patil A, Corpa M, Whitehouse A, Tan B, de Paula A, Rossetti C, Lang C, Mahon S, Giacometti C, Linderholm B, Deman F, Montagna G, Gong G, Pavcovich M, Chaer Y, Cabrero IA, de Brito ML, Ilieva N, Fulop A, Souza M, Bilancia D, Idowu M, Johri R, Szpor J, Bachani L, Schmitt F, Giannotti M, Kurebayashi Y, Ramirez B, Salido E, Bortesi L, Bonetto S, Elomina K, Lopez P, Sharma V, Edirisinghe A, Mathur D, Sahay A, Mouloud MA, Giang CH, Mukolwe E, Kiruka E, Samberg N, Abe N, Brown M, Millar E, Li XB, Yuan Z, Pasupathy A, Miele R, Luff R, Porfirio E, Ajemba O, Soni R, Orvieto E, DiMaio M, Thomas J, Merard R, Subramaniam MM, Apolinario T, Preda O, Preda R, Makanga A, Maior MS, Li L, Saghatchian M, Saurine T, Janssen E, Cochran J, Vlada N, Cappellesso R, Elfer K, Hollick M, Desai S, Oner G, Schreurs A, Liu S, Perera R, Mercurio P, Garcia F, Hosny K, Matsumoto H, van C, Bianchini G, Coban I, Jahangir A, Rahman A, Stover D, Luz P, Martel A, Waumans Y, Stenzinger A, Cortes J, Dimitrova P, Nauwelaers I, Velasco M, Fan F, Akturk G, Firer M, Roxanis I, Schneck M, Wen H, Cockenpot V, Konstantinov A, Calatrava A, Vidya MN, Choi HJ, Jank P, ÇÏinen AH, Sabanathan D, Floris G, Hoeflmayer D, Hamada T, Laudus N, Grigoriadis A, Porcellato I, Acs B, Miglietta F, Parrodi J, Clunie D, Calhoun B, Lu FI, Lefevre A, Tabbarah S, Tran W, Garcia I, Jelinic P, Boeckx C, Souza S, Cebollero M, Felip E, Rendon JLS, El Gabry E, Saltz J, Bria E, Garufi G, Hartman J, Sebastian M, Olofsson H, Kooreman L, Cucherousset J, Mathieu MC, Ballesteros C, Siziopikou P, Fong J, Klein M, Qulis I, Wesseling J, Bellolio E, Araya JC, Naber S, Cheang M, Castellano I, Ales A, Laenkholm AV, Kulka J, Quinn C, Sapino A, Amendoeira I, Marchio C, Braybrooke J, Vincent A, Korski KP, Sofopoulos M, Stovgaard E, Bianchi S, Bago Z, Yu C, Regitnig P, Hall S, Kos Z, Sant S, Tille JC, Gallas B, Bethmann D, Savas P, Mendes L, Soler T, van M, Gruosso T, Quintana A, Giltnane J, Van den Eynden G, Duregon E, de Cabo R, Recamo PC, Gaboury L, Zimmerman J, Pop CS, Wernicke A, Williams D, Gill A, Solomon B, Thapa B, Farshid G, Gilham L, Christie M, O’Toole S, Hendry S, Fox SB, Luen SJ, Lakhani SR, Fuchs T, John T, Brcic I, Hainfellner J, Sigurd L, Preusser M, Poortmans P, Decaluwe A, Carey C, Colpaert C, Larsimont D, Peeters D, Broeckx G, van de Vijver K, Buisseret L, Dirix L, Hertoghs M, Piccart M, Ignatiadis M, Van M, Sirtaine N, Vermeulen P, de Wind R, Declercq S, Gevaert T, Haibe B, Nelson BH, Watson PH, Leung S, Nielsen T, Shi L, Balslev E, Thagaard J, Almangush A, Makitie A, Joensuu H, Lundin J, Drubay D, Roblin E, Andre F, Penault F, Lemonnier J, Adam J, Lacroix M, Ternes N, Radosevic N, Klaushen F, Weber K, Harbeck N, Gluz O, Wienert S, Cserni G, Vingiani A, Criscitiello C, Solinas C, Curigliano G, Konishi E, Suzuki E, Yoshikawa K, Kawaguchi K, Takada M, Toi M, Ishida M, Shibata N, Saji S, Kogawa T, Sakatani T, Okamoto T, Moriya T, Kataoka T, Shimoi T, Sugie T, Sugie T, Mukohara T, Shu Y, Kikawa Y, Kozuka Y, Sayed S, Rahayu R, Ramsaroop R, Senkus E, Chmielik E, Cardoso F, Ribeiro J, Chan J, Dent R, Martin M, Hagen C, Guerrero A, Rojo F, Comerma L, Nuciforo P, et al. NPJ Breast Cancer. 2021 Dec 1;7(1):150. IF: 6.923.

The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers. De Mattos-Arruda L, Cortes J, Blanco-Heredia J, Tiezzi DG, Villacampa G, Gonçalves-Ribeiro S, Paré L, Souza CA, Ortega V, Sammut SJ, Cusco P, Fasani R, Chin SF, Perez-Garcia J, Dienstmann R, Nuciforo P, Villagrasa P, Rubio IT, Prat A, Caldas C. NPJ Breast Cancer. 2021 Jun 7;7(1):73. IF: 6.923.

A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia. Vives S, Martínez-Cuadrón D, Bergua Burgues J, Algarra L, Tormo M, Martínez-Sánchez MP, Serrano J, Herrera P, Ramos F, Salamero O, Lavilla E, López-Lorenzo JL, Gil C, Vidriales B, Falantes JF, Serrano A, Labrador J, Sayas MJ, Foncillas MÁ, Amador Barciela ML, Olave MT, Colorado M, Gascón A, Fernández MÁ, Simiele A, Pérez-Encinas MM, Rodríguez-Veiga R, García O, Martínez-López J, Barragán E, Paiva B, Sanz MÁ, Montesinos P; PETHEMA Group. Cancer. 2021 Jun 15;127(12):2003-2014. IF: 6.860.

Olmutinib in T790M-positive non-small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study. Park K, Jänne PA, Kim DW, Han JY, Wu MF, Lee JS, Kang JH, Lee DH, Cho BC, Yu CJ, Pang YK, Felip E, Kim H, Baek E, Noh YS. Cancer. 2021 May 1;127(9):1407-1416. IF: 6.860.

ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project. Shustov A, Cabrera ME, Civallero M, Bellei M, Ko YH, Manni M, Skrypets T, Horwitz SM, De Souza CA, Radford JA, Bobillo S, Prates MV, Ferreri AJM, Chiattone C, Spina M, Vose JM, Chiappella A, Laszlo D, Marino D, Stelitano C, Federico M. Blood Adv. 2021 Feb 9;5(3):640-648. IF: 6.799.

Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma. Pighi C, Cheong TC, Compagno M, Patrucco E, Arigoni M, Olivero M, Wang Q, López C, Bernhart SH, Grande BM, Poggio T, Langellotto F, Bonello L, Dall’Olio R, Martínez-Martín S, Molinaro L, Francia di Celle P, Whitfield JR, Soucek L, Voena C, Calogero RA, Morin RD, Staudt LM, Siebert R, Zamò A, Chiarle R. Blood Adv. 2021 Dec 14;5(23):5239-5257.IF: 6.799.

Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPS. Baronciani L, Peake I, Schneppenheim R, Goodeve A, Ahmadinejad M, Badiee Z, Baghaipour MR, Benitez O, Bodó I, Budde U, Cairo A, Castaman G, Eshghi P, Goudemand J, Hassenpflug W, Hoorfar H, Karimi M, Keikhaei B, Lassila R, Leebeek FWG, Lopez Fernandez MF, Mannucci PM, Marino R, Nikšić N, Oyen F, Santoro C, Tiede A, Toogeh G, Tosetto A, Trossaert M, Zetterberg EMK, Eikenboom J, Federici AB, Peyvandi F. Blood Adv. 2021 Aug 10;5(15):2987-3001. IF: 6.799.

Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial. Simoes C, Paiva B, Martínez-Cuadrón D, Bergua JM, Vives S, Algarra L, Tormo M, Martinez P, Serrano J, Herrera P, Ramos F, Salamero O, Lavilla E, Gil C, Lopez JL, Vidriales MB, Labrador J, Falantes JF, Sayas MJ, Ayala R, Martinez-Lopez J, Villar S, Calasanz MJ, Prosper F, San-Miguel JF, Sanz MÁ, Montesinos P. Blood Adv. 2021 Feb 9;5(3):760-770. IF: 6.799.

TUNAR lncRNA Encodes a Microprotein that Regulates Neural Differentiation and Neurite Formation by Modulating Calcium Dynamics. Senís E, Esgleas M, Najas S, Jiménez-Sábado V, Bertani C, Giménez-Alejandre M, Escriche A, Ruiz-Orera J, Hergueta-Redondo M, Jiménez M, Giralt A, Nuciforo P, Albà MM, Peinado H, Del Toro D, Hove-Madsen L, Götz M, Abad M. Front Cell Dev Biol. 2021 Dec 31;9:747667. IF: 6.684.

Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. Schettini F, Giuliano M, Lambertini M, Bartsch R, Pinato DJ, Onesti CE, Harbeck N, Lüftner D, Rottey S, van Dam PA, Zaman K, Mustacchi G, Gligorov J, Awada A, Campone M, Wildiers H, Gennari A, Tjan-Heijnen VCG, Cortes J, Locci M, Paris I, Del Mastro L, De Placido S, Martín M, Jerusalem G, Venturini S, Curigliano G, Generali D. Cancers (Basel). 2021 Sep 1;13(17):4421. IF: 6.639.

Biomarker-Guided Anti-Egfr Rechallenge Therapy in Metastatic Colorectal Cancer. Ciardiello D, Martini G, Famiglietti V, Napolitano S, De Falco V, Troiani T, Latiano TP, Ros J, Elez Fernandez E, Vitiello PP, Maiello E, Ciardiello F, Martinelli E. Cancers (Basel). 2021 Apr 17;13(8):1941. IF: 6.639.

Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies. Garcia-Alvarez A, Papakonstantinou A, Oliveira M. Cancers (Basel). 2021 Jun 11;13(12):2927. IF: 6.639.

Clinical, Pathological, and Molecular Features of Breast Carcinoma Cutaneous Metastasis. González-Martínez S, Pizarro D, Pérez-Mies B, Caniego-Casas T, Curigliano G, Cortés J, Palacios J. Cancers (Basel). 2021 Oct 28;13(21):5416. IF: 6.639.

Combined Treatment with Immunotherapy-Based Strategies for MSS Metastatic Colorectal Cancer. Baraibar I, Mirallas O, Saoudi N, Ros J, Salvà F, Tabernero J, Élez E. Cancers (Basel). 2021 Dec 16;13(24):6311. IF: 6.639.

ctDNA-Based Liquid Biopsy of Cerebrospinal Fluid in Brain Cancer. Escudero L, Martínez-Ricarte F, Seoane J. Cancers (Basel). 2021 Apr 21;13(9):1989. IF: 6.639.

Evolution of Angiogenic Factors in Pregnant Patients with Breast Cancer Treated with Chemotherapy. Saura C, Sánchez O, Martínez S, Domínguez C, Dienstmann R, Ruíz-Pace F, Céspedes MC, Peñuelas Á, Cortés J, Llurba E, Córdoba O. Cancers (Basel). 2021 Feb 23;13(4):923. IF:6,639.

Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms. Palomo L, Acha P, Solé F. Cancers (Basel). 2021 Apr 27;13(9):2120. IF: 6.639.

Interrelations between Patients’ Clinicopathological Characteristics and Their Association with Response to Immunotherapy in a Real-World Cohort of NSCLC Patients. Callejo A, Frigola J, Iranzo P, Carbonell C, Diaz N, Marmolejo D, Assaf JD, Cedrés S, Martinez-Marti A, Navarro A, Pardo N, Amat R, Felip E. Cancers (Basel). 2021 Jun 29;13(13):3249. IF: 6.639.

Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular Plasticity. Wright SCE, Vasilevski N, Serra V, Rodon J, Eichhorn PJA. Cancers (Basel). 2021 Mar 26;13(7):1538. IF: 6.639.

Overview of Oral Potentially Malignant Disorders: From Risk Factors to Specific Therapies. Lorini L, Bescós Atín C, Thavaraj S, Müller-Richter U, Alberola Ferranti M, Pamias Romero J, Sáez Barba M, de Pablo García-Cuenca A, Braña García I, Bossi P, Nuciforo P, Simonetti S. Cancers (Basel). 2021 Jul 23;13(15):3696. IF: 6.639.

Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study. de la Cruz-Merino L, Gion M, Cruz-Jurado J, Quiroga V, Andrés R, Moreno F, Alonso-Romero JL, Ramos M, Holgado E, Cortés J, López-Miranda E, Henao-Carrasco F, Palazón-Carrión N, Rodríguez LM, Ceballos I, Casas M, Benito S, Chiesa M, Bezares S, Caballero R, Jiménez-Cortegana C, Sánchez-Margalet V, Rojo F. Cancers (Basel). 2021 Oct 29;13(21):5432. IF: 6.639.

Performance of 16S Metagenomic Profiling in Formalin-Fixed Paraffin-Embedded versus Fresh-Frozen Colorectal Cancer Tissues. Borgognone A, Serna G, Noguera-Julian M, Alonso L, Parera M, Català-Moll F, Sanchez L, Fasani R, Paredes R, Nuciforo P. Cancers (Basel). 2021 Oct 29;13(21):5421. IF: 6.639.

Role of Splicing Regulatory Elements and In Silico Tools Usage in the Identification of Deep Intronic Splicing Variants in Hereditary Breast/Ovarian Cancer Genes. Moles-Fernández A, Domènech-Vivó J, Tenés A, Balmaña J, Diez O, Gutiérrez-Enríquez S. Cancers (Basel). 2021 Jul 3;13(13):3341. IF: 6.639.

Targeting DNA Damage Repair Mechanisms in Pancreas Cancer. Perkhofer L, Golan T, Cuyle PJ, Matysiak-Budnik T, Van Laethem JL, Macarulla T, Cauchin E, Kleger A, Beutel AK, Gout J, Stenzinger A, Van Cutsem E, Bellmunt J, Hammel P, O’Reilly EM, Seufferlein T. Cancers (Basel). 2021 Aug 24;13(17):4259. IF: 6.639.

The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial. Ayala R, Rapado I, Onecha E, Martínez-Cuadrón D, Carreño-Tarragona G, Bergua JM, Vives S, Algarra JL, Tormo M, Martinez P, Serrano J, Herrera P, Ramos F, Salamero O, Lavilla E, Gil C, López Lorenzo JL, Vidriales MB, Labrador J, Falantes JF, Sayas MJ, Paiva B, Barragán E, Prosper F, Sanz MÁ, Martínez-López J, Montesinos P, On Behalf Of The Programa Para El Estudio de la Terapeutica En Hemopatias Malignas Pethema Cooperative Study Group. Cancers (Basel). 2021 May 18;13(10):2458. IF: 6.639.

Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients. Lozano R, Lorente D, Aragon IM, Romero-Laorden N, Nombela P, Mateo J, Reid AHM, Cendón Y, Bianchini D, Llacer C, Sandhu SK, Sharp A, Rescigno P, Garcés T, Pacheco MI, Flohr P, Massard C, López-Casas PP, Castro E, de Bono JS, Olmos D. Cancers (Basel). 2021 May 12;13(10):2334. IF: 6.639.

A DNA damage repair gene-associated signature predicts responses of patients with advanced soft-tissue sarcoma to treatment with trabectedin. Moura DS, Peña-Chilet M, Cordero Varela JA, Alvarez-Alegret R, Agra-Pujol C, Izquierdo F, Ramos R, Ortega-Medina L, Martin-Davila F, Castilla-Ramirez C, Hernandez-Leon CN, Romagosa C, Vaz Salgado MA, Lavernia J, Bagué S, Mayodormo-Aranda E, Vicioso L, Hernández Barceló JE, Rubio-Casadevall J, de Juan A, Fiaño-Valverde MC, Hindi N, Lopez-Alvarez M, Lacerenza S, Dopazo J, Gutierrez A, Alvarez R, Valverde C, Martinez-Trufero J, Martín-Broto J. Mol Oncol. 2021 Dec;15(12):3691-3705. IF: 6.603.

Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer. Frigola J, Navarro A, Carbonell C, Callejo A, Iranzo P, Cedrés S, Martinez-Marti A, Pardo N, Saoudi-Gonzalez N, Martinez D, Jimenez J, Sansano I, Mancuso FM, Nuciforo P, Montuenga LM, Sánchez-Cespedes M, Prat A, Vivancos A, Felip E, Amat R. Mol Oncol. 2021 Apr;15(4):887-900. IF: 6.603.

The Porto European Cancer Research Summit 2021. Ringborg U, Berns A, Celis JE, Heitor M, Tabernero J, Schüz J, Baumann M, Henrique R, Aapro M, Basu P, Beets-Tan R, Besse B, Cardoso F, Carneiro F, van den Eede G, Eggermont A, Fröhling S, Galbraith S, Garralda E, Hanahan D, Hofmarcher T, Jönsson B, Kallioniemi O, Kásler M, Kondorosi E, Korbel J, Lacombe D, Carlos Machado J, Martin-Moreno JM, Meunier F, Nagy P, Nuciforo P, Oberst S, Oliveiera J, Papatriantafyllou M, Ricciardi W, Roediger A, Ryll B, Schilsky R, Scocca G, Seruca R, Soares M, Steindorf K, Valentini V, Voest E, Weiderpass E, Wilking N, Wren A, Zitvogel L. Mol Oncol. 2021 Oct;15(10):2507-2543. IF: 6.603.

Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib. Taylor MH, Takahashi S, Capdevila J, Tahara M, Leboulleux S, Kiyota N, Dutcus CE, Xie R, Robinson B, Sherman S, Habra MA, Elisei R, Wirth LJ. Thyroid. 2021 Aug;31(8):1226-1234. IF: 6.568.

Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival. Cabezón M, Malinverni R, Bargay J, Xicoy B, Marcé S, Garrido A, Tormo M, Arenillas L, Coll R, Borras J, Jiménez MJ, Hoyos M, Valcárcel D, Escoda L, Vall-Llovera F, Garcia A, Font LL, Rámila E, Buschbeck M, Zamora L; CETLAM group. Clin Epigenetics. 2021 Jan 14;13(1):9. IF: 6.551.

Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study. de Wit R, Wülfing C, Castellano D, Kramer G, Eymard JC, Sternberg CN, Fizazi K, Tombal B, Bamias A, Carles J, Iacovelli R, Melichar B, Sverrisdóttir Á, Theodore C, Feyerabend S, Helissey C, Foster MC, Ozatilgan A, Geffriaud-Ricouard C, de Bono J. ESMO Open. 2021 Oct;6(5):100241. IF: 6.540.

Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology. Castelo-Branco L, Awada A, Pentheroudakis G, Perez-Gracia JL, Mateo J, Curigliano G, Banerjee S, Giuliani R, Lordick F, Cervantes A, Tabernero J, Peters S. ESMO Open. 2021 Oct;6(5):100237. IF: 6.540.

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring. Gyawali B, de Vries EGE, Dafni U, Amaral T, Barriuso J, Bogaerts J, Calles A, Curigliano G, Gomez-Roca C, Kiesewetter B, Oosting S, Passaro A, Pentheroudakis G, Piccart M, Roitberg F, Tabernero J, Tarazona N, Trapani D, Wester R, Zarkavelis G, Zielinski C, Zygoura P, Cherny NI. ESMO Open. 2021 Jun;6(3):100117. IF: 6.540.

Female leadership in oncology-has progress stalled? Data from the ESMO W4O authorship and monitoring studies. Berghoff AS, Sessa C, Yang JC, Tsourti Z, Tsang J, Tabernero J, Peters S, Linardou H, Letsch A, Haanen J, Garralda E, Garassino MC, Furness AJS, Felip E, Dimopoulou G, Dafni U, Choo SP, Banerjee S, Bajpai J, Adjei AA, Garrido P. ESMO Open. 2021 Dec;6(6):100281. IF: 6.540.

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update. Reck M, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O, Alexandru A, Sakai H, Lingua A, Reyes F, Souquet PJ, De Marchi P, Martin C, Pérol M, Scherpereel A, Lu S, Paz-Ares L, Carbone DP, Memaj A, Marimuthu S, Zhang X, Tran P, John T. ESMO Open. 2021 Oct;6(5):100273. IF: 6.540.

Gender influence on work satisfaction and leadership for medical oncologists: a survey of the Spanish Society of Medical Oncology (SEOM). Elez E, Ayala F, Felip E, García Campelo R, García Carbonero R, García Donás J, González Del Alba A, González Flores E, Hidalgo J, Isla D, Majem M, Rodríguez Lescure Á, Safont MJ, Santaballa A, Villacampa G, Vera R, Garrido P. ESMO Open. 2021 Apr;6(2):100048. IF: 6.540.

Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey. Garrido P, Adjei AA, Bajpai J, Banerjee S, Berghoff AS, Choo SP, Felip E, Furness AJS, Garralda E, Haanen J, Letsch A, Linardou H, Peters S, Sessa C, Tabernero J, Tsang J, Yang JC, Garassino MC. ESMO Open. 2021 Jun;6(3):100131. IF: 6.540.

Identifying and preventing burnout in young oncologists, an overwhelming challenge in the COVID-19 era: a study of the Spanish Society of Medical Oncology (SEOM). Jiménez-Labaig P, Pacheco-Barcia V, Cebrià A, Gálvez F, Obispo B, Páez D, Quílez A, Quintanar T, Ramchandani A, Remon J, Rogado J, Sánchez DA, Sánchez-Cánovas M, Sanz-García E, Sesma A, Tarazona N, Cotés A, González E, Bosch-Barrera J, Fernández A, Felip E, Vera R, Rodríguez-Lescure Á, Élez E. ESMO Open. 2021 Aug;6(4):100215. IF: 6.540.

Impact of COVID-19 on social media as perceived by the oncology community: results from a survey in collaboration with the European Society for Medical Oncology (ESMO) and the OncoAlert Network. Morgan G, Tagliamento M, Lambertini M, Devnani B, Westphalen B, Dienstmann R, Bozovic-Spasojevic I, Calles A, Criscitiello C, Curioni A, Garcia AM, Lamarca A, Pilotto S, Scheffler M, Strijbos M, Wong R, de Azambuja E, Peters S. ESMO Open. 2021 Apr;6(2):100104. IF: 6.540.

Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study. Tabernero J, Velez L, Trevino TL, Grothey A, Yaeger R, Van Cutsem E, Wasan H, Desai J, Ciardiello F, Yoshino T, Gollerkeri A, Maharry K, Christy-Bittel J, Kopetz S. Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study. ESMO Open. 2021 Dec;6(6):100328. IF: 6.540.

Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study). Perez-Fidalgo JA, Cortés A, Guerra E, García Y, Iglesias M, Bohn Sarmiento U, Calvo García E, Manso Sánchez L, Santaballa A, Oaknin A, Redondo A, Rubio MJ, González-Martín A. ESMO Open. 2021 Aug;6(4):100212. IF: 6.540.

Quality of life with first-line pembrolizumab for PD-L1-positive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study. Van Cutsem E, Valderrama A, Bang YJ, Fuchs CS, Shitara K, Janjigian YY, Qin S, Larson TG, Shankaran V, Stein S, Norquist JM, Kher U, Shah S, Alsina M. ESMO Open. 2021 Aug;6(4):100189. IF: 6.540.

Remembering Professor José Baselga. Tabernero J. ESMO Open. 2021 Apr 6(3): 100121. IF: 6.540.

Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer. Condorelli M, Bruzzone M, Ceppi M, Ferrari A, Grinshpun A, Hamy AS, de Azambuja E, Carrasco E, Peccatori FA, Di Meglio A, Paluch-Shimon S, Poorvu PD, Venturelli M, Rousset-Jablonski C, Senechal C, Livraghi L, Ponzone R, De Marchis L, Pogoda K, Sonnenblick A, Villarreal-Garza C, Córdoba O, Teixeira L, Clatot F, Punie K, Graffeo R, Dieci MV, Pérez-Fidalgo JA, Duhoux FP, Puglisi F, Ferreira AR, Blondeaux E, Peretz-Yablonski T, Caron O, Saule C, Ameye L, Balmaña J, Partridge AH, Azim HA, Demeestere I, Lambertini M. ESMO Open. 2021 Dec;6(6):100300. IF: 6.540.

Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study. Bordonaro R, Calvo A, Auriemma A, Hollebecque A, Rubovszky G, Saunders MP, Pápai Z, Prager G, Stein A, André T, Argilés G, Cubillo A, Dahan L, Edeline J, Leger C, Cattan V, Fougeray R, Amellal N, Tabernero J. ESMO Open. 2021 Oct;6(5):100270. IF: 6.540.

Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study. Tabernero J, Shitara K, Zaanan A, Doi T, Lorenzen S, Van Cutsem E, Fornaro L, Catenacci DVT, Fougeray R, Moreno SR, Azcue P, Arkenau HT, Alsina M, Ilson DH. ESMO Open. 2021 Aug;6(4):100200. IF: 6.540.

A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer. Schmid P, Sablin MP, Bergh J, Im SA, Lu YS, Martínez N, Neven P, Lee KS, Morales S, Pérez-Fidalgo JA, Adamson D, Gonçalves A, Prat A, Jerusalem G, Schlieker L, Espadero RM, Bogenrieder T, Huang DC, Crown J, Cortés J. Breast Cancer Res. 2021 Jan 15;23(1):8. IF: 6.488.

RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer. Sanz-Moreno A, Palomeras S, Pedersen K, Morancho B, Pascual T, Galván P, Benítez S, Gomez-Miragaya J, Ciscar M, Jimenez M, Pernas S, Petit A, Soler-Monsó MT, Viñas G, Alsaleem M, Rakha EA, Green AR, Santamaria PG, Mulder C, Lemeer S, Arribas J, Prat A, Puig T, Gonzalez-Suarez E. Breast Cancer Res. 2021 Mar 30;23(1):42. IF: 6.488.

Systemic treatment of newly diagnosed advanced epithelial ovarian cancer: From chemotherapy to precision medicine. Perez-Fidalgo JA, Grau F, Fariñas L, Oaknin A. Crit Rev Oncol Hematol. 2021 Feb;158:103209. IF: 6.312.

A Novel Antagonistic CD73 Antibody for Inhibition of the Immunosuppressive Adenosine Pathway. Wurm M, Schaaf O, Reutner K, Ganesan R, Mostböck S, Pelster C, Böttcher J, de Andrade Pereira B, Taubert C, Alt I, Serna G, Auguste A, Stadermann KB, Delic D, Han F, Capdevila J, Nuciforo PG, Kroe-Barrett R, Adam PJ, Vogt AB, Hofmann I. Mol Cancer Ther. 2021 Nov;20(11):2250-2261. IF: 6.261.

Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STS 1001 Randomized Phase III Trial. Martin-Broto J, Lopez-Alvarez M, Moura DS, Ramos R, Collini P, Romagosa C, Bagué S, Renne SL, Barisella M, Velasco V, Coindre JM, Lopez-Lopez D, Dopazo J, Gambarotti M, Braglia L, Merlo DF, Palmerini E, Stacchiotti S, Quagliuolo VL, Lopez-Pousa A, Grignani G, Blay JY, Brunello A, Gutierrez A, Valverde C, Hindi N, Dei Tos AP, Picci P, Casali PG, Gronchi A. Mol Cancer Ther. 2021 Dec;20(12):2539-2552. IF: 6.261.

Ripretinib and MEK Inhibitors Synergize to Induce Apoptosis in Preclinical Models of GIST and Systemic Mastocytosis. Gupta A, Singh J, García-Valverde A, Serrano C, Flynn DL, Smith BD. Mol Cancer Ther. 2021 Jul;20(7):1234-1245. IF: 6.261.

30-Day Mortality Following Palliative Radiotherapy. Vázquez M, Altabas M, Moreno DC, Geng AA, Pérez-Hoyos S, Giralt J. Front Oncol. 2021 Apr 23;11:668481. IF:6.244.

Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer. Brasó-Maristany F, Sansó M, Chic N, Martínez D, González-Farré B, Sanfeliu E, Ghiglione L, Carcelero E, Garcia-Corbacho J, Sánchez M, Soy D, Jares P, Peg V, Saura C, Muñoz M, Prat A, Vivancos A. Front Oncol. 2021 Sep 20;11:710596. IF: 6.244.

Early Toxicities After High Dose Rate Proton Therapy in Cancer Treatments. Doyen J, Sunyach MP, Almairac F, Bourg V, Naghavi AO, Duhil de Bénazé G, Claren A, Padovani L, Benezery K, Noël G, Hannoun-Lévi JM, Guedea F, Giralt J, Vidal M, Baudin G, Opitz L, Claude L, Bondiau PY. Front Oncol. 2021 Jan 14;10:613089. IF: 6.244.

First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study. Pernas S, Villagrasa P, Vivancos A, Scaltriti M, Rodón J, Burgués O, Nuciforo P, Canes J, Paré L, Dueñas M, Vidal M, Cejalvo JM, Perelló A, Llommbard-Cussac A, Dorca J, Montaño A, Pascual T, Oliveira M, Ribas G, Rapado I, Prat A, Ciruelos E. Front Oncol. 2021 Nov 4;11:744112. IF: 6.244.

Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study. Gil-Gil MJ, Bellet M, Bergamino M, Morales S, Barnadas A, Manso L, Saura C, Fernández-Ortega A, Garcia-Martinez E, Martinez-Jañez N, Melé M, Villagrasa P, Celiz P, Perez Martin X, Ciruelos E, Pernas S. Front Oncol. 2021 Jul 9;11:645026. IF: 6.244.

Obesity and Breast Cancer: A Paradoxical and Controversial Relationship Influenced by Menopausal Status. García-Estévez L, Cortés J, Pérez S, Calvo I, Gallegos I, Moreno-Bueno G. Front Oncol. 2021 Aug 13;11:705911. IF: 6.244.

SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer. Pascual T, Oliveira M, Ciruelos E, Bellet Ezquerra M, Saura C, Gavilá J, Pernas S, Muñoz M, Vidal MJ, Margelí Vila M, Cejalvo JM, González-Farré B, Espinosa-Bravo M, Cruz J, Salvador-Bofill FJ, Guerra JA, Luna Barrera AM, Arumi de Dios M, Esker S, Fan PD, Martínez-Sáez O, Villacampa G, Paré L, Ferrero-Cafiero JM, Villagrasa P, Prat A. Front Oncol. 2021 Apr 23;11:638482. IF: 6.244.

Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia. Jiménez I, Tazón-Vega B, Abrisqueta P, Nieto JC, Bobillo S, Palacio-García C, Carabia J, Valdés-Mas R, Munuera M, Puigdefàbregas L, Parra G, Esteve-Codina A, Franco-Jarava C, Iacoboni G, Terol MJ, García-Marco JA, Crespo M, Bosch F. Biomark Res. 2021 May 20;9(1):37. IF: 6.148.

Co-infections and superinfections complicating COVID-19 in cancer patients: A multicentre, international study. Gudiol C, Durà-Miralles X, Aguilar-Company J, Hernández-Jiménez P, Martínez-Cutillas M, Fernandez-Avilés F, Machado M, Vázquez L, Martín-Dávila P, de Castro N, Abdala E, Sorli L, Andermann TM, Márquez-Gómez I, Morales H, Gabilán F, Ayaz CM, Kayaaslan B, Aguilar-Guisado M, Herrera F, Royo-Cebrecos C, Peghin M, González-Rico C, Goikoetxea J, Salgueira C, Silva-Pinto A, Gutiérrez-Gutiérrez B, Cuellar S, Haidar G, Maluquer C, Marin M, Pallarès N, Carratalà J. J Infect. 2021 Sep;83(3):306-313. IF: 6.072.

Elucidating the Mechanism of Action of the Attributed Immunomodulatory Role of Eltrombopag in Primary Immune Thrombocytopenia: An In Silico Approach. Lozano ML, Segú-Vergés C, Coma M, Álvarez-Roman MT, González-Porras JR, Gutiérrez L, Valcárcel D, Butta N. Int J Mol Sci. 2021 Jun 27;22(13):6907. IF: 5.924.

Epithelial Mesenchymal Transition and Immune Response in Metaplastic Breast Carcinoma. González-Martínez S, Pérez-Mies B, Pizarro D, Caniego-Casas T, Cortés J, Palacios J. Int J Mol Sci. 2021 Jul 9;22(14):7398. IF: 5.924.

Inactivation of EMILIN-1 by Proteolysis and Secretion in Small Extracellular Vesicles Favors Melanoma Progression and Metastasis. Amor López A, Mazariegos MS, Capuano A, Ximénez-Embún P, Hergueta-Redondo M, Recio JÁ, Muñoz E, Al-Shahrour F, Muñoz J, Megías D, Doliana R, Spessotto P, Peinado H. Int J Mol Sci. 2021 Jul 9;22(14):7406. IF: 5.924.

Tumor-Associated Microbiome: Where Do We Stand? Oliva M, Mulet-Margalef N, Ochoa-De-Olza M, Napoli S, Mas J, Laquente B, Alemany L, Duell EJ, Nuciforo P, Moreno V. Tumor-Associated Microbiome: Where Do We Stand? Int J Mol Sci. 2021 Feb 1;22(3):1446. IF: 5.924.

Expanding the Diversity at the C-4 Position of Pyrido[2,3-d]pyrimidin-7(8H)-ones to Achieve Biological Activity against ZAP-70. Masip V, Lirio Á, Sánchez-López A, Cuenca AB, Puig de la Bellacasa R, Abrisqueta P, Teixidó J, Borrell JI, Gibert A, Estrada-Tejedor R. Pharmaceuticals (Basel). 2021 Dec 15;14(12):1311. IF: 5.863.

Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer. Popat S, Brustugun OT, Cadranel J, Felip E, Garassino MC, Griesinger F, Helland Å, Hochmair M, Pérol M, Bent-Ennakhil N, Kruhl C, Novello S. Lung Cancer. 2021 Jul;157:9-16. IF: 5.705.

PARP inhibitors in advanced prostate cancer: when to use them? Díaz-Mejía N, García-Illescas D, Morales-Barrera R, Suarez C, Planas J, Maldonado X, Carles J, Mateo J. Endocr Relat Cancer. 2021 Jul 15;28(8):T79-T93. IF: 5.678.

Treatment outcomes of advanced digestive well-differentiated grade 3 NETs. de Mestier L, Lamarca A, Hernando J, Zandee W, Alonso-Gordoa T, Perrier M, Walenkamp AM, Chakrabarty B, Landolfi S, Van Velthuysen MF, Kats-Ugurlu G, Caminoa A, Ronot M, Manoharan P, Garcia-Alvarez A, Brabander T, García Gómez-Muriel MI, Cadiot G, Couvelard A, Capdevila J, Pavel ME, Cros J. Endocr Relat Cancer. 2021 Jun 23;28(8):549-561. IF: 5.678.

Human Microbiota and Breast Cancer-Is There Any Relevant Link?-A Literature Review and New Horizons Toward Personalised Medicine. Alpuim Costa D, Nobre JG, Batista MV, Ribeiro C, Calle C, Cortes A, Marhold M, Negreiros I, Borralho P, Brito M, Cortes J, Braga SA, Costa L. Front Microbiol. 2021 Feb 25;12:584332. IF: 5.640.

Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer. Gonzalez D, Mateo J, Stenzinger A, Rojo F, Shiller M, Wyatt AW, Penault-Llorca F, Gomella LG, Eeles R, Bjartell A. J Pathol Clin Res. 2021 Jul;7(4):311-325. IF: 5.638.

Integrative Multi-omics Analysis to Characterize Human Brain Ischemia. Ramiro L, García-Berrocoso T, Briansó F, Goicoechea L, Simats A, Llombart V, Gonzalo R, Hainard A, Martínez-Saez E, Canals F, Sanchez JC, Sánchez-Pla A, Montaner J. Mol Neurobiol. 2021 Aug;58(8):4107-4121. IF: 5.590.

Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. Esagian SM, Khaki AR, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Santos VS, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt ME, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Lythgoe MP, Pinato DJ, Murgic J, Fröbe A, Joshi M, Isaacsson Velho P, Hahn N, Alonso Buznego L, Duran I, Moses M, Barata P, Galsky MD, Sonpavde G, Yu EY, Msaouel P, Koshkin VS, Grivas P. BJU Int. 2021 Aug;128(2):196-205. IF: 5.588.

Paired Somatic-Germline Testing of 15 Polyposis and Colorectal Cancer-Predisposing Genes Highlights the Role of APC Mosaicism in de Novo Familial Adenomatous Polyposis. Rofes P, González S, Navarro M, Moreno-Cabrera JM, Solanes A, Darder E, Carrasco E, Iglesias S, Salinas M, Gómez C, Velasco À, Tuset N, Varela M, Llort G, Ramon Y Cajal T, Grau È, Dueñas N, de la Ossa Merlano N, Matías-Guiu X, Rivera B, Balmaña J, Pineda M, Brunet J, Capellá G, Del Valle J, Lázaro C. J Mol Diagn. 2021 Nov;23(11):1452-1459. IF: 5.568.

Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson’s Syndrome: A Case Report. Mirallas O, Filippi-Arriaga F, Hernandez Hernandez I, Aubanell A, Chaachou A, Garcia-Alvarez A, Hernando J, Martínez-Saez E, Biagetti B, Capdevila J. Front Endocrinol (Lausanne). 2021 Nov 11;12:731631. IF: 5.555.

Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy. George S, Jones RL, Bauer S, Kang YK, Schöffski P, Eskens F, Mir O, Cassier PA, Serrano C, Tap WD, Trent J, Rutkowski P, Patel S, Chawla SP, Meiri E, Gordon M, Zhou T, Roche M, Heinrich MC, von Mehren M. Oncologist. 2021 Apr;26(4):e639-e649. IF: 5.550.

Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab. Makker V, Taylor MH, Oaknin A, Casado Herraez A, Orlowski R, Dutta L, Ren M, Zale M, O’Malley DM. Oncologist. 2021 Sep;26(9):e1599-e1608. IF: 5.550.

Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study. Zalcberg JR, Heinrich MC, George S, Bauer S, Schöffski P, Serrano C, Gelderblom H, Jones RL, Attia S, D’Amato G, Chi P, Reichardt P, Somaiah N, Meade J, Reichert V, Shi K, Sherman ML, Ruiz-Soto R, von Mehren M, Blay JY. Oncologist. 2021 Nov;26(11):e2053-e2060. IF: 5.550.

Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial. Hurvitz SA, Saura C, Oliveira M, Trudeau ME, Moy B, Delaloge S, Gradishar W, Kim SB, Haley B, Ryvo L, Dai MS, Milovanov V, Alarcón J, Kalmadi S, Cronemberger E, Souza C, Landeiro L, Bose R, Bebchuk J, Kabbinavar F, Bryce R, Keyvanjah K, Brufsky AM. Oncologist. 2021 Aug;26(8):e1327-e1338. IF: 5.550.

Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors. Joseph CP, Abaricia SN, Angelis MA, Polson K, Jones RL, Kang YK, Riedel RF, Schöffski P, Serrano C, Trent J, Tetzlaff ED, Si TD, Zhou T, Doyle A, Bauer S, Roche M, Havnaer T. Oncologist. 2021 Apr;26(4):e622-e631. IF: 5.550.

Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Babiker H, Brana I, Mahadevan D, Owonikoko T, Calvo E, Rischin D, Moreno V, Papadopoulos KP, Crittenden M, Formenti S, Giralt J, Garrido P, Soria A, Hervás-Morón A, Mohan KK, Fury M, Lowy I, Mathias M, Feng M, Li J, Stankevich E. Oncologist. 2021 Sep;26(9):e1508-e1513. IF: 5.550.

Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki-67 Is >= 10%? Merola E, Alonso Gordoa T, Zhang P, Al-Toubah T, Pellè E, Kolasińska-Ćwikła A, Zandee W, Laskaratos F, de Mestier L, Lamarca A, Hernando J, Cwikla J, Strosberg J, de Herder W, Caplin M, Cives M, van Leeuwaarde R. Oncologist. 2021 Apr;26(4):294-301. IF: 5.550.

Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial. Grande E, Rodriguez-Antona C, López C, Alonso-Gordoa T, Benavent M, Capdevila J, Teulé A, Custodio A, Sevilla I, Hernando J, Gajate P, Molina-Cerrillo J, Díez JJ, Santos M, Lanillos J, García-Carbonero R. Oncologist. 2021 Nov;26(11):941-949. IF: 5.550.

NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma. Haakensen VD, Nowak AK, Ellingsen EB, Farooqi SJ, Bjaanæs MM, Horndalsveen H, Mcculloch T, Grundberg O, Cedres SM, Helland Å. J Transl Med. 2021 May 31;19(1):232. IF: 5.531.

Clinical outcomes of allogeneic hematopoietic stem cell transplant recipients developing Cytomegalovirus DNAemia prior to engraftment. Bone Marrow Transplant. Solano C, Vázquez L, Giménez E, de la Cámara R, Albert E, Rovira M, Espigado I, Calvo CM, López-Jiménez J, Suárez-Lledó M, Chinea A, Esquirol A, Pérez A, Bermúdez A, Saldaña R, Heras I, González-Huerta AJ, Torrado T, Batlle M, Jiménez S, Vallejo C, Barba P, Cuesta MÁ, Piñana JL, Navarro D; Spanish Group of Hematopoietic Transplantation and Cell Therapy (GETH). Bone Marrow Transplant. 2021 Jun;56(6):1281-1290. IF: 5.483.

Cryopreservation of unrelated donor hematopoietic stem cells: the right answer for transplantations during the COVID-19 pandemic? Fernandez-Sojo J, Azqueta C, Valdivia E, Martorell L, Medina-Boronat L, Martínez-Llonch N, Torrents S, Codinach M, Canals C, Elorza I, Parody R, Martino R, Trabazo M, Díaz de Heredia C, Ferra C, Valcárcel D, Linares M, Ancochea Á, García-Rey E, García-Muñoz N, Medina L, Castillo N, Carreras E, Villa J, Querol S. Bone Marrow Transplant. 2021 Oct;56(10):2489-2496. IF: 5.483.

Lymphoid and myeloid immune cell reconstitution after nicotinamide-expanded cord blood transplantation. de Koning C, Tao W, Lacna A, van Veghel K, Horwitz ME, Sanz G, Jagasia MH, Wagner JE, Stiff PJ, Hanna R, Cilloni D, Valcárcel D, Peled T, Galamidi Cohen E, Goshen U, Pandit A, Lindemans CA, Jan Boelens J, Nierkens S. Bone Marrow Transplant. 2021 Nov;56(11):2826-2833. IF: 5.483.

Predictors of return to work after autologous stem cell transplantation in patients with multiple myeloma. Granell M, Senín A, Barata A, Cibeira MT, Gironella M, López-Pardo J, Motlló C, Garcia-Guiñón A, Ben-Azaiz R, Abella E, Soler A, Canet M, Martí JM, Martino R, Sierra J, de Larrea CF, Oriol A, Rosiñol L; Group for the Study of Myeloma and Amyloidosis of Catalonia (GEMMAC). Bone Marrow Transplant. 2021 Dec;56(12):2904-2910. IF: 5.483.

Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT. Battipaglia G, Mauff K, Wendel L, Angelucci E, Mohty M, Arcese W, Santarone S, Rubio MT, Kroger N, Fox ML, Blaise D, Iori AP, Fanin R, Chalandon Y, Pioltelli P, Marotta G, Chiusolo P, Sever M, Solano C, Contentin N, de Wreede LC, Czerw T, Hernandez-Boluda JC, Hayden P, McLornan D, Yakoub-Agha I. Bone Marrow Transplant. 2021 Jul;56(7):1593-1602. IF: 5.483.

Use of checkpoint inhibitors in patients with lymphoid malignancies receiving allogeneic cell transplantation: a review. Bobillo S, Nieto JC, Barba P. Bone Marrow Transplant. 2021 Aug;56(8):1784-1793. IF: 5.483.

Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer. Swisher EM, Kristeleit RS, Oza AM, Tinker AV, Ray-Coquard I, Oaknin A, Coleman RL, Burris HA, Aghajanian C, O’Malley DM, Leary A, Welch S, Provencher D, Shapiro GI, Chen LM, Shapira-Frommer R, Kaufmann SH, Goble S, Maloney L, Kwan T, Lin KK, McNeish IA. Gynecol Oncol. 2021 Dec;163(3):490-497. IF: 5.482.

Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL). Gaillard S, Oaknin A, Ray-Coquard I, Vergote I, Scambia G, Colombo N, Fernandez C, Alfaro V, Kahatt C, Nieto A, Zeaiter A, Aracil M, Vidal L, Pardo-Burdalo B, Papai Z, Kristeleit R, O’Malley DM, Benjamin I, Pautier P, Lorusso D. Gynecol Oncol. 2021 Nov;163(2):237-245. IF: 5.482.

Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer. O’Malley DM, Oaknin A, Monk BJ, Selle F, Rojas C, Gladieff L, Berton D, Leary A, Moore KN, Estevez-Diz MDP, Hardy-Bessard AC, Alexandre J, Opperman CP, de Azevedo CRAS, Randall LM, Feliu WO, Ancukiewicz M, Ray-Coquard I. Gynecol Oncol. 2021 Nov;163(2):274-280. IF: 5.482.

Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2. Konecny GE, Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, Ray-Coquard I, Aghajanian C, Coleman RL, O’Malley DM, Leary A, Chen LM, Provencher D, Ma L, Brenton JD, Castro C, Green M, Simmons AD, Beltman J, Harding T, Lin KK, Goble S, Maloney L, Kristeleit RS, McNeish IA, Swisher EM, Xiao JJ. Gynecol Oncol. 2021 Jun;161(3):668-675. IF: 5.482.

Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial. Colombo N, Moore K, Scambia G, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley WH, Kim JW, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P. Gynecol Oncol. 2021 Oct;163(1):41-49. IF: 5.482.

Evaluation of Minimal Important Difference and Responder Definition in the EORTC QLQ-PAN26 Module for Assessing Health-Related Quality of Life in Patients with Surgically Resected Pancreatic Adenocarcinoma. Reni M, Braverman J, Hendifar A, Li CP, Macarulla T, Oh DY, Riess H, Tempero M, Lu B, Marcus J, Joshi N, Botteman M, Dueck AC. Ann Surg Oncol. 2021 Nov;28(12):7545-7554. IF: 5.344.

Minimizing acquisition-related radiomics variability by image resampling and batch effect correction to allow for large-scale data analysis. Ligero M, Jordi-Ollero O, Bernatowicz K, Garcia-Ruiz A, Delgado-Muñoz E, Leiva D, Mast R, Suarez C, Sala-Llonch R, Calvo N, Escobar M, Navarro-Martin A, Villacampa G, Dienstmann R, Perez-Lopez R. Eur Radiol. 2021 Mar;31(3):1460-1470. IF: 5.315.

Outcomes and prognostic factors of adults with refractory or relapsed T-cell acute lymphoblastic leukemia included in measurable residual disease-oriented trials. Ribera JM, Morgades M, Genescà E, Chapchap EC, Montesinos P, Acuña-Cruz E, Gil C, García-Cadenas I, Barba P, González-Campos J, Queipo de Llano MP, Torrent A, Ribera J, Granada I, Bernal T, Díaz-Beyá M, Amigo ML, Coll R, Tormo M, Vall-Llovera F, Gómez-Centurión I, Sánchez-Sánchez MJ, Soria B, Cladera A, Artola MT, Garcia-Guiñon A, Giménez-Conca A, Amador ML, Martínez-Sánchez P, Algarra JL, Vidal MJ, Alonso N, Maluquer C, Llorente L, García-Boyero R, Ciudad J, Feliu E, Orfao A; on behalf of the PETHEMA Group. Hematol Oncol. 2021 Oct;39(4):529-538. IF: 5.271.

The Impact of Excluding Nonrandomized Studies From Systematic Reviews in Rare Diseases: “The Example of Meta-Analyses Evaluating the Efficacy and Safety of Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis”. Sampayo-Cordero M, Miguel-Huguet B, Malfettone A, Pérez-García JM, Llombart-Cussac A, Cortés J, Pardo A, Pérez-López J. Front Mol Biosci. 2021 Jun 22;8:690615. IF: 5.246.

Advanced Pancreatic Neuroendocrine Neoplasms: Which Systemic Treatment Should I Start With? Rodriguez-Freixinos V, Thawer A, Capdevila J, Ferone D, Singh S. Curr Oncol Rep. 2021 May 3;23(7):80. IF: 5.075.

Drug Development in Neuroendocrine Tumors: What Is on the Horizon? Garcia-Alvarez A, Hernando Cubero J, Capdevila J. Curr Treat Options Oncol. 2021 Mar 30;22(5):43. IF: 5.036.

Liquid Biopsy in Gastrointestinal Stromal Tumors: Ready for Prime Time? Gómez-Peregrina D, García-Valverde A, Pilco-Janeta D, Serrano C. Curr Treat Options Oncol. 2021 Feb 27;22(4):32. IF: 5.036.

The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer. Ros J, Baraibar I, Martini G, Salvà F, Saoudi N, Cuadra-Urteaga JL, Dienstmann R, Tabernero J, Élez E. Curr Treat Options Oncol. 2021 Nov 6;22(12):113. IF: 5.036.

gcProfileMakeR: An R Package for Automatic Classification of Constitutive and Non-Constitutive Metabolites. Perez-Sanz F, Ruiz-Hernández V, Terry MI, Arce-Gallego S, Weiss J, Navarro PJ, Egea-Cortines M. Metabolites. 2021 Mar 31;11(4):211. IF: 4.932.

Serum Metabolomic Analysis Suggests Impairment of Myocardial Energy Production in Takotsubo Syndrome. Nuñez-Gil IJ, Andrés M, Benito B, Bernardo E, Vedia O, Ferreira-Gonzalez I, Barba I. Metabolites. 2021 Jul 3;11(7):439. IF: 4.932.

HMGA1, Moonlighting Protein Function, and Cellular. Pujals M,Resar L,Villanueva J. Biomolecules. 2021 Sep 9;11(9):1334.IF: 4.879.

Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer. Dent R, Oliveira M, Isakoff SJ, Im SA, Espié M, Blau S, Tan AR, Saura C, Wongchenko MJ, Xu N, Bradley D, Reilly SJ, Mani A, Kim SB; LOTUS investigators. Breast Cancer Res Treat. 2021 Sep;189(2):377-386. IF: 4.872.

Neratinib plus capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and >= 2 prior HER2-directed regimens. Moy B, Oliveira M, Saura C, Gradishar W, Kim SB, Brufsky A, Hurvitz SA, Ryvo L, Fagnani D, Kalmadi S, Silverman P, Delaloge S, Alarcon J, Kwong A, Lee KS, Ang PCS, Ow SGW, Chu SC, Bryce R, Keyvanjah K, Bebchuk J, Zhang B, Oestreicher N, Bose R, Chan N. Breast Cancer Res Treat. 2021 Jul;188(2):449-458. IF: 4.872.

Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study. Kuemmel S, Tondini CA, Abraham J, Nowecki Z, Itrych B, Hitre E, Karaszewska B, Juárez-Ramiro A, Morales-Vásquez F, Pérez-García JM, Cardona-Huerta S, Monturus E, Sequi M, Restuccia E, Benyunes M, Martín M. Breast Cancer Res Treat. 2021 Jun;187(2):467-476. IF: 4.872.

The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer. Wardley A, Cortes J, Provencher L, Miller K, Chien AJ, Rugo HS, Steinberg J, Sugg J, Tudor IC, Huizing M, Young R, Abramson V, Bose R, Hart L, Chan S, Cameron D, Wright GS, Graas MP, Neven P, Rocca A, Russo S, Krop IE. Breast Cancer Res Treat. 2021 May;187(1):155-165. IF: 4.872.

Is It Time to Implement Adjuvant Targeted Therapy in EGFR-Mutant Non-Small-Cell Lung Cancer? Kulkarni AA, Naqash AR, Puri S, Dienstmann R. JCO Precis Oncol. 2021 Feb 17;5:PO.20.00460. IF: 4.853.

A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer. Byers LA, Navarro A, Schaefer E, Johnson M, Özgüroğlu M, Han JY, Bondarenko I, Cicin I, Dragnev KH, Abel A, Wang X, McNeely S, Hynes S, Lin AB, Forster M. Clin Lung Cancer. 2021 Nov;22(6):531-540. IF: 4.785.

miRNA landscape in primary tumors and matched metastases in gastrointestinal stromal tumors. Ravegnini G, Serrano C, Ricci R, Zhang Q, Terrenato I, Graziosi A, Valori G, Landolfi S, Hrelia P, Angelini S. Epigenomics. 2021 Mar;13(5):369-377. IF: 4.778.

The Wnt signaling receptor Fzd9 is essential for Myc-driven tumorigenesis in pancreatic islets. Zacarías-Fluck MF, Jauset T, Martínez-Martín S, Kaur J, Casacuberta-Serra S, Massó-Vallés D, Serrano Del Pozo E, Martín-Fernández G, González-Larreategui Í, López-Estévez S, Brown-Swigart L, Beaulieu ME, Whitfield JR, Madan B, Virshup DM, Evan GI, Soucek L. Life Sci Alliance. 2021 Mar 2;4(5):e201900490. IF: 4.591.

A data science approach for early-stage prediction of Patient’s susceptibility to acute side effects of advanced radiotherapy. Aldraimli M, Soria D, Grishchuck D, Ingram S, Lyon R, Mistry A, Oliveira J, Samuel R, Shelley LEA, Osman S, Dwek MV, Azria D, Chang-Claude J, Gutiérrez-Enríquez S, De Santis MC, Rosenstein BS, De Ruysscher D, Sperk E, Symonds RP, Stobart H, Vega A, Veldeman L, Webb A, Talbot CJ, West CM, Rattay T; REQUITE consortium, Chaussalet TJ. Comput Biol Med. 2021 Aug;135:104624. IF: 4.589.

Usefulness of NGS for Diagnosis of Dominant Beta-Thalassemia and Unstable Hemoglobinopathies in Five Clinical Cases. Rizzuto V, Koopmann TT, Blanco-Álvarez A, Tazón-Vega B, Idrizovic A, Díaz de Heredia C, Del Orbe R, Pampliega MV, Velasco P, Beneitez D, Santen GWE, Waisfisz Q, Elting M, Smiers FJW, de Pagter AJ, Kerkhoffs JH, Harteveld CL, Mañú-Pereira MDM. Front Physiol. 2021 Feb 5;12:628236. IF: 4.566.

Avapritinib in unresectable or metastatic gastrointestinal stromal tumor with PDGFRA exon 18 mutation: safety and efficacy. Henriques-Abreu M, Serrano C. Expert Rev Anticancer Ther. 2021 Oct;21(10):1081-1088. IF: 4.512.

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-ß and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort. Tan B, Khattak A, Felip E, Kelly K, Rich P, Wang D, Helwig C, Dussault I, Ojalvo LS, Isambert N. Target Oncol. 2021 Jul;16(4):435-446. IF: 4.493.

Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience. Oleas D, Bolufer M, Agraz I, Felip E, Muñoz E, Gabaldón A, Bury R, Espinel E, Serón D, García-Carro C, Soler MJ. Clin Kidney J. 2020 Feb 10;14(5):1364-1370. IF: 4.452.

LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology. Garrido P, Paz-Ares L, Majem M, Morán T, Trigo JM, Bosch-Barrera J, García-Campelo R, González-Larriba JL, Sánchez-Torres JM, Isla D, Viñolas N, Camps C, Insa A, Juan Ó, Massuti B, Paredes A, Artal Á, López-Brea M, Palacios J, Felip E. Cancer Med. 2021 Sep;10(17):5878-5888. IF: 4.452.

Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety. Oaknin A, Oza AM, Lorusso D, Aghajanian C, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Amenedo Gancedo M, Fong PC, Goh JC, O’Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cameron T, Maloney L, Goble S, Ledermann JA, Coleman RL. Cancer Med. 2021 Oct;10(20):7162-7173. IF: 4.452.

Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma. Iacoboni G, Villacampa G, Martinez-Cibrian N, Bailén R, Lopez Corral L, Sanchez JM, Guerreiro M, Caballero AC, Mussetti A, Sancho JM, Hernani R, Abrisqueta P, Solano C, Sureda A, Briones J, Martin Garcia-Sancho A, Kwon M, Reguera-Ortega JL, Barba P; GETH, GELTAMO Spanish Groups. Cancer Med. 2021 May;10(10):3214-3223. IF: 4.452.

Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS). Grivas P, Loriot Y, Morales-Barrera R, Teo MY, Zakharia Y, Feyerabend S, Vogelzang NJ, Grande E, Adra N, Alva A, Necchi A, Rodriguez-Vida A, Gupta S, Josephs DH, Srinivas S, Wride K, Thomas D, Simmons A, Loehr A, Dusek RL, Nepert D, Chowdhury S. BMC Cancer. 2021 May 24;21(1):593. IF: 4.430.

Expert opinion paper on the treatment of hemophilia B with albutrepenonacog alfa. Álvarez Román MT, Benítez O, Canaro MI, López Fernández MF, López Jaime FJ, Mateo Arranz J, Núñez R, Rodríguez López M, Sierra Aisa C, Jiménez-Yuste V. Expert Opin Biol Ther. 2021 Sep;21(9):1165-1171. IF: 4.388.

Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond. Perez J, Garrigós L, Gion M, Jänne PA, Shitara K, Siena S, Cortés J. Expert Opin Biol Ther. 2021 Jul;21(7):811-824. IF: 4.388.

Up-to-date role of aflibercept in the treatment of colorectal cancer. Saoudi Gonzalez N, Salvà F, Ros J, Baraibar I, Marmolejo D, Valdivia A, Cuadra-Urteaga JL, Mulet N, Tabernero J, Élez E. Expert Opin Biol Ther. 2021 Oct;21(10):1315-1324. IF: 4.388.

Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy. Partridge AH, Niman SM, Ruggeri M, Peccatori FA, Azim HA Jr, Colleoni M, Saura C, Shimizu C, Sætersdal AB, Kroep JR, Mailliez A, Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Walshe JM, Borrego MR, Moore HC, Saunders C, Cardoso F, Susnjar S, Bjelic-Radisic V, Smith KL, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O. Breast. 2021 Oct;59:327-338. IF: 4.380.

A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors. Poveda A, Oaknin A, Romero I, Guerrero-Zotano A, Fariñas-Madrid L, Rodriguez-Freixinos V, Mallol P, Lopez-Reig R, Lopez-Guerrero JA. Sci Rep. 2021 Feb 24;11(1):4433. IF: 4.379.

Combining microfluidics with machine learning algorithms for RBC classification in rare hereditary hemolytic anemia. Rizzuto V, Mencattini A, Álvarez-González B, Di Giuseppe D, Martinelli E, Beneitez-Pastor D, Mañú-Pereira MDM, Lopez-Martinez MJ, Samitier J. Sci Rep. 2021 Jun 30;11(1):13553. IF: 4.379.

Description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumab. Trilla-Fuertes L, Gámez-Pozo A, Maurel J, Garcia-Carbonero R, Capdevila J, G-Pastrián L, Mendiola M, Peña C, López-Vacas R, Cuatrecasas M, García-Alfonso P, Ramos-Ruiz R, Llorens C, Ghanem I, Conill C, Heredia-Soto V, Campos-Barros Á, Fresno Vara JÁ, Feliu J. Sci Rep. 2021 Apr 1;11(1):7402. IF: 4.379.

Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort. Cedres S, Assaf JD, Iranzo P, Callejo A, Pardo N, Navarro A, Martinez-Marti A, Marmolejo D, Rezqallah A, Carbonell C, Frigola J, Amat R, Pedrola A, Dienstmann R, Felip E. Sci Rep. 2021 Nov 1;11(1):21357. IF: 4.379.

Precise enhancement quantification in post-operative MRI as an indicator of residual tumor impact is associated with survival in patients with glioblastoma. Garcia-Ruiz A, Naval-Baudin P, Ligero M, Pons-Escoda A, Bruna J, Plans G, Calvo N, Cos M, Majós C, Perez-Lopez R. Sci Rep. 2021 Jan 12;11(1):695. IF: 4.379.

Robust imaging habitat computation using voxel-wise radiomics features. Bernatowicz K, Grussu F, Ligero M, Garcia A, Delgado E, Perez-Lopez R. Sci Rep. 2021 Oct 11;11(1):20133. IF: 4.379.

Ultrasound evaluation of joint damage and disease activity in adult patients with severe haemophilia A using the HEAD-US system. Jiménez-Yuste V, de la Corte-Rodríguez H, Álvarez-Román MT, Martín-Salces M, Querol F, Bonanad S, Mingot-Castellano ME, Fernández-Mosteirín N, Canaro M, Santamaría A, Núñez R, García-Frade LJ, Martinoli C, Kim HK. Haemophilia. 2021 May;27(3):479-487. IF: 4.287.

Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter’s transformation. Hodkinson BP, Schaffer M, Brody JD, Jurczak W, Carpio C, Ben-Yehuda D, Avivi I, Forslund A, Özcan M, Alvarez J, Ceulemans R, Fourneau N, Younes A, Balasubramanian S. Transl Oncol. 2021 Jan;14(1):100977. IF: 4.243.

Limited Liver or Lung Colorectal Cancer Metastases. Systemic Treatment, Surgery, Ablation or SBRT. Molla M, Fernandez-Plana J, Albiol S, Fondevila C, Vollmer I, Cases C, Garcia-Criado A, Capdevila J, Conill C, Fundora Y, Fernandez-Martos C, Pineda E. J Clin Med. 2021 May 14;10(10):2131. IF: 4.242.

Management of advanced ovarian cancer in Spain: an expert Delphi consensus. Redondo A, Oaknin A, Rubio MJ, Barretina-Ginesta MP, de Juan A, Manso L, Romero I, Martin-Lorente C, Poveda A, Gonzalez-Martin A. J Ovarian Res. 2021 May 26;14(1):72. IF: 4.234.

Emerging drugs for the treatment of gastrointestinal stromal tumors. Pilco-Janeta DF, García-Valverde A, Gomez-Peregrina D, Serrano C. Expert Opin Emerg Drugs. 2021 Mar;26(1):53-62. IF: 4.191.

Emerging biological drugs for the treatment of gastroesophageal adenocarcinoma. Alsina M, Diez M, Tabernero J. Expert Opin Emerg Drugs. 2021 Dec;26(4):385-400. IF: 4.191.

Current Perspectives and Novel Strategies of NRAS-Mutant Melanoma. Garcia-Alvarez A, Ortiz C, Muñoz-Couselo E. Onco Targets Ther. 2021 Jun 9;14:3709-3719. IF: 4.147.

Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice. Álamo MDC, Ochenduszko S, Crespo G, Corral M, Oramas J, Sancho P, Medina J, Garicano F, López P, Campos Balea B, Rodríguez Garzotto A, Muñoz-Couselo E. Onco Targets Ther. 2021 Nov 27;14:5345-5352. IF: 4.147.

BARD1 Pathogenic Variants are Associated with Triple-Negative Breast Cancer in a Spanish Hereditary Breast and Ovarian Cancer Cohort. Rofes P, Del Valle J, Torres-Esquius S, Feliubadaló L, Stradella A, Moreno-Cabrera JM, López-Doriga A, Munté E, De Cid R, Campos O, Cuesta R, Teulé Á, Grau È, Sanz J, Capellá G, Díez O, Brunet J, Balmaña J, Lázaro C. Genes (Basel). 2021 Jan 23;12(2):150. IF: 4.096.

Fibroglandular tissue distribution in the breast during mammography and tomosynthesis based on breast CT data: A patient-based characterization of the breast parenchyma. Fedon C, Caballo M, García E, Diaz O, Boone JM, Dance DR, Sechopoulos I. Med Phys. 2021 Mar;48(3):1436-1447. IF: 4.071.

Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer. Brendel K, Bekaii-Saab T, Boland PM, Dayyani F, Dean A, Macarulla T, Maxwell F, Mody K, Pedret-Dunn A, Wainberg ZA, Zhang B. CPT Pharmacometrics Syst Pharmacol. 2021 Dec;10(12):1550-1563. IF: 4.054.

Mastocytosis in the skin accompanied by pseudo-Kaposi’s sarcoma. Vergara-de-la-Campa L, Torrado I, Recuero-Pradillo M, Torrelo A, Gironella M, Pardal E, Godoy AC, Matito A, Pérez-Hortet C, Mollejo M, Álvarez-Twöse I. Mastocytosis in the skin accompanied by pseudo-Kaposi’s sarcoma. J Dermatol. 2021 May;48(5):657-660. IF: 4.005.

Comparison of Neurite Orientation Dispersion and Density Imaging and Two-Compartment Spherical Mean Technique Parameter Maps in Multiple Sclerosis. Johnson D, Ricciardi A, Brownlee W, Kanber B, Prados F, Collorone S, Kaden E, Toosy A, Alexander DC, Gandini Wheeler-Kingshott CAM, Ciccarelli O, Grussu F. Front Neurol. 2021 Jun 14;12:662855. IF: 4.003.

Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1. Chen LT, Macarulla T, Blanc JF, Mirakhur B, de Jong FA, Belanger B, Bekaii-Saab T, Siveke JT. Pancreatology. 2021 Jan;21(1):192-199. IF: 3.996.

Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus. Viúdez A, Crespo G, Gómez Dorronsoro ML, Arozarena I, Marín-Méndez JJ, Custodio A, Benavent M, Goñi S, García-Paredes B, Hernando J, Durantez M, Alonso V, Riesco MDC, López C, Jiménez-Fonseca P, San Vicente BL, González-Borja I, Sevilla I, Hernández-Garcia I, Carmona-Bayonas A, Capdevila J, Pérez-Sanz J, García-Carbonero R, Pérez-Ricarte L, Llanos M, Vera R, De Jesús Acosta A. Pancreatology. 2021 Jan;21(1):215-223. IF: 3.996.

First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis. García-Alfonso P, Díaz-Rubio E, Abad A, Carrato A, Massutí B, Ortiz-Morales MJ, Manzano Mozo JL, Muñoz A, Durán G, Sastre J, Safont MJ, Ferreiro R, Rivera F, González E, Valladares-Ayerbes M, Grávalos C, Alonso-Orduña V, Viéitez JM, Yubero A, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD): A Abad, J L Manzano, A Antón, V Alonso Orduña, A Arrivi, E Falcó, A Carrato, F Longo-Muñoz, C Guillén-Ponce, J L García López, J Gallego, A Rodriguez Lescure, A Cervantes, A Etxeberría, A La Casta, A López-Ladrón, A M García Tapiador, A Ruiz, A Salud, A Sánchez Ruiz, M Provencio, A Velasco, A Viudez, V Arrazubi, B Massutí, A Yuste, B Queralt, X Hernández-Yagüe, C Alonso, C Fernández-Martos, C García-Girón, C Grávalos, L Robles, C Martín, S Albiol, C Pericay, D Almenar, E Aranda, A Gómez, E Barrajón, E Cabrera, L Del Río, A Oltra, E Díaz-Rubio, J Sastre, B García-Paredes, E González, V Conde, E Jiménez, E Marcuello, F Losa, F Rivera, C López-López, F J Dorta, R Afonso, H Manzano, J Alcaide, J Alfaro, J Cassinello, J García-Foncillas, J L García Puche, J M Campos, V Alberola, J M Tabernero, et al. Drugs Aging. 2021 Mar;38(3):219-231. IF: 3.923.

Between immunomodulation and immunotolerance: The role of IFNY in SARS-CoV-2 disease. Todorović-Raković N, Whitfield JR. Cytokine. 2021 Oct;146:155637. IF: 3.861.

A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations. Piha-Paul SA, Azaro A, Arkenau HT, Oh DY, Galsky MD, Pal SK, Hamada K, He Y, Yamamiya I, Benhadji KA, Hollebecque A. Invest New Drugs. 2021 Oct;39(5):1324-1334. IF: 3.850.

Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study. Olmedo ME, Forster M, Moreno V, López-Criado MP, Braña I, Flynn M, Doger B, de Miguel M, López-Vilariño JA, Núñez R, Kahatt C, Cullell-Young M, Zeaiter A, Calvo E. Invest New Drugs. 2021 Oct;39(5):1275-1283. IF: 3.850.

Phase 1 study of 2 high dose intensity schedules of the pan-Notch inhibitor crenigacestat (LY3039478) in combination with prednisone in patients with advanced or metastatic cancer. Azaro A,Baldini C,Rodon J,Soria JC,Yuen E,Lithio A,Oakley G,Benhadji KA,Massard C. Invest New Drugs. 2021. 39. (1):p. 193-201. Azaro A, Baldini C, Rodon J, Soria JC, Yuen E, Lithio A, Oakley G, Benhadji KA, Massard C. Invest New Drugs. 2021 Feb;39(1):193-201. IF: 3.850.

The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial. How JA, Jazaeri A, Westin SN, Sood AK, Ramondetta LM, Xu M, Abonofal A, Karp DD, Subbiah V, Stephen B, Rodon JA, Yang F, Naing A. Invest New Drugs. 2021 Jun;39(3):829-835. IF: 3.850.

A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors. Azaro A, Massard C, Tap WD, Cassier PA, Merchan J, Italiano A, Anderson B, Yuen E, Yu D, Oakley G 3rd, Benhadji KA, Pant S. Invest New Drugs. 2021 Aug;39(4):1089-1098. IF: 3.850.

Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative. Bosch F, Navarro B, Crespo M, Alcoceba M, Sánchez JB, Tazón B, Serrano A, Álvarez MG, Serrano LG, Alonso-Torres P, Villanueva M, Loriente C, Abrisqueta P, Peiró M, García-Marco JA, González M, Terol MJ. Ann Hematol. 2021 Mar;100(3):825-830. IF: 3.673.

Combination of novel molecular targeted agent plus R-CHOP-based regimen versus R-CHOP alone in previously untreated diffuse large B-cell lymphoma (DLBCL) patients: a systematic review and meta-analysis. Villacampa G, Dienstmann R, Bosch F, Abrisqueta P. Ann Hematol. 2021 Dec;100(12):2969-2978. IF: 3.673.

Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients. González-Barca E, Capote FJ, Gómez-Codina J, Panizo C, Salar A, Sancho JM, López A, Briones J, Muñoz A, Encuentra M, Mercadal S, Domingo-Domenech E, de Sevilla AF; GELTAMO (Spanish Lymphoma Group) and GOTEL (Group of Oncology for Therapy and Study of Lymphomas). Ann Hematol. 2021 Apr;100(4):1023-1029. IF: 3.673.

Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy. Iacoboni G, Simó M, Villacampa G, Catalá E, Carpio C, Díaz-Lagares C, Vidal-Jordana Á, Bobillo S, Marín-Niebla A, Pérez A, Jiménez M, Abrisqueta P, Bosch F, Barba P. Ann Hematol. 2021 Sep;100(9):2303-2310. IF: 3.673.

New treatments in advanced gastrointestinal stromal tumor. Serrano C. Curr Opin Oncol. 2021 Jul 1;33(4):323-328. IF: 3.645.

Incidence and clinical pattern of contralateral synchronous and metachronous germ cell testicular cancer. Maroto P, García Del Muro X, Valverde C, Pinto A, Sanchez A, Guma J, Alonso T, Martínez Del Prado P, Vazquez S, Mellado B, Aparicio J, Fernandez-Aramburo A, Girones R, Terrasa J; Spanish Germ Cell Cancer Group. Urol Oncol. 2021 Feb;39(2):135.e17-135.e23. IF: 3.498.

ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer. Monk BJ, Coleman RL, Fujiwara K, Wilson MK, Oza AM, Oaknin A, O’Malley DM, Lorusso D, Westin SN, Safra T, Herzog TJ, Marmé F, N Eskander R, Lin KK, Shih D, Goble S, Grechko N, Hume S, Maloney L, McNeish IA, Kristeleit RS. Int J Gynecol Cancer. 2021 Dec;31(12):1589-1594. IF: 3.437.

Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3. Clamp AR, Lorusso D, Oza AM, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Scambia G, Leary A, Holloway RW, Amenedo Gancedo M, Fong PC, Goh JC, O’Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cameron T, Goble S, Coleman RL, Ledermann JA. Int J Gynecol Cancer. 2021 Jul;31(7):949-958. IF: 3.437.

Is there a procoagulant state long-term after lung transplantation? A prospective study. Sáez-Giménez B, Clofent D, López Meseguer M, Bravo Masgoret C, Monforte V, Berastegui C, Revilla-Lopez E, Barrecheguren M, Arjona-Peris M, Ruiz V, Ramon MA, Gómez-Ollés S, Santamaría A, Roman A. Respir Med. 2021 Nov;188:106584. IF: 3.415.

Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies. Sotelo M, Alonso-Gordoa T, Gajate P, Gallardo E, Morales-Barrera R, Pérez-Gracia JL, Puente J, Sánchez P, Castellano D, Durán I. Clin Transl Oncol. 2021 Apr;23(4):882-891. IF: 3.405.

Controversies in the treatment of RAS wild-type metastatic colorectal cancer. Vera R, Salgado M, Safont MJ, Gallego J, González E, Élez E, Aranda E. Clin Transl Oncol. 2021 Apr;23(4):827-839. IF: 3.405.

Dynamics of clinical biomarkers as predictors of immunotherapy benefit in metastatic melanoma patients. Hernando-Calvo A, García-Alvarez A, Villacampa G, Ortiz C, Bodet D, García-Patos V, Recio JA, Dienstmann R, Muñoz-Couselo E. Clin Transl Oncol. 2021 Feb;23(2):311-317. IF: 3.405.

GEIS-SEHOP clinical practice guidelines for the treatment of rhabdomyosarcoma. Gallego S, Bernabeu D, Garrido-Pontnou M, Guillen G, Hindi N, Juan-Ribelles A, Márquez C, Mata C, Orcajo J, Ramírez G, Ramos M, Romagosa C, Ruano D, Rubio P, Vergés R, Valverde C; GEIS (Grupo Español de Investigación en Sarcomas), SEHOP (Sociedad Española de Hematología y Oncología Pediátrica): S Gallego, D Bernabeu, N Hindi, C Mata, C Marquez, J Orcajo, G Ramírez, C Romagosa, C Valverde, R Vergés, A Juan-Ribelles, D Ruano, P Rubio. Clin Transl Oncol. 2021 Dec;23(12):2460-2473. IF: 3.405.

Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept. González Astorga B, Salvà Ballabrera F, Aranda Aguilar E, Élez Fernández E, García-Alfonso P, González Flores E, Vera García R, Fernández Montes A, López Muñoz AM, Salud Salvia A. Clin Transl Oncol. 2021 Aug;23(8):1520-1528. IF: 3.405.

Randomized placebo-controlled phase II trial of high-dose melatonin mucoadhesive oral gel for the prevention and treatment of oral mucositis in patients with head and neck cancer undergoing radiation therapy concurrent with systemic treatment. Lozano A, Marruecos J, Rubió J, Farré N, Gómez-Millán J, Morera R, Planas I, Lanzuela M, Vázquez-Masedo MG, Cascallar L, Giralt J, Escames G, Valentí V, Grima P, Bosser R, Tarragó C, Mesía R. Clin Transl Oncol. 2021 Sep;23(9):1801-1810. IF: 3.405.

SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020). Nadal E, Bosch-Barrera J, Cedrés S, Coves J, García-Campelo R, Guirado M, López-Castro R, Ortega AL, Vicente D, de Castro-Carpeño J. Clin Transl Oncol. 2021 May;23(5):980-987. IF: 3.405.

SEOM clinical guideline for the management of cutaneous melanoma (2020). Majem M, Manzano JL, Marquez-Rodas I, Mujika K, Muñoz-Couselo E, Pérez-Ruiz E, de la Cruz-Merino L, Espinosa E, Gonzalez-Cao M, Berrocal A. Clin Transl Oncol. 2021 May;23(5):948-960. IF: 3.405.

SEOM clinical guideline for management of adult medulloblastoma (2020). Luque R, Benavides M, Del Barco S, Egaña L, García-Gómez J, Martínez-García M, Pérez-Segura P, Pineda E, Sepúlveda JM, Vieito M. Clin Transl Oncol. 2021 May;23(5):940-947. IF: 3.405.

Chart review of diagnostic methods, baseline characteristics and symptoms for European patients with pancreatic cancer. Carrato A, Melisi D, Prager G, Westphalen CB, Ferreras A, D’Esquermes N, Taieb J, Mercadé TM. Future Oncol. 2021 May;17(15):1843-1854. IF: 3.404.

Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer. Oaknin A, Tinker AV, Gilbert L, Samouëlian V, Mathews C, Brown J, Barretina-Ginesta MP, Moreno V, Gravina A, Abdeddaim C, Banerjee S, Guo W, Danaee H, Im E, Sabatier R. Future Oncol. 2021 Oct 1;17(29):3781-3785. IF: 3.404.

First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811. Chung HC, Bang YJ, S Fuchs C, Qin SK, Satoh T, Shitara K, Tabernero J, Van Cutsem E, Alsina M, Cao ZA, Lu J, Bhagia P, Shih CS, Janjigian YY. Future Oncol. 2021 Feb;17(5):491-501. IF: 3.404.

FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer. Dasari A, Sobrero A, Yao J, Yoshino T, Schelman W, Yang Z, Chien C, Kania M, Tabernero J, Eng C. Future Oncol. 2021 Aug;17(24):3151-3162. IF: 3.404.

KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma. Tabernero J, Bang YJ, Van Cutsem E, Fuchs CS, Janjigian YY, Bhagia P, Li K, Adelberg D, Qin SK. Future Oncol. 2021 Aug;17(22):2847-2855. IF: 3.404.

MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. Verstovsek S, Chen CC, Egyed M, Ellis M, Fox L, Goh YT, Gupta V, Harrison C, Kiladjian JJ, Lazaroiu MC, Mead A, McLornan D, McMullin MF, Oh ST, Perkins A, Platzbecker U, Scheid C, Vannucchi A, Yoon SS, Kowalski MM, Mesa RA. Future Oncol. 2021 Apr;17(12):1449-1458. IF: 3.404.

Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancer. Solomon BJ, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, Thurm H, Calella AM, Peltz G, Shaw AT. Future Oncol. 2021 Dec 1;17(34):4649-4656. IF: 3.404.

Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design. Tabernero J, Taieb J, Prager GW, Ciardiello F, Fakih M, Leger C, Fougeray R, Amellal N, van Cutsem E. Future Oncol. 2021 Jun;17(16):1977-1985. IF:3.404.

Genetics of Chronic Lymphocytic Leukemia. Bosch F, Dalla-Favera R. Cancer J. 2021 Jul-Aug 01;27(4):259-265. IF: 3.360.

Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysis. Fudio S, Tabernero J, Subbiah V, Chawla SP, Moreno V, Longo F, Lopez R, Anton A, Trigo JM, Shapiro G, Jeong W, Villalobos VM, Lubomirov R, Fernandez-Teruel C, Alfaro V, Boni V. Cancer Chemother Pharmacol. 2021 Jan;87(1):113-124. IF: 3.333.

Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study. Feliu J, Jorge Fernández M, Macarulla T, Massuti B, Albero A, González González JF, Quintero-Aldana G, Delgado-Mingorance JI, Fernández Montes A, García Piernavieja C, Valladares-Ayerbes M, López Muñoz AM, Mondéjar Solís R, Vicente P, Casado Gonzalez E, González Cebrián I, López-Vivanco G. Cancer Chemother Pharmacol. 2021 Apr;87(4):543-553. IF: 3.333.

Single- and multiple-dose pharmacokinetics, potential for CYP3A inhibition, and food effect in patients with cancer and healthy subjects receiving ipatasertib. Malhi V, Budha N, Sane R, Huang J, Liederer B, Meng R, Patel P, Deng Y, Cervantes A, Tabernero J, Musib L. Cancer Chemother Pharmacol. 2021 Dec;88(6):921-930. IF: 3.333.

Emerging Treatment Strategies in Pancreatic Cancer. Trunk A, Miotke L, Nevala-Plagemann C, Verdaguer H, Macarulla T, Garrido-Laguna I. Pancreas. 2021 Jul 1;50(6):773-787. IF: 3.327.

Is acute lymphoblastic leukemia with mature B-cell phenotype and KMT2A rearrangements a new entity? A systematic review and meta-analysis. Hidalgo-Gómez G, Palacio-Garcia C, Gallur L, Blanco A, Tazón-Vega B, Saumell S, Martínez N, Murillo L, Murciano T, Velasco P, Bosch F, Diaz-Heredia C, Ortega M. Leuk Lymphoma. 2021 Sep;62(9):2202-2210. IF: 3.280.

Selection process and causes of non-eligibility for CD19 CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma in a European center. Carpio C, Iacoboni G, Villacampa G, Catalá E, Bobillo S, Pérez A, Jiménez M, Segura L, Olivé M, Farriols A, Abrisqueta P, Valcárcel D, Carreras MJ, Bosch F, Barba P. Leuk Lymphoma. 2021 Sep;62(9):2288-2291. IF: 3.280.

Frequency, Clinical Characteristics and Outcome of Adults With Acute Lymphoblastic Leukemia and COVID 19 Infection in the First vs. Second Pandemic Wave in Spain. Ribera JM, Morgades M, Coll R, Barba P, López-Lorenzo JL, Montesinos P, Foncillas MA, Cabrero M, Gómez-Centurión I, Morales MD, Varela MR, Herrera P, García-Cadenas I, Calbacho M, Torrent A, Maluquer C, Calabuig M, Garcia-Guiñon A, Bautista G, Llorente L, Gil C, Artola MT, González-Campos J, Fernández-Moreno A, Bárez A, Giménez-Pérez T, Bergua J, Sánchez-Sánchez MJ, Mateos MC, Piñana JL. Clin Lymphoma Myeloma Leuk. 2021 Oct;21(10):e801-e809. IF: 3.230.

Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study). Abrisqueta P, Loscertales J, Terol MJ, Ramírez Payer Á, Ortiz M, Pérez I, Cuellar-García C, Fernández de la Mata M, Rodríguez A, Lario A, Delgado J, Godoy A, Arguiñano Pérez JM, Berruezo MJ, Oliveira A, Hernández-Rivas JÁ, García Malo MD, Medina Á, García Martin P, Osorio S, Baltasar P, Fernández-Zarzoso M, Marco F, Vidal Manceñido MJ, Smucler Simonovich A, López Rubio M, Jarque I, Suarez A, Fernández Álvarez R, Lancharro Anchel A, Ríos E, Losada Castillo MDC, Pérez Persona E, García Muñoz R, Ramos R, Yáñez L, Bello JL, Loriente C, Acha D, Villanueva M. Clin Lymphoma Myeloma Leuk. 2021 Dec;21(12):e985-e999. IF: 3.231.

Physician-perceived utility of the EORTC QLQ-GINET21 questionnaire in the treatment of patients with gastrointestinal neuroendocrine tumours: a multicentre, cross-sectional survey (QUALINETS). Benavent M, Sastre J, Escobar IG, Segura A, Capdevila J, Carmona A, Sevilla I, Alonso T, Crespo G, García L, Canal N, de la Cruz G, Gallego J. Health Qual Life Outcomes. 2021 Jan 30;19(1):38. IF: 3.186.

Adverse prognostic impact of complex karyotype (>= 3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL). Genescà E, Morgades M, González-Gil C, Fuster-Tormo F, Haferlach C, Meggendorfer M, Montesinos P, Barba P, Gil C, Coll R, Moreno MJ, Martínez-Carballeira D, García-Cadenas I, Vives S, Ribera J, González-Campos J, Díaz-Beya M, Mercadal S, Artola MT, Cladera A, Tormo M, Bermúdez A, Vall-Llovera F, Martínez-Sánchez P, Amigo ML, Monsalvo S, Novo A, Cervera M, García-Guiñon A, Ciudad J, Cervera J, Hernández-Rivas JM, Granada I, Haferlach T, Orfao A, Solé F, Ribera JM. Leuk Res. 2021 Oct;109:106612. IF: 3.156.

Genetic characterization of acute myeloid leukemia patients with mutations in IDH1/2 genes. Acha P, Hoyos M, Pratcorona M, Fuster-Tormo F, Palomo L, Ortega E, Zamora L, Vives S, Granada I, Montoro J, Garcia A, Arnan M, Cervera M, Canet M, Gallardo D, Arenillas L, Esteve J, Baragay J, Salamero O, Motlló C, Ortín X, Sierra J, Solé F. Leuk Res. 2021 Feb;101:106492. IF: 3.156.

Chronic lymphocytic leukemia-like monoclonal B-cell lymphocytosis exhibits an increased inflammatory signature that is reduced in early-stage chronic lymphocytic leukemia. Blanco G, Puiggros A, Sherry B, Nonell L, Calvo X, Puigdecanet E, Chiu PY, Kieso Y, Ferrer G, Palacios F, Arnal M, Rodríguez-Rivera M, Gimeno E, Abella E, Rai KR, Abrisqueta P, Bosch F, Calon A, Ferrer A, Chiorazzi N, Espinet B. Exp Hematol. 2021 Mar;95:68-80. IF: 3.084.

A decade of changes in management of immune thrombocytopenia, with special focus on elderly patients. Lozano ML, Mingot-Castellano ME, Perera MM, Jarque I, Campos-Alvarez RM, González-López TJ, Carreño-Tarragona G, Bermejo N, Lopez-Fernandez MF, de Andrés A, Valcarcel D, Casado-Montero LF, Alvarez-Roman MT, Orts MI, Novelli S, González-Porras JR, Bolaños E, López-Ansoar E, Orna-Montero E, Vicente V. Blood Cells Mol Dis. 2021 Feb;86:102505. IF: 3.039.

Ex vivo T-cell depletion vs post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil as graft-vs-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Montoro J, Roldán E, Piñana JL, Barba P, Chorão P, Quintero A, Hernani R, Ortí G, Lorenzo JI, Balaguer-Roselló A, Salamero O, Fox L, Solves P, Gómez I, Guerreiro M, Hernández Boluda JC, Sanz G, Solano C, Sanz MÁ, Valcárcel D, Sanz J. Eur J Haematol. 2021 Jan;106(1):114-125. IF: 2.997.

Treatment of steroid-refractory chronic graft-versus-host disease with imatinib: Real-life experience of the Spanish group of hematopoietic transplantation (GETH). Parra Salinas I, Bermudez A, López Corral L, Lopez Godino O, Móles-Poveda P, Martín G, Costilla Barriga L, Ferrá Coll C, Márquez-Malaver F, Ortí G, Zudaire Ripa MT, Rifon J, Martinez C; Spanish Group of Hematopoietic Transplantation (GETH). Clin Transplant. 2021 May;35(5):e14255. IF: 2.863.

A Phase 1 Study of a CDH6-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors with Evaluation of Inflammatory and Neurological Adverse Events. Schöffski P, Concin N, Suarez C, Subbiah V, Ando Y, Ruan S, Wagner JP, Mansfield K, Zhu X, Origuchi S, DiDominick S, Bialucha CU, Faris JE, Tran B. Oncol Res Treat. 2021;44(10):547-556. IF: 2.825.

Overview of hereditary breast and ovarian cancer (HBOC) guidelines across Europe. Marmolejo DH, Wong MYZ, Bajalica-Lagercrantz S, Tischkowitz M, Balmaña J; extended ERN-GENTURIS Thematic Group 3: Patócs AB, Chappuis P, Colas C, Genuardi M, Haanpää M, Vetti HH, Hoogerbrugge N, Irmejs A, Kahre T, Klink B, Krajc M, Milagre TH, de Putter R, Steinke V, Wadt K, Wimmer K. Overview of hereditary breast and ovarian cancer (HBOC) guidelines across Europe. Eur J Med Genet. 2021 Dec;64(12):104350. IF: 2.708.

Clinical development and evaluation of a VEGF-D assay in plasma from patients with metastatic colorectal cancer in the RAISE study. Taniguchi H, Yoshino T, Yamaguchi K, Yamazaki K, Nixon AB, Tabernero J, Van Cutsem E, Robling KR, Abada PB, Hozak RR, Siegel R, Fill JA, Wijayawardana S, Walgren RA, Giles B, Jones A, Pitts KR, Drove N, Muro K. Curr Med Res Opin. 2021 Oct;37(10):1769-1778. IF: 2.580.

BRCA1 and BRCA2 whole cDNA analysis in unsolved hereditary breast/ovarian cancer patients. Montalban G, Bonache S, Bach V, Gisbert-Beamud A, Tenés A, Moles-Fernández A, López-Fernández A, Carrasco E, Balmaña J, Diez O, Gutiérrez-Enríquez S. Cancer Genet. 2021 Nov;258-259:10-17. IF: 2.523.

LILRB1: A Novel Diagnostic B-Cell Marker to Distinguish Neoplastic B Lymphoblasts From Hematogones. Saumell Tutusaus S, Pirruccello E, Fuda F, Churchill H, Chen D, Zhang CC, Chen W. Am J Clin Pathol. 2021 Nov 8;156(6):941-949. IF: 2.493.

Evaluation of the Effects of Repeat-Dose Dabrafenib on the Single-Dose Pharmacokinetics of Rosuvastatin (OATP1B1/1B3 Substrate) and Midazolam (CYP3A4 Substrate). Nebot N, Won CS, Moreno V, Muñoz-Couselo E, Lee DY, Gasal E, Bouillaud E. Clin Pharmacol Drug Dev. 2021 Sep;10(9):1054-1063. IF: 2.448.

Results of a Dose-Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer. Felip E, Burotto M, Zvirbule Z, Herraez-Baranda LA, Chanu P, Kshirsagar S, Maiya V, Chan P, Pozzi E, Marchand M, Monchalin M, Tanaka K, Tosti N, Wang B, Restuccia E. Clin Pharmacol Drug Dev. 2021 Oct;10(10):1142-1155. IF: 2.448.

Metastatic nonclear renal cell carcinoma current review in evolving treatment strategies. Suárez C, Díaz-Mejía N, Morales-Barrera R, González M, Mateo J, Carles J. Curr Opin Urol. 2021 May 1;31(3):242-248. IF: 2.309.

Assessment of the association between cytomegalovirus DNAemia and subsequent acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation: A multicenter study from the Spanish hematopoietic transplantation and cell therapy group. Bueno F, Solano C, Vázquez L, Giménez E, de la Cámara R, Albert E, Rovira M, Espigado I, Martín Calvo C, López-Jiménez J, Suárez-Lledó M, Chinea A, Esquirol A, Pérez A, Bermúdez A, Saldaña R, Heras I, González-Huerta AJ, Torrado T, Batlle M, Jiménez S, Vallejo C, Barba P, Cuesta MÁ, Duarte R, Piñana JL, Navarro D; Spanish Group of Hematopoietic Transplantation, Cell Therapy (GETH). Transpl Infect Dis. 2021 Aug;23(4):e13627. IF: 2.228.

Reduced expansion of CD94/NKG2C+ NK cells in chronic lymphocytic leukemia and CLL-like monoclonal B-cell lymphocytosis is not related to increased human cytomegalovirus seronegativity or NKG2C deletions. Puiggros A, Blanco G, Muntasell A, Rodríguez-Rivera M, Nonell L, Altadill M, Puigdecanet E, Arnal M, Calvo X, Gimeno E, Abella E, Abrisqueta P, Bosch F, Yélamos J, Ferrer A, López-Botet M, Espinet B. Int J Lab Hematol. 2021 Oct;43(5):1032-1040. IF: 2.141.

Hepatic sinusoidal obstruction syndrome associated with nivolumab: an uncommon adverse event related to immune checkpoint inhibitors. Riveiro-Barciela M, González-Sans D, Marmolejo D, Salcedo MT, Muñoz-Couselo E. J Gastrointestin Liver Dis. 2021 Mar 13;30(1):171-172. IF: 2.008.

Consensus document for the diagnosis and treatment of pyruvate kinase deficiency. Morado M, Villegas AM, de la Iglesia S, Martínez-Nieto J, Del Orbe Barreto R, Beneitez D, Salido E; en representación del Grupo Español de Eritropatología. Med Clin (Barc). 2021 Sep 10;157(5):253.e1-253.e8. IF: 1.725.

Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. Reig M, Forner A, Ávila MA, Ayuso C, Mínguez B, Varela M, Bilbao I, Bilbao JI, Burrel M, Bustamante J, Ferrer J, Gómez MÁ, Llovet JM, De la Mata M, Matilla A, Pardo F, Pastrana MA, Rodríguez-Perálvarez M, Tabernero J, Urbano J, Vera R, Sangro B, Bruix J. Med Clin (Barc). 2021 May 7;156(9):463.e1-463.e30. IF: 1.725.

Applicability and results of liver transplant combined with neoadjuvant chemo-radiotherapy in the treatment of unresectable hilar cholangiocarcinoma. Dopazo C, Lladó L, Fondevila C, Macarulla T, Navalpotro B, Ramos E, Fabregat J, Laquente B, Navasa M, Castells L, Bilbao I, C García Valdecasas J, Charco R. Cir Esp (Engl Ed). 2021 Mar;99(3):190-199. IF: 1.653.

Overview of virus and cancer relationships. Position paper. Bouza E, Martín Jiménez M, Alemany L, Arribas J, Bañares R, Barragán MB, Eiros Bouza JM, Felip E, Fernández-Capetillo O, Gracia D, López-Vélez R, Bautista Mollar J, Muñoz P, Paz-Ares L, Torné A, Tovar J, Valencia E, Palomo E. Rev Esp Quimioter. 2021 Dec;34(6):525-555. IF: 1.553.

Genetic counseling in prostate cancer: How to implement it in daily clinical practice? Borque-Fernando A, Espílez R, Miramar D, Corbatón D, Rodríguez A, Castro E, Mateo J, Rello L, Méndez A, Gil Sanz MJ. Actas Urol Esp (Engl Ed). 2021 Jan-Feb;45(1):8-20. IF: 0.994.

Articles published by VHIO Investigators in 2021 in journals with no Impact Factor (IF) allocated at the time of publication of this Scientific Report:

Mediastinal FDG-positive lymph nodes simulating melanoma progression: drug-induced sarcoidosis like/lymphadenopathy related to ipilimumab. González-Cruz C, Bodet D, Muñoz-Couselo E, García-Patos V. BMJ Case Rep. 2021 Jan 28;14(1):e237310.

Myositis and myasteniform syndrome related to pembrolizumab. Sanchez-Sancho P, Selva-O’Callaghan A, Trallero-Araguás E, Ros J, Montoro B. BMJ Case Rep. 2021 Jul 21;14(7):e241766.

Impact of Neratinib on Outcomes in HER2-Positive Metastatic Breast Cancer Patients With Central Nervous System Disease at Baseline: Findings From the Phase 3 NALA Trial. Saura C, Ryvo L, Hurvitz S, Gradishar W, Moy B, Delaloge S, Kim S, Oliveira M, Trudeau M, Dai M, Haley B, Bose R, Landeiro L, Bebchuk J, Frazier A, Keyvanjah K, Bryce R, Brufsky A. Clin Adv Hematol Oncol. 2021 Feb;19(2): 11-12.

Results From CONTESSA: A Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2-, Hormone Receptor+ Metastatic Breast Cancer Who Have Previously Received a Taxane. O’Shaughnessy J, Schwartzberg L, Piccart M, Rugo HS, Yardley DA, Cortes J, Untch M, Harbeck N, Wright GS, Bondarenko I, Glaspy J, Nowecki Z, Kayali F, Chan A, Levy C, Liu M, Kim S, Lemieux J, Manikhas A, Tolaney S, Lim E, Gombos A, Stradella A, Pegram M, Fasching P, Mangel L, Semiglazov V, Dieras V, Gianni L, Danso MA, Vacirca J, Kroll S, O’Connell J, Tang K, Wei T, Seidman A. Clin Adv Hematol Oncol. 2021 Feb;19(2): 11-12.

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial. Goss GD, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Isla D, Morabito A, Min YJ, Ardizzoni A, Bender S, Cseh A, Felip E. EClinicalMedicine. 2021 Jun 18;37:100940.

Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial. Döhner H, Symeonidis A, Deeren D, Demeter J, Sanz MA, Anagnostopoulos A, Esteve J, Fiedler W, Porkka K, Kim HJ, Lee JH, Usuki K, D’Ardia S, Won Jung C, Salamero O, Horst HA, Recher C, Rousselot P, Sandhu I, Theunissen K, Thol F, Döhner K, Teleanu V, DeAngelo DJ, Naoe T, Sekeres MA, Belsack V, Ge M, Taube T, Ottmann OG. Hemasphere. 2021 Aug 2;5(8):e617.

OncoTree: A Cancer Classification System for Precision Oncology. Kundra R, Zhang H, Sheridan R, Sirintrapun SJ, Wang A, Ochoa A, Wilson M, Gross B, Sun Y, Madupuri R, Satravada BA, Reales D, Vakiani E, Al-Ahmadie HA, Dogan A, Arcila M, Zehir A, Maron S, Berger MF, Viaplana C, Janeway K, Ducar M, Sholl L, Dogan S, Bedard P, Surrey LF, Sanchez IH, Syed A, Rema AB, Chakravarty D, Suehnholz S, Nissan M, Iyer GV, Murali R, Bouvier N, Soslow RA, Hyman D, Younes A, Intlekofer A, Harding JJ, Carvajal RD, Sabbatini PJ, Abou-Alfa GK, Morris L, Janjigian YY, Gallagher MM, Soumerai TA, Mellinghoff IK, Hakimi AA, Fury M, Huse JT, Bagrodia A, Hameed M, Thomas S, Gardos S, Cerami E, Mazor T, Kumari P, Raman P, Shivdasani P, MacFarland S, Newman S, Waanders A, Gao J, Solit D, Schultz N. JCO Clin Cancer Inform. 2021 Feb;5:221-230.

Determinants of COVID-19 Mortality in Patients With Cancer From a Community Oncology Practice in Brazil. Ferrari BL, Ferreira CG, Menezes M, De Marchi P, Canedo J, Melo AC, Jácome AA, Reinert T, Paes RD, Sodré B, Barrios CH, Dienstmann R. JCO Glob Oncol. 2021 Jan;7:46-55.

Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology. Onesti CE, Tagliamento M, Curigliano G, Harbeck N, Bartsch R, Wildiers H, Tjan-Heijnen V, Martin M, Rottey S, Generali D, Campone M, Cristofanilli M, Pusztai L, Peeters M, Berchem G, Cortes J, Ruhstaller T, Ciruelos E, Rugo HS, Jerusalem G. JCO Glob Oncol. 2021 Feb;7:162-172.

A Versatile In Vivo System to Study Myc in Cell Reprogramming. Senís E, Mosteiro L, Grimm D, Abad M. Methods Mol Biol. 2021;2318:267-279.

An “-omycs” Toolbox to Work with MYC. Whitfield J, Soucek L. Methods Mol Biol. 2021;2318:1-11.

MYC Copy Number Detection in Clinical Samples Using a Digital DNA-Hybridization and Detection Method. Ogbah Z, Mancuso FM, Vivancos A. Methods Mol Biol. 2021;2318:321-336.

Uncovering Sequence-Specific Transcription Factors Interacting with TET2. Tian TV, Sardina JL. Methods Mol Biol. 2021;2272:239-250.

A machine learning model for ranking candidate HLA class I neoantigens based on known neoepitopes from multiple human tumor types. Gartner JJ, Parkhurst MR, Gros A, Tran E, Jafferji MS, Copeland A, Hanada KI, Zacharakis N, Lalani A, Krishna S, Sachs A, Prickett TD, Li YF, Florentin M, Kivitz S, Chatmon SC, Rosenberg SA, Robbins PF. Nat Cancer. 2021 May;2(5):563-574.

Understanding Patient Experience in Biliary Tract Cancer: A Qualitative Patient Interview Study. Patel N, Lie X, Gwaltney C, Rokutanda N, Barzi A, Melisi D, Macarulla T, Ueno M, Kim ST, Meyers O, Workman C, Bachini M, Cohen G. Oncol Ther. 2021 Dec;9(2):557-573.

Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Sahebi F, Eikema DJ, Koster L, Kroger N, Meijer E, van Doesum JA, Rovira M, Koc Y, Angelucci E, Blaise D, Sammassimo S, McDonald A, Arroyo CH, Sanchez JF, Forcade E, Castagna L, Stölzel F, Sanz J, Tischer J, Ciceri F, Valcarcel D, Proia A, Hayden PJ, Beksac M, Yakoub-Agha I, Schönland S. Transplant Cell Ther. 2021 Dec;27(12):999.e1-999.e10.

Sequential Organ Failure Assessment Score and the Need for Organ Support Predict Mortality in Allogeneic Stem Cell Transplant Patients Admitted to the Intensive Care. Díaz-Lagares C, Fox L, García-Roche A, Santafe M, Romera I, Barba P, Pacheco A, Roldán E, Plata-Menchaca E, Roca O, Pérez M, Valcarcel D, Ferrer R. Transplant Cell Ther. 2021 Oct;27(10):865.

Acquired hepatocerebral degeneration in a metastatic neuroendocrine tumor long-term survivor - an update on neuroendocrine neoplasm’s treatment: A case report. Mirallas O, Saoudi N, Gómez-Puerto D, Riveiro-Barciela M, Merino X, Auger C, Landolfi S, Blanco L, Garcia-Burillo A, Molero X, Salcedo-Allende MT, Capdevila J. World J Hepatol. 2021 May 27;13(5):611-619.

Articles published by VHIO Investigators in 2021 with allocated Impact Factor (IF):

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr; OlympiA Clinical Trial Steering Committee and Investigators. N Engl J Med. 2021 Jun 24;384(25):2394-2405. IF: 91.253.

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Oyervides Juárez VM, Hsieh JJ, Basso U, Shah AY, Suárez C, Hamzaj A, Goh JC, Barrios C, Richardet M, Porta C, Kowalyszyn R, Feregrino JP, Żołnierek J, Pook D, Kessler ER, Tomita Y, Mizuno R, Bedke J, Zhang J, Maurer MA, Simsek B, Ejzykowicz F, Schwab GM, Apolo AB, Motzer RJ; CheckMate 9ER Investigators. N Engl J Med. 2021 Mar 4;384(9):829-841. IF: 91.253.

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, O’Shaughnessy J, Diéras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS; ASCENT Clinical Trial Investigators. N Engl J Med. 2021 Apr 22;384(16):1529-1541. IF: 91.253.

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Felip E, Altorki N, Zhou C, Csőszi T, Vynnychenko I, Goloborodko O, Luft A, Akopov A, Martinez-Marti A, Kenmotsu H, Chen YM, Chella A, Sugawara S, Voong D, Wu F, Yi J, Deng Y, McCleland M, Bennett E, Gitlitz B, Wakelee H; IMpower010 Investigators. Lancet. 2021 Oct 9;398(10308):1344-1357. IF: 79.323.

Enhancing anti-tumour efficacy with immunotherapy combinations. Meric-Bernstam F, Larkin J, Tabernero J, Bonini C. Lancet. 2021 Mar 13;397(10278):1010-1022. IF: 79.323.

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, Kojima T, Metges JP, Li Z, Kim SB, Cho BC, Mansoor W, Li SH, Sunpaweravong P, Maqueda MA, Goekkurt E, Hara H, Antunes L, Fountzilas C, Tsuji A, Oliden VC, Liu Q, Shah S, Bhagia P, Kato K; KEYNOTE-590 Investigators. Lancet. 2021 Aug 28;398(10302):759-771. IF: 79.323.

Precision oncology in metastatic colorectal cancer - from biology to medicine. Di Nicolantonio F, Vitiello PP, Marsoni S, Siena S, Tabernero J, Trusolino L, Bernards R, Bardelli A. Nat Rev Clin Oncol. 2021 Aug;18(8):506-525. IF: 66.675.

An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer. Powles T, Carroll D, Chowdhury S, Gravis G, Joly F, Carles J, Fléchon A, Maroto P, Petrylak D, Rolland F, Cook N, Balar AV, Sridhar SS, Galsky MD, Grivas P, Ravaud A, Jones R, Cosaert J, Hodgson D, Kozarewa I, Mather R, McEwen R, Mercier F, Landers D. Nat Med. 2021 May;27(5):793-801. IF: 53.440.

CDK4/6 inhibitors in breast cancer: spotting the difference. Perez-Garcia JM, Cortes J, Llombart-Cussac A. Nat Med. 2021 Nov;27(11):1868-1869. IF: 53.440.

Endometrial cancer. Makker V, MacKay H, Ray-Coquard I, Levine DA, Westin SN, Aoki D,Oaknin A. Nat Rev Dis Primers 7, 88 (2021). IF: 52.329.

The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Janjigian YY, Kawazoe A, Yañez P, Li N, Lonardi S, Kolesnik O, Barajas O, Bai Y, Shen L, Tang Y, Wyrwicz LS, Xu J, Shitara K, Qin S, Van Cutsem E, Tabernero J, Li L, Shah S, Bhagia P, Chung HC. Nature. 2021 Dec;600(7890):727-730. IF: 49.962.

Anthracyclines for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Are We Ready to Let Them Go? Tarantino P, Tolaney SM, Harbeck N, Cortes J, Curigliano G. J Clin Oncol. 2021 Nov 10;39(32):3541-3545. IF: 44.544.

Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. Pal SK, McGregor B, Suárez C, Tsao CK, Kelly W, Vaishampayan U, Pagliaro L, Maughan BL, Loriot Y, Castellano D, Srinivas S, McKay RR, Dreicer R, Hutson T, Dubey S, Werneke S, Panneerselvam A, Curran D, Scheffold C, Choueiri TK, Agarwal N. J Clin Oncol. 2021 Nov 20;39(33):3725-3736. IF:44.544.

Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Elez E, Gollerkeri A, Maharry K, Christy-Bittel J, Kopetz S. J Clin Oncol. 2021 Feb 1;39(4):273-284. IF: 44.544.

First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors. Baird RD, Linossi C, Middleton M, Lord S, Harris A, Rodón J, Zitt C, Fiedler U, Dawson KM, Leupin N, Stumpp MT, Harstrick A, Azaro A, Fischer S, Omlin A. J Clin Oncol. 2021 Jan 10;39(2):145-154. IF: 44.544.

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. Borghaei H, Gettinger S, Vokes EE, Chow LQM, Burgio MA, de Castro Carpeno J, Pluzanski A, Arrieta O, Frontera OA, Chiari R, Butts C, Wójcik-Tomaszewska J, Coudert B, Garassino MC, Ready N, Felip E, García MA, Waterhouse D, Domine M, Barlesi F, Antonia S, Wohlleber M, Gerber DE, Czyzewicz G, Spigel DR, Crino L, Eberhardt WEE, Li A, Marimuthu S, Brahmer J. J Clin Oncol. 2021 Mar 1;39(7):723-733. IF: 44.544.

Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. Hutchings M, Morschhauser F, Iacoboni G, Carlo-Stella C, Offner FC, Sureda A, Salles G, Martínez-Lopez J, Crump M, Thomas DN, Morcos PN, Ferlini C, Bröske AE, Belousov A, Bacac M, Dimier N, Carlile DJ, Lundberg L, Perez-Callejo D, Umaña P, Moore T, Weisser M, Dickinson MJ. J Clin Oncol. 2021 Jun 20;39(18):1959-1970. IF: 44.544.

Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509). Capdevila J, Fazio N, Lopez C, Teulé A, Valle JW, Tafuto S, Custodio A, Reed N, Raderer M, Grande E, Garcia-Carbonero R, Jimenez-Fonseca P, Hernando J, Bongiovanni A, Spada F, Alonso V, Antonuzzo L, Spallanzani A, Berruti A, La Casta A, Sevilla I, Kump P, Giuffrida D, Merino X, Trejo L, Gajate P, Matos I, Lamarca A, Ibrahim T. J Clin Oncol. 2021 Jul 10;39(20):2304-2312. IF: 44.544.

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451. Owonikoko TK, Park K, Govindan R, Ready N, Reck M, Peters S, Dakhil SR, Navarro A, Rodríguez-Cid J, Schenker M, Lee JS, Gutierrez V, Percent I, Morgensztern D, Barrios CH, Greillier L, Baka S, Patel M, Lin WH, Selvaggi G, Baudelet C, Baden J, Pandya D, Doshi P, Kim HR. J Clin Oncol. 2021 Apr 20;39(12):1349-1359. IF: 44.544.

Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma. McDermott DF, Lee JL, Ziobro M, Suarez C, Langiewicz P, Matveev VB, Wiechno P, Gafanov RA, Tomczak P, Pouliot F, Donskov F, Alekseev BY, Shin SJ, Bjarnason GA, Castellano D, Silverman RK, Perini RF, Schloss C, Atkins MB. J Clin Oncol. 2021 Mar 20;39(9):1029-1039. IF: 44.544.

Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes. Garcia-Manero G, Santini V, Almeida A, Platzbecker U, Jonasova A, Silverman LR, Falantes J, Reda G, Buccisano F, Fenaux P, Buckstein R, Diez Campelo M, Larsen S, Valcarcel D, Vyas P, Giai V, Olíva EN, Shortt J, Niederwieser D, Mittelman M, Fianchi L, La Torre I, Zhong J, Laille E, Lopes de Menezes D, Skikne B, Beach CL, Giagounidis A. J Clin Oncol. 2021 May 1;39(13):1426-1436. IF: 44.544.

Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis. Lambertini M, Blondeaux E, Bruzzone M, Perachino M, Anderson RA, de Azambuja E, Poorvu PD, Kim HJ, Villarreal-Garza C, Pistilli B, Vaz-Luis I, Saura C, Ruddy KJ, Franzoi MA, Sertoli C, Ceppi M, Azim HA Jr, Amant F, Demeestere I, Del Mastro L, Partridge AH, Pagani O, Peccatori FA. J Clin Oncol. 2021 Oct 10;39(29):3293-3305. IF: 44.544.

Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA). Hecht JR, Lonardi S, Bendell J, Sim HW, Macarulla T, Lopez CD, Van Cutsem E, Muñoz Martin AJ, Park JO, Greil R, Wang H, Hozak RR, Gueorguieva I, Lin Y, Rao S, Ryoo BY. J Clin Oncol. 2021 Apr 1;39(10):1108-1118. IF: 44.544.

Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations. Ho AL, Brana I, Haddad R, Bauman J, Bible K, Oosting S, Wong DJ, Ahn MJ, Boni V, Even C, Fayette J, Flor MJ, Harrington K, Kim SB, Licitra L, Nixon I, Saba NF, Hackenberg S, Specenier P, Worden F, Balsara B, Leoni M, Martell B, Scholz C, Gualberto A. J Clin Oncol. 2021 Jun 10;39(17):1856-1864. IF: 44.544.

Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. Brose MS, Robinson B, Sherman SI, Krajewska J, Lin CC, Vaisman F, Hoff AO, Hitre E, Bowles DW, Hernando J, Faoro L, Banerjee K, Oliver JW, Keam B, Capdevila J. Lancet Oncol. 2021 Aug;22(8):1126-1138. IF: 41.316.

Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial. Pérez-García JM, Gebhart G, Ruiz Borrego M, Stradella A, Bermejo B, Schmid P, Marmé F, Escrivá-de-Romani S, Calvo L, Ribelles N, Martinez N, Albacar C, Prat A, Dalenc F, Kerrou K, Colleoni M, Afonso N, Di Cosimo S, Sampayo-Cordero M, Malfettone A, Cortés J, Llombart-Cussac A; PHERGain steering committee and trial investigators. Lancet Oncol. 2021 Jun;22(6):858-871. IF: 41.316.

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O, Alexandru A, Sakai H, Lingua A, Salman P, Souquet PJ, De Marchi P, Martin C, Pérol M, Scherpereel A, Lu S, John T, Carbone DP, Meadows-Shropshire S, Agrawal S, Oukessou A, Yan J, Reck M. Lancet Oncol. 2021 Feb;22(2):198-211. IF: 41.316.

Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. Andre T, Amonkar M, Norquist JM, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt CJA, Smith D, Garcia-Carbonero R, Sevilla I, De La Fouchardiere C, Rivera F, Elez E, Diaz LA Jr, Yoshino T, Van Cutsem E, Yang P, Farooqui M, Le DT. Lancet Oncol. 2021 May;22(5):665-677. IF: 41.316.

Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Banerjee S, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Oza A, González-Martín A, Aghajanian C, Bradley WH, Holmes E, Lowe ES, DiSilvestro P. Lancet Oncol. 2021 Dec;22(12):1721-1731. IF: 41.316.

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Mayer EL, Dueck AC, Martin M, Rubovszky G, Burstein HJ, Bellet-Ezquerra M, Miller KD, Zdenkowski N, Winer EP, Pfeiler G, Goetz M, Ruiz-Borrego M, Anderson D, Nowecki Z, Loibl S, Moulder S, Ring A, Fitzal F, Traina T, Chan A, Rugo HS, Lemieux J, Henao F, Lyss A, Antolin Novoa S, Wolff AC, Vetter M, Egle D, Morris PG, Mamounas EP, Gil-Gil MJ, Prat A, Fohler H, Metzger Filho O, Schwarz M, DuFrane C, Fumagalli D, Theall KP, Lu DR, Bartlett CH, Koehler M, Fesl C, DeMichele A, Gnant M. Lancet Oncol. 2021 Feb;22(2):212-222. IF: 41.316.

Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial. Friedlander M, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, Lisyanskaya A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley WH, Liu J, Mathews C, Selle F, Lortholary A, Lowe ES, Hettle R, Flood E, Parkhomenko E, DiSilvestro P. Lancet Oncol. 2021 May;22(5):632-642. IF: 41,316.

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Morales Barrera R, Fléchon A, Gunduz S, Loriot Y, Rodriguez-Vida A, Mamtani R, Yu EY, Nam K, Imai K, Homet Moreno B, Alva A; KEYNOTE-361 Investigators. Lancet Oncol. 2021 Jul;22(7):931-945. IF: 41.316.

Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Winer EP, Lipatov O, Im SA, Goncalves A, Muñoz-Couselo E, Lee KS, Schmid P, Tamura K, Testa L, Witzel I, Ohtani S, Turner N, Zambelli S, Harbeck N, Andre F, Dent R, Zhou X, Karantza V, Mejia J, Cortes J; KEYNOTE-119 investigators. Lancet Oncol. 2021 Apr;22(4):499-511. IF: 41.316.

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Gainor JF, Curigliano G, Kim DW, Lee DH, Besse B, Baik CS, Doebele RC, Cassier PA, Lopes G, Tan DSW, Garralda E, Paz-Ares LG, Cho BC, Gadgeel SM, Thomas M, Liu SV, Taylor MH, Mansfield AS, Zhu VW, Clifford C, Zhang H, Palmer M, Green J, Turner CD, Subbiah V. Lancet Oncol. 2021 Jul;22(7):959-969. IF: 41.316.

Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. Pinato DJ, Tabernero J, Bower M, Scotti L, Patel M, Colomba E, Dolly S, Loizidou A, Chester J, Mukherjee U, Zambelli A, Dalla Pria A, Aguilar-Company J, Ottaviani D, Chowdhury A, Merry E, Salazar R, Bertuzzi A, Brunet J, Lambertini M, Tagliamento M, Pous A, Sita-Lumsden A, Srikandarajah K, Colomba J, Pommeret F, Seguí E, Generali D, Grisanti S, Pedrazzoli P, Rizzo G, Libertini M, Moss C, Evans JS, Russell B, Harbeck N, Vincenzi B, Biello F, Bertulli R, Liñan R, Rossi S, Carmona-García MC, Tondini C, Fox L, Baggi A, Fotia V, Parisi A, Porzio G, Saponara M, Cruz CA, García-Illescas D, Felip E, Roqué Lloveras A, Sharkey R, Roldán E, Reyes R, Earnshaw I, Ferrante D, Marco-Hernández J, Ruiz-Camps I, Gaidano G, Patriarca A, Bruna R, Sureda A, Martinez-Vila C, Sanchez de Torre A, Cantini L, Filetti M, Rimassa L, Chiudinelli L, Franchi M, Krengli M, Santoro A, Prat A, Van Hemelrijck M, Diamantis N, Newsom-Davis T, Gennari A, Cortellini A; OnCovid study group. Lancet Oncol. 2021 Dec;22(12):1669-1680. IF: 41.316.

SARS-CoV-2 vaccination and phase 1 cancer clinical trials. Yap TA, Siu LL, Calvo E, Lolkema MP, LoRusso PM, Soria JC, Plummer R, de Bono JS, Tabernero J, Banerji U. Lancet Oncol. 2021 Mar;22(3):298-301. IF: 41.316.

Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg EM, Roodvoets AGH, Nagtegaal ID, Beets-Tan RGH, Blomqvist LK, Fokstuen T, Ten Tije AJ, Capdevila J, Hendriks MP, Edhemovic I, Cervantes A, Nilsson PJ, Glimelius B, van de Velde CJH, Hospers GAP; RAPIDO collaborative investigators. Lancet Oncol. 2021 Jan;22(1):29-42. IF: 41.316.

Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Siena S, Di Bartolomeo M, Raghav K, Masuishi T, Loupakis F, Kawakami H, Yamaguchi K, Nishina T, Fakih M, Elez E, Rodriguez J, Ciardiello F, Komatsu Y, Esaki T, Chung K, Wainberg Z, Sartore-Bianchi A, Saxena K, Yamamoto E, Bako E, Okuda Y, Shahidi J, Grothey A, Yoshino T; DESTINY-CRC01 investigators. Lancet Oncol. 2021 Jun;22(6):779-789. IF: 41.316.

Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial. Carreira S, Porta N, Arce-Gallego S, Seed G, Llop-Guevara A, Bianchini D, Rescigno P, Paschalis A, Bertan C, Baker C, Goodall J, Miranda S, Riisnaes R, Figueiredo I, Ferreira A, Pereira R, Crespo M, Gurel B, Nava Rodrigues D, Pettitt SJ, Yuan W, Serra V, Rekowski J, Lord CJ, Hall E, Mateo J, de Bono JS. Cancer Discov. 2021 Nov;11(11):2812-2827. IF: 39.397.

Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. Aftimos P, Oliveira M, Irrthum A, Fumagalli D, Sotiriou C, Gal-Yam EN, Robson ME, Ndozeng J, Di Leo A, Ciruelos EM, de Azambuja E, Viale G, Scheepers ED, Curigliano G, Bliss JM, Reis-Filho JS, Colleoni M, Balic M, Cardoso F, Albanell J, Duhem C, Marreaud S, Romagnoli D, Rojas B, Gombos A, Wildiers H, Guerrero-Zotano A, Hall P, Bonetti A, Larsson KF, Degiorgis M, Khodaverdi S, Greil R, Sverrisdóttir Á, Paoli M, Seyll E, Loibl S, Linderholm B, Zoppoli G, Davidson NE, Johannsson OT, Bedard PL, Loi S, Knox S, Cameron DA, Harbeck N, Montoya ML, Brandão M, Vingiani A, Caballero C, Hilbers FS, Yates LR, Benelli M, Venet D, Piccart MJ. Cancer Discov. 2021 Nov;11(11):2796-2811. IF: 39.397.

José “Pepe” Baselga, MD, PhD: In Memoriam (1959-2021). Tabernero J, Hyman DM, Soria JC. Cancer Discov. 2021 Jul;11(7):1614-1616. IF: 39.397.

Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Woo XY, Giordano J, Srivastava A, Zhao ZM, Lloyd MW, de Bruijn R, Suh YS, Patidar R, Chen L, Scherer S, Bailey MH, Yang CH, Cortes-Sanchez E, Xi Y, Wang J, Wickramasinghe J, Kossenkov AV, Rebecca VW, Sun H, Mashl RJ, Davies SR, Jeon R, Frech C, Randjelovic J, Rosains J, Galimi F, Bertotti A, Lafferty A, O’Farrell AC, Modave E, Lambrechts D, Ter Brugge P, Serra V, Marangoni E, El Botty R, Kim H, Kim JI, Yang HK, Lee C, Dean DA 2nd, Davis-Dusenbery B, Evrard YA, Doroshow JH, Welm AL, Welm BE, Lewis MT, Fang B, Roth JA, Meric-Bernstam F, Herlyn M, Davies MA, Ding L, Li S, Govindan R, Isella C, Moscow JA, Trusolino L, Byrne AT, Jonkers J, Bult CJ, Medico E, Chuang JH; PDXNET Consortium; EurOPDX Consortium: Bailey MH, Rebecca VW, Davies MA, Robinson PN, Sanderson BJ, Neuhauser SB, Dobrolecki LE, Zheng X, Majidi M, Zhang R, Zhang X, Akcakanat A, Evans KW, Yap TA, Li D,Yucan E, Lanier CD, Saridogan T, Kirby BP, Ha MJ, Chen H, Kopetz S, Menter DG, Zhang J, Westin SN, Kim MP, Dai B, Gibbons DL, Tapia C, Jensen VB, Boning G, Minna JD, Park H, Timmons BC, Girard L, Fingerman D, Liu Q, Somasundaram R, Xiao M, Yennu VG, Tetzlaff MT, Xu X, Nathanson KL, Cao S, Chen F, DiPersio JF, Lim KH, Ma CX, Rodriguez FM, Van BA, Wang A, Wendl MC, Wu Y, Wyczalkowski MA, Yao L, Jayasinghe R, Aft RL, Fields RC, Luo J, Fuh KC, Chin V, DiGiovanna J, Grover J, Koc S, Seepo S, Wallace T, Pan CX, Chen Jr. MS, Carvajal LG, Kirane AR, Cho M, Gandara DR, Riess JW, Le T, deVere RW, Tepper CG, Zhang H, Coggins NB, Lott P, Estrada A, Toal T, Arana AM, Polanco G, Rocha S, Ma AH, Mitsiades N, Kaochar S, O’Malley BW, Ellis MJ, Hilsenbeck SG, Ittmann M, de Bruijn R, Ter P, Corso S, Fiori A, Giordano S, van de Ven M, Peeper DS, Miller I, Bernadó C, Morancho B, Ramírez L, Arribas J, Palmer HG, Piris A, Soucek L, et al. Nat Genet. 2021 Jan;53(1):86-99. IF: 38.330.

Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial. Llop-Guevara A, Loibl S, Villacampa G, Vladimirova V, Schneeweiss A, Karn T, Zahm DM, Herencia-Ropero A, Jank P, van Mackelenbergh M, Fasching PA, Marmé F, Stickeler E, Schem C, Dienstmann R, Florian S, Nekljudova V, Balmaña J, Hahnen E, Denkert C, Serra V. Ann Oncol. 2021 Dec;32(12):1590-1596. IF: 32.976.

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Harbeck N, Rastogi P, Martin M, Tolaney SM, Shao ZM, Fasching PA, Huang CS, Jaliffe GG, Tryakin A, Goetz MP, Rugo HS, Senkus E, Testa L, Andersson M, Tamura K, Del Mastro L, Steger GG, Kreipe H, Hegg R, Sohn J, Guarneri V, Cortés J, Hamilton E, André V, Wei R, Barriga S, Sherwood S, Forrester T, Munoz M, Shahir A, San Antonio B, Nabinger SC, Toi M, Johnston SRD, O’Shaughnessy J; monarchE Committee Members. Ann Oncol. 2021 Dec;32(12):1571-1581. IF: 32.976.

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Bardia A, Tolaney SM, Punie K, Loirat D, Oliveira M, Kalinsky K, Zelnak A, Aftimos P, Dalenc F, Sardesai S, Hamilton E, Sharma P, Recalde S, Gil EC, Traina T, O’Shaughnessy J, Cortes J, Tsai M, Vahdat L, Diéras V, Carey LA, Rugo HS, Goldenberg DM, Hong Q, Olivo M, Itri LM, Hurvitz SA. Ann Oncol. 2021 Sep;32(9):1148-1156. IF: 32.976.

Building bridges between drug development and cancer science: a tribute to José Baselga’s legacy. Hyman DM, Soria JC, Tabernero J. Ann Oncol. 2021 Jul;32(7):825-828. IF: 32.976.

Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer. Schoenfeld AJ, Antonia SJ, Awad MM, Felip E, Gainor J, Gettinger SN, Hodi FS, Johnson ML, Leighl NB, Lovly CM, Mok T, Perol M, Reck M, Solomon B, Soria JC, Tan DSW, Peters S, Hellmann MD. Ann Oncol. 2021 Dec;32(12):1597-1607. IF: 32.976.

EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. Le Rhun E, Guckenberger M, Smits M, Dummer R, Bachelot T, Sahm F, Galldiks N, de Azambuja E, Berghoff AS, Metellus P, Peters S, Hong YK, Winkler F, Schadendorf D, van den Bent M, Seoane J, Stahel R, Minniti G, Wesseling P, Weller M, Preusser M; EANO Executive Board and ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Ann Oncol. 2021 Nov;32(11):1332-1347. IF: 32.976.

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A, Dent R, Fenlon D, Gligorov J, Hurvitz SA, Im SA, Krug D, Kunz WG, Loi S, Penault-Llorca F, Ricke J, Robson M, Rugo HS, Saura C, Schmid P, Singer CF, Spanic T, Tolaney SM, Turner NC, Curigliano G, Loibl S, Paluch-Shimon S, Harbeck N; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Ann Oncol. 2021 Dec;32(12):1475-1495. IF: 32.976.

ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. Powles T, Albiges L, Bex A, Grünwald V, Porta C, Procopio G, Schmidinger M, Suárez C, de Velasco G; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Ann Oncol. 2021 Dec;32(12):1511-1519. IF: 32.976.

ESMO pays tribute to Professor José Baselga. Peters S, Tabernero J, Cervantes A, Banerjee S, Giuliani R, Lordick F. Ann Oncol. 2021 Jul;32(7):823-824. IF: 32.976.

Genomic testing for targeted oncology drugs: hopes against hype. Dienstmann R, Tamborero D. Ann Oncol. 2021 Jul;32(7):837-838. IF: 32.976.

Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study. Tempero M, Oh DY, Tabernero J, Reni M, Van Cutsem E, Hendifar A, Waldschmidt DT, Starling N, Bachet JB, Chang HM, Maurel J, Garcia-Carbonero R, Lonardi S, Coussens LM, Fong L, Tsao LC, Cole G Jr, James D, Macarulla T. Ann Oncol. 2021 May;32(5):600-608. IF: 32.976.

Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. Felip E, Shaw AT, Bearz A, Camidge DR, Solomon BJ, Bauman JR, Bauer TM, Peters S, Toffalorio F, Abbattista A, Thurm H, Peltz G, Wiltshire R, Besse B. Ann Oncol. 2021 May;32(5):620-630. IF: 32.976.

Longitudinal whole-exome sequencing of cell-free DNA for tracking the co-evolutionary tumor and immune evasion dynamics: longitudinal data from a single patient. Hastings RK, Openshaw MR, Vazquez M, Moreno-Cardenas AB, Fernandez-Garcia D, Martinson L, Kulbicki K, Primrose L, Guttery DS, Page K, Toghill B, Richards C, Thomas A, Tabernero J, Coombes RC, Ahmed S, Toledo RA, Shaw JA. Ann Oncol. 2021 May;32(5):681-684. IF: 32.976.

Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines. Grothey A, Fakih M, Tabernero J. Ann Oncol. 2021 Aug;32(8):959-967. IF: 32.976.

Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. Eikesdal HP, Yndestad S, Elzawahry A, Llop-Guevara A, Gilje B, Blix ES, Espelid H, Lundgren S, Geisler J, Vagstad G, Venizelos A, Minsaas L, Leirvaag B, Gudlaugsson EG, Vintermyr OK, Aase HS, Aas T, Balmaña J, Serra V, Janssen EAM, Knappskog S, Lønning PE. Ann Oncol. 2021 Feb;32(2):240-249. IF: 32.976.

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. Yoshino T, Argilés G, Oki E, Martinelli E, Taniguchi H, Arnold D, Mishima S, Li Y, Smruti BK, Ahn JB, Faud I, Chee CE, Yeh KH, Lin PC, Chua C, Hasbullah HH, Lee MA, Sharma A, Sun Y, Curigliano G, Bando H, Lordick F, Yamanaka T, Tabernero J, Baba E, Cervantes A, Ohtsu A, Peters S, Ishioka C, Pentheroudakis G. Ann Oncol. 2021 Dec;32(12):1496-1510. IF: 32.976.

Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial. Hughes BGM, Munoz-Couselo E, Mortier L, Bratland Å, Gutzmer R, Roshdy O, González Mendoza R, Schachter J, Arance A, Grange F, Meyer N, Joshi A, Billan S, Zhang P, Gumuscu B, Swaby RF, Grob JJ. Ann Oncol. 2021 Oct;32(10):1276-1285. IF: 32.976.

Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Rodríguez-Abreu D, Powell SF, Hochmair MJ, Gadgeel S, Esteban E, Felip E, Speranza G, De Angelis F, Dómine M, Cheng SY, Bischoff HG, Peled N, Reck M, Hui R, Garon EB, Boyer M, Kurata T, Yang J, Pietanza MC, Souza F, Garassino MC. Ann Oncol. 2021 Jul;32(7):881-895. IF: 32.976.

Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial. Dent S, Cortés J, Im YH, Diéras V, Harbeck N, Krop IE, Wilson TR, Cui N, Schimmoller F, Hsu JY, He J, De Laurentiis M, Sousa S, Drullinsky P, Jacot W. Ann Oncol. 2021 Feb;32(2):197-207. IF: 32.976.

Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Moore KN, Oza AM, Colombo N, Oaknin A, Scambia G, Lorusso D, Konecny GE, Banerjee S, Murphy CG, Tanyi JL, Hirte H, Konner JA, Lim PC, Prasad-Hayes M, Monk BJ, Pautier P, Wang J, Berkenblit A, Vergote I, Birrer MJ. Ann Oncol. 2021 Jun;32(6):757-765. IF: 32.976.

Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331. Spigel DR, Vicente D, Ciuleanu TE, Gettinger S, Peters S, Horn L, Audigier-Valette C, Pardo Aranda N, Juan-Vidal O, Cheng Y, Zhang H, Shi M, Luft A, Wolf J, Antonia S, Nakagawa K, Fairchild J, Baudelet C, Pandya D, Doshi P, Chang H, Reck M. Ann Oncol. 2021 May;32(5):631-641. IF: 32.976.

Therapeutic cancer vaccines revamping: technology advancements and pitfalls. Antonarelli G, Corti C, Tarantino P, Ascione L, Cortes J, Romero P, Mittendorf EA, Disis ML, Curigliano G. Ann Oncol. 2021 Dec;32(12):1537-1551. IF: 32.976.

VP2-2021: Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small cell lung cancer (Nsq-NSCLC) with high PD-L1 expression using real-world data. Peters S, Dafni U, Perol M, Felip E, Polito L, Pal N, Ton TGN, Merritt D, Morris S, Stahel RA. Ann Oncol. 2021. 32(5): 687-688. IF: 32.976.

VP4-2021: EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs. investigator’s choice (IC) chemotherapy (chemo) in recurrent/metastatic (R/M) cervical carcinoma. Tewari KS, Monk BJ, Vergote I, Miller A, de Melo AC, Kim HS, Kim YM, Lisyanskaya A, Samouelian V, Lorusso D, Damian F, Chang C-L, Gotovkin EA, Takahashi S, Ramone D, Pikiel J, Li J, Mathias M, Fury MG, Oaknin A. Ann Oncol. 2021. 32(7):940-941. IF: 32.976.

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Subbiah V, Hu MI, Wirth LJ, Schuler M, Mansfield AS, Curigliano G, Brose MS, Zhu VW, Leboulleux S, Bowles DW, Baik CS, Adkins D, Keam B, Matos I, Garralda E, Gainor JF, Lopes G, Lin CC, Godbert Y, Sarker D, Miller SG, Clifford C, Zhang H, Turner CD, Taylor MH. Lancet Diabetes Endocrinol. 2021 Aug;9(8):491-501. IF: 32.069.

Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. Chao J, Fuchs CS, Shitara K, Tabernero J, Muro K, Van Cutsem E, Bang YJ, De Vita F, Landers G, Yen CJ, Chau I, Elme A, Lee J, Özgüroglu M, Catenacci D, Yoon HH, Chen E, Adelberg D, Shih CS, Shah S, Bhagia P, Wainberg ZA. JAMA Oncol. 2021 Jun 1;7(6):895-902. IF: 31.777.

Clarification of Definitions of Hyperprogressive Disease During Immunotherapy. Matos I, Garralda E. JAMA Oncol. 2021 Jan 1;7(1):136-137. IF: 31.777.

Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial. Rugo HS, Im SA, Cardoso F, Cortés J, Curigliano G, Musolino A, Pegram MD, Wright GS, Saura C, Escrivá-de-Romaní S, De Laurentiis M, Levy C, Brown-Glaberman U, Ferrero JM, de Boer M, Kim SB, Petráková K, Yardley DA, Freedman O, Jakobsen EH, Kaufman B, Yerushalmi R, Fasching PA, Nordstrom JL, Bonvini E, Koenig S, Edlich S, Hong S, Rock EP, Gradishar WJ; SOPHIA Study Group. JAMA Oncol. 2021 Apr 1;7(4):573-584. IF: 31.777.

Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial. Zhu AX, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DVT, Borad MJ, Bridgewater JA, Harris WP, Murphy AG, Oh DY, Whisenant JR, Lowery MA, Goyal L, Shroff RT, El-Khoueiry AB, Chamberlain CX, Aguado-Fraile E, Choe S, Wu B, Liu H, Gliser C, Pandya SS, Valle JW, Abou-Alfa GK. JAMA Oncol. 2021 Nov 1;7(11):1669-1677. IF: 31.777.

Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial. Llombart-Cussac A, Pérez-García JM, Bellet M, Dalenc F, Gil-Gil M, Ruíz-Borrego M, Gavilá J, Sampayo-Cordero M, Aguirre E, Schmid P, Marmé F, Di Cosimo S, Gligorov J, Schneeweiss A, Albanell J, Zamora P, Wheatley D, Martínez-de Dueñas E, Amillano K, Malfettone A, Cortés J; PARSIFAL Steering Committee and Trial Investigators. JAMA Oncol. 2021 Dec 1;7(12):1791-1799. IF: 31.777.

Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A Review. Tarantino P, Modi S, Tolaney SM, Cortés J, Hamilton EP, Kim SB, Toi M, Andrè F, Curigliano G. JAMA Oncol. 2021 Dec 1;7(12):1873-1881. IF: 31.777.

Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib. Kwan TT, Oza AM, Tinker AV, Ray-Coquard I, Oaknin A, Aghajanian C, Lorusso D, Colombo N, Dean A, Weberpals J, Severson E, Vo LT, Goble S, Maloney L, Harding T, Kaufmann SH, Ledermann JA, Coleman RL, McNeish IA, Lin KK, Swisher EM. JAMA Oncol. 2021 Dec 1;7(12):1772-1781. IF: 31,777.

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial. Zhou C, Ramalingam SS, Kim TM, Kim SW, Yang JC, Riely GJ, Mekhail T, Nguyen D, Garcia Campelo MR, Felip E, Vincent S, Jin S, Griffin C, Bunn V, Lin J, Lin HM, Mehta M, Jänne PA. JAMA Oncol. 2021 Dec 1;7(12):e214761. IF: 31.777.

Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial. Jabbour SK, Lee KH, Frost N, Breder V, Kowalski DM, Pollock T, Levchenko E, Reguart N, Martinez-Marti A, Houghton B, Paoli JB, Safina S, Park K, Komiya T, Sanford A, Boolell V, Liu H, Samkari A, Keller SM, Reck M. JAMA Oncol. 2021 Jun 4;7(9):1–9. IF: 31.777.

I-SPY2 platform: New lessons from the olaparib and durvalumab combination in breast cancer treatment. Perez-Garcia J, Gion M, Cortes J. Cancer Cell. 2021 Jul 12;39(7):902-904. IF: 31.743.

Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. Yap TA, Nakagawa K, Fujimoto N, Kuribayashi K, Guren TK, Calabrò L, Shapira-Frommer R, Gao B, Kao S, Matos I, Planchard D, Chatterjee A, Jin F, Norwood K, Kindler HL. Lancet Respir Med. 2021 Jun;9(6):613-621. IF: 30.700.

B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide. Fürstenau M, Fink AM, Schilhabel A, Weiss J, Robrecht S, Eckert R, de la Serna J, Crespo M, Coscia M, Vitale C, Böttcher S, Weppner G, Ritgen M, Stilgenbauer S, Tausch E, Fischer K, Hallek M, Eichhorst B, Brüggemann M, Herling CD. Blood. 2021 Apr 22;137(16):2267-2271. IF: 23.629.

Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia. Ribera JM, Morgades M, Ciudad J, Montesinos P, Esteve J, Genescà E, Barba P, Ribera J, García-Cadenas I, Moreno MJ, Martínez-Carballeira D, Torrent A, Martínez-Sánchez P, Monsalvo S, Gil C, Tormo M, Artola MT, Cervera M, González-Campos J, Rodríguez C, Bermúdez A, Novo A, Soria B, Coll R, Amigo ML, López-Martínez A, Fernández-Martín R, Serrano J, Mercadal S, Cladera A, Giménez-Conca A, Peñarrubia MJ, Abella E, Vall-Llovera F, Hernández-Rivas JM, Garcia-Guiñon A, Bergua JM, de Rueda B, Sánchez-Sánchez MJ, Serrano A, Calbacho M, Alonso N, Méndez-Sánchez JÁ, García-Boyero R, Olivares M, Barrena S, Zamora L, Granada I, Lhermitte L, Feliu E, Orfao A. Blood. 2021 Apr 8;137(14):1879-1894. IF: 23.629.

Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era. Bobillo S, Joffe E, Lavery JA, Sermer D, Ghione P, Noy A, Caron PC, Hamilton A, Hamlin PA, Horwitz SM, Kumar A, Matasar MJ, Moskowitz A, Owens CN, Palomba ML, Batlevi CL, Straus D, von Keudell G, Zelenetz AD, Yahalom J, Dogan A, Seshan VE, Younes A. Blood. 2021 Jan 7;137(1):39-48. IF: 23.629.

Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study. Horwitz ME, Stiff PJ, Cutler C, Brunstein C, Hanna R, Maziarz RT, Rezvani AR, Karris NA, McGuirk J, Valcarcel D, Schiller GJ, Lindemans CA, Hwang WYK, Koh LP, Keating A, Khaled Y, Hamerschlak N, Frankfurt O, Peled T, Segalovich I, Blackwell B, Wease S, Freedman LS, Galamidi-Cohen E, Sanz G. Blood. 2021 Oct 21;138(16):1429-1440. IF: 23.629.

Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development. Alameda D, Goicoechea I, Vicari M, Arriazu E, Nevone A, Rodriguez S, Lasa M, Puig N, Cedena MT, Alignani D, Garate S, Lara-Astiaso D, Vilas-Zornoza A, Sarvide S, Ocio EM, Lecumberri R, Garcia de Coca A, Labrador J, Gonzalez ME, Palomera L, Gironella M, Cabañas V, Casanova M, Oriol A, Krsnik I, Perez-Montaña A, de la Rubia J, de la Puerta JE, de Arriba F, Fazio VM, Martinez-Lopez J, Lahuerta JJ, Mateos MV, Odero MD, Prosper F, Weiner A, Amit I, Nuvolone M, San Miguel JF, Paiva B. Blood. 2021 Oct 28;138(17):1583-1589. IF: 23.629.

Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. Powles T, Atkins MB, Escudier B, Motzer RJ, Rini BI, Fong L, Joseph RW, Pal SK, Sznol M, Hainsworth J, Stadler WM, Hutson TE, Ravaud A, Bracarda S, Suarez C, Choueiri TK, Reeves J, Cohn A, Ding B, Leng N, Hashimoto K, Huseni M, Schiff C, McDermott DF. Eur Urol. 2021 May;79(5):665-673. IF: 20.096.

Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study. Sternberg CN, Castellano D, de Bono J, Fizazi K, Tombal B, Wülfing C, Kramer G, Eymard JC, Bamias A, Carles J, Iacovelli R, Melichar B, Sverrisdóttir Á, Theodore C, Feyerabend S, Helissey C, Poole EM, Ozatilgan A, Geffriaud-Ricouard C, de Wit R. Eur Urol. 2021 Oct;80(4):497-506. IF: 20.096.

Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA. Sumanasuriya S, Seed G, Parr H, Christova R, Pope L, Bertan C, Bianchini D, Rescigno P, Figueiredo I, Goodall J, Fowler G, Flohr P, Mehra N, Neeb A, Rekowski J, Eisenberger M, Sartor O, Oudard S, Geffriaud-Ricouard C, Ozatilgan A, Chadjaa M, Macé S, Lord C, Baxter J, Pettitt S, Lambros M, Sharp A, Mateo J, Carreira S, Yuan W, de Bono JS. Eur Urol. 2021 Aug;80(2):243-253. IF: 20.096.

Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians. Merseburger AS, Waldron N, Ribal MJ, Heidenreich A, Perner S, Fizazi K, Sternberg CN, Mateo J, Wirth MP, Castro E, Olmos D, Petrylak DP, Chowdhury S. Eur Urol. 2021 Apr;79(4):519-529. IF: 20.096.

Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer. Casanova-Salas I, Athie A, Boutros PC, Del Re M, Miyamoto DT, Pienta KJ, Posadas EM, Sowalsky AG, Stenzl A, Wyatt AW, Mateo J. Eur Urol. 2021 Jun;79(6):762-771. IF: 20.096.

Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study. Pleyer L, Leisch M, Kourakli A, Padron E, Maciejewski JP, Xicoy Cirici B, Kaivers J, Ungerstedt J, Heibl S, Patiou P, Hunter AM, Mora E, Geissler K, Dimou M, Jimenez Lorenzo MJ, Melchardt T, Egle A, Viniou AN, Patel BJ, Arnan M, Valent P, Roubakis C, Bernal Del Castillo T, Galanopoulos A, Calabuig Muñoz M, Bonadies N, Medina de Almeida A, Cermak J, Jerez A, Montoro MJ, Cortés A, Avendaño Pita A, Lopez Andrade B, Hellstroem-Lindberg E, Germing U, Sekeres MA, List AF, Symeonidis A, Sanz GF, Larcher-Senn J, Greil R. Lancet Haematol. 2021 Feb;8(2):e135-e148. IF: 18.959.

Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study. Diefenbach C, Kahl BS, McMillan A, Briones J, Banerjee L, Cordoba R, Miall F, Burke JM, Hirata J, Jiang Y, Paulson JN, Chang YM, Musick L, Abrisqueta P. Lancet Haematol. 2021 Dec;8(12):e891-e901. IF: 18.959.

Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Javle M, Roychowdhury S, Kelley RK, Sadeghi S, Macarulla T, Weiss KH, Waldschmidt DT, Goyal L, Borbath I, El-Khoueiry A, Borad MJ, Yong WP, Philip PA, Bitzer M, Tanasanvimon S, Li A, Pande A, Soifer HS, Shepherd SP, Moran S, Zhu AX, Bekaii-Saab TS, Abou-Alfa GK. Lancet Gastroenterol Hepatol. 2021 Oct;6(10):803-815. IF: 18.486.

DNA hypomethylating agents increase activation and cytolytic activity of CD8+ T cells. Loo Yau H, Bell E, Ettayebi I, de Almeida FC, Boukhaled GM, Shen SY, Allard D, Morancho B, Marhon SA, Ishak CA, Gonzaga IM, da Silva Medina T, Singhania R, Chakravarthy A, Chen R, Mehdipour P, Pommey S, Klein C, Amarante-Mendes GP, Roulois D, Arribas J, Stagg J, Brooks DG, De Carvalho DD. Mol Cell. 2021 Apr 1;81(7):1469-1483. IF: 17.970.

COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). Pagano L, Salmanton-García J, Marchesi F, Busca A, Corradini P, Hoenigl M, Klimko N, Koehler P, Pagliuca A, Passamonti F, Verga L, Víšek B, Ilhan O, Nadali G, Weinbergerová B, Córdoba-Mascuñano R, Marchetti M, Collins GP, Farina F, Cattaneo C, Cabirta A, Gomes-Silva M, Itri F, van Doesum J, Ledoux MP, Čerňan M, Jakšić O, Duarte RF, Magliano G, Omrani AS, Fracchiolla NS, Kulasekararaj A, Valković T, Poulsen CB, Machado M, Glenthøj A, Stoma I, Ráčil Z, Piukovics K, Navrátil M, Emarah Z, Sili U, Maertens J, Blennow O, Bergantim R, García-Vidal C, Prezioso L, Guidetti A, Del Principe MI, Popova M, de Jonge N, Ormazabal-Vélez I, Fernández N, Falces-Romero I, Cuccaro A, Meers S, Buquicchio C, Antić D, Al-Khabori M, García-Sanz R, Biernat MM, Tisi MC, Sal E, Rahimli L, Čolović N, Schönlein M, Calbacho M, Tascini C, Miranda-Castillo C, Khanna N, Méndez GA, Petzer V, Novák J, Besson C, Duléry R, Lamure S, Nucci M, Zambrotta G, Žák P, Seval GC, Bonuomo V, Mayer J, López-García A, Sacchi MV, Booth S, Ciceri F, Oberti M, Salvini M, Izuzquiza M, Nunes-Rodrigues R, Ammatuna E, Obr A, Herbrecht R, Núñez-Martín-Buitrago L, Mancini V, Shwaylia H, Sciumè M, Essame J, Nygaard M, Batinić J, Gonzaga Y, Regalado-Artamendi I, Karlsson LK, Shapetska M, Hanakova M, El-Ashwah S, Borbényi Z, Çolak GM, Nordlander A, Dragonetti G, Maraglino AME, Rinaldi A, De Ramón-Sánchez C, Cornely OA; EPICOVIDEHA working group. J Hematol Oncol. 2021 Oct 14;14(1):168. IF: 17.388.

Variable interplay of UV-induced DNA damage and repair at transcription factor binding sites. Frigola J, Sabarinathan R, Gonzalez-Perez A, Lopez-Bigas N. Nucleic Acids Res. 2021 Jan 25;49(2):891-901. IF: 16.971.

Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, Lee KH, Delmonte A, Garcia Campelo MR, Kim DW, Griesinger F, Felip E, Califano R, Spira AI, Gettinger SN, Tiseo M, Lin HM, Liu Y, Vranceanu F, Niu H, Zhang P, Popat S. J Thorac Oncol. 2021 Dec;16(12):2091-2108. IF: 15.609.

Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14). Peters S, Felip E, Dafni U, Tufman A, Guckenberger M, Álvarez R, Nadal E, Becker A, Vees H, Pless M, Martinez-Marti A, Lambrecht M, Andratschke N, Tsourti Z, Piguet AC, Roschitzki-Voser H, Gasca-Ruchti A, Vansteenkiste J, Stahel RA, De Ruysscher D. J Thorac Oncol. 2021 Feb;16(2):278-288. IF: 15.609.

Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC. Jassem J, de Marinis F, Giaccone G, Vergnenegre A, Barrios CH, Morise M, Felip E, Oprean C, Kim YC, Andric Z, Mocci S, Enquist I, Komatsubara K, McCleland M, Kuriki H, Villalobos M, Phan S, Spigel DR, Herbst RS. J Thorac Oncol. 2021 Nov;16(11):1872-1882. IF: 15.609.

A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Coignard J, Lush M, Beesley J, O’Mara TA, Dennis J, Tyrer JP, Barnes DR, McGuffog L, Leslie G, Bolla MK, Adank MA, Agata S, Ahearn T, Aittomäki K, Andrulis IL, Anton-Culver H, Arndt V, Arnold N, Aronson KJ, Arun BK, Augustinsson A, Azzollini J, Barrowdale D, Baynes C, Becher H, Bermisheva M, Bernstein L, Białkowska K, Blomqvist C, Bojesen SE, Bonanni B, Borg A, Brauch H, Brenner H, Burwinkel B, Buys SS, Caldés T, Caligo MA, Campa D, Carter BD, Castelao JE, Chang-Claude J, Chanock SJ, Chung WK, Claes KBM, Clarke CL; GEMO Study Collaborators; EMBRACE Collaborators, Collée JM, Conroy DM, Czene K, Daly MB, Devilee P, Diez O, Ding YC, Domchek SM, Dörk T, Dos-Santos-Silva I, Dunning AM, Dwek M, Eccles DM, Eliassen AH, Engel C, Eriksson M, Evans DG, Fasching PA, Flyger H, Fostira F, Friedman E, Fritschi L, Frost D, Gago-Dominguez M, Gapstur SM, Garber J, Garcia-Barberan V, García-Closas M, García-Sáenz JA, Gaudet MM, Gayther SA, Gehrig A, Georgoulias V, Giles GG, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Greene MH, Guénel P, Haeberle L, Hahnen E, Haiman CA, Håkansson N, Hall P, Hamann U, Harrington PA, Hart SN, He W, Hogervorst FBL, Hollestelle A, Hopper JL, Horcasitas DJ, Hulick PJ, Hunter DJ, Imyanitov EN; KConFab Investigators; HEBON Investigators; ABCTB Investigators, Jager A, Jakubowska A, James PA, Jensen UB, John EM, Jones ME, Kaaks R, Kapoor PM, Karlan BY, Keeman R, Khusnutdinova E, Kiiski JI, Ko YD, Kosma VM, Kraft P, Kurian AW, Laitman Y, Lambrechts D, Le Marchand L, Lester J, Lesueur F, Lindstrom T, Lopez-Fernández A, et al. Nat Commun. 2021 Feb 17;12(1):1078. IF: 14.919.

Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation. Arenas EJ, Martínez-Sabadell A, Rius Ruiz I, Román Alonso M, Escorihuela M, Luque A, Fajardo CA, Gros A, Klein C, Arribas J. Nat Commun. 2021 Feb 23;12(1):1237. IF: 14.919.

Dynamics of genome architecture and chromatin function during human B cell differentiation and neoplastic transformation. Vilarrasa-Blasi R, Soler-Vila P, Verdaguer-Dot N, Russiñol N, Di Stefano M, Chapaprieta V, Clot G, Farabella I, Cuscó P, Kulis M, Agirre X, Prosper F, Beekman R, Beà S, Colomer D, Stunnenberg HG, Gut I, Campo E, Marti-Renom MA, Martin-Subero JI. Nat Commun. 2021 Jan 28;12(1):651. IF: 14.919.

HER2+breast cancers evade anti-HER2 therapy via a switch in driver pathway. Smith AE, Ferraro E, Safonov A, Morales CB, Lahuerta EJA, Li Q, Kulick A, Ross D, Solit DB, de Stanchina E, Reis-Filho J, Rosen N, Arribas J, Razavi P, Chandarlapaty S. HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway. Nat Commun. 2021. Nov18; 12(1):6667. IF: 14.919.

Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment. Rubio-Perez C, Planas-Rigol E, Trincado JL, Bonfill-Teixidor E, Arias A, Marchese D, Moutinho C, Serna G, Pedrosa L, Iurlaro R, Martínez-Ricarte F, Escudero L, Cordero E, Cicuendez M, Ruiz S, Parra G, Nuciforo P, Gonzalez J, Pineda E, Sahuquillo J, Tabernero J, Heyn H, Seoane J. Nat Commun. 2021 Mar 8;12(1):1503. IF: 14.919.

Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial. Gonzalez-Cao M, Mayo de Las Casas C, Oramas J, Berciano-Guerrero MA, de la Cruz L, Cerezuela P, Arance A, Muñoz-Couselo E, Espinosa E, Puertolas T, Diaz Beveridge R, Ochenduszko S, Villanueva MJ, Basterretxea L, Bellido L, Rodriguez D, Campos B, Montagut C, Drozdowskyj A, Molina MA, Lopez-Martin JA, Berrocal A. Nat Commun. 2021 Dec 1;12(1):7008. IF: 14.919.

Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response. Georgopoulou D, Callari M, Rueda OM, Shea A, Martin A, Giovannetti A, Qosaj F, Dariush A, Chin SF, Carnevalli LS, Provenzano E, Greenwood W, Lerda G, Esmaeilishirazifard E, O’Reilly M, Serra V, Bressan D; IMAXT Consortium, Mills GB, Ali HR, Cosulich SS, Hannon GJ, Bruna A, Caldas C. IMAXT Consortium: H R Ali, M Al Sa’d, S Alon, S Aparicio, G Battistoni, S Balasubramanian, R Becker, B Bodenmiller, E S Boyden, D Bressan, A Bruna, Marcel Burger, C Caldas, M Callari, I G Cannell, H Casbolt, N Chornay, Y Cui, A Dariush, K Dinh, A Emenari, Y Eyal-Lubling, J Fan, A Fatemi, E Fisher, E A González-Solares, C González-Fernández, D Goodwin, W Greenwood, F Grimaldi, G J Hannon, O Harris, S Harris, C Jauset, J A Joyce, E D Karagiannis, T Kovačević, L Kuett, R Kunes, Yoldaş A Küpcü, D Lai, E Laks, H Lee, M Lee, G Lerda, Y Li, A McPherson, N Millar, C M Mulvey, F Nugent, C H O’Flanagan, M Paez-Ribes, I Pearsall, F Qosaj, A J Roth, O M Rueda, T Ruiz, K Sawicka, L A Sepúlveda, S P Shah, A Shea, A Sinha, A Smith, S Tavaré, S Tietscher, I Vázquez-García, S L Vogl, N A Walton, A T Wassie, S S Watson, J Weselak, S A Wild, E Williams, J Windhager, T Whitmarsh, C Xia, P Zheng, X Zhuang. Nat Commun. 2021 Mar 31;12(1):1998. IF: 14.919.

Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). Swisher EM, Kwan TT, Oza AM, Tinker AV, Ray-Coquard I, Oaknin A, Coleman RL, Aghajanian C, Konecny GE, O’Malley DM, Leary A, Provencher D, Welch S, Chen LM, Wahner Hendrickson AE, Ma L, Ghatage P, Kristeleit RS, Dorigo O, Musafer A, Kaufmann SH, Elvin JA, Lin DI, Chambers SK, Dominy E, Vo LT, Goble S, Maloney L, Giordano H, Harding T, Dobrovic A, Scott CL, Lin KK, McNeish IA. Nat Commun. 2021 May 3;12(1):2487. IF: 14.919.

Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma. Frontzek F, Staiger AM, Zapukhlyak M, Xu W, Bonzheim I, Borgmann V, Sander P, Baptista MJ, Heming JN, Berning P, Wullenkord R, Erdmann T, Lutz M, Veratti P, Ehrenfeld S, Wienand K, Horn H, Goodlad JR, Wilson MR, Anagnostopoulos I, Lamping M, Gonzalez-Barca E, Climent F, Salar A, Castellvi J, Abrisqueta P, Menarguez J, Aldamiz T, Richter J, Klapper W, Tzankov A, Dirnhofer S, Rosenwald A, Mate JL, Tapia G, Lenz P, Miething C, Hartmann W, Chapuy B, Fend F, Ott G, Navarro JT, Grau M, Lenz G. Nat Commun. 2021 Aug 31;12(1):5183. IF: 14.919.

SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade. Romero OA, Vilarrubi A, Alburquerque-Bejar JJ, Gomez A, Andrades A, Trastulli D, Pros E, Setien F, Verdura S, Farré L, Martín-Tejera JF, Llabata P, Oaknin A, Saigi M, Piulats JM, Matias-Guiu X, Medina PP, Vidal A, Villanueva A, Sanchez-Cespedes M. Nat Commun. 2021 Jul 14;12(1):4319. IF: 14.919.

Severe SARS-CoV-2 placenta infection can impact neonatal outcome in the absence of vertical transmission. Cribiù FM, Erra R, Pugni L, Rubio-Perez C, Alonso L, Simonetti S, Croci GA, Serna G, Ronchi A, Pietrasanta C, Lunghi G, Fagnani AM, Piñana M, Matter M, Tzankov A, Terracciano L, Anton A, Ferrazzi E, Ferrero S, Iurlaro E, Seoane J, Nuciforo P. J Clin Invest. 2021 Mar 15;131(6):e145427. IF: 14.808.

Acute kidney injury in patients treated with immune checkpoint inhibitors. Gupta S, Short SAP, Sise ME, Prosek JM, Madhavan SM, Soler MJ, Ostermann M, Herrmann SM, Abudayyeh A, Anand S, Glezerman I, Motwani SS, Murakami N, Wanchoo R, Ortiz-Melo DI, Rashidi A, Sprangers B, Aggarwal V, Malik AB, Loew S, Carlos CA, Chang WT, Beckerman P, Mithani Z, Shah CV, Renaghan AD, Seigneux S, Campedel L, Kitchlu A, Shin DS, Rangarajan S, Deshpande P, Coppock G, Eijgelsheim M, Seethapathy H, Lee MD, Strohbehn IA, Owen DH, Husain M, Garcia-Carro C, Bermejo S, Lumlertgul N, Seylanova N, Flanders L, Isik B, Mamlouk O, Lin JS, Garcia P, Kaghazchi A, Khanin Y, Kansal SK, Wauters E, Chandra S, Schmidt-Ott KM, Hsu RK, Tio MC, Sarvode Mothi S, Singh H, Schrag D, Jhaveri KD, Reynolds KL, Cortazar FB, Leaf DE; ICPi-AKI Consortium Investigators. ICPi-AKI Consortium Investigators; Campedel L, Salem JE, Bagnis CI, Gupta S, Leaf DE, Singh H, Motwani SS, Murakami N, Tio MC, Rahma OE, Mothi SS, Selamet U, Schrag D, Loew S, Schmidt KM, Chang W, Jhaveri KD, Wanchoo R, Khanin Y, Hirsch JS, Sakhiya V, Stalbow D, Wu S, Ortiz DI, Ostermann M, Lumlertgul N, Seylanova N, Flanders L, Cennamo A, Papa S, Rigg A, Shaunak N, Kibbelaar ZA, Benesova K, Deshpande P, Sise ME, Reynolds KL, Seethapathy HS, Lee M, Strohbhen IA, Herrmann SM, Isik B, Glezerman IG, Cortazar FB, Aggarwal V, Chandra S, Prosek JM, Madhavan SM, Owen DH, Husain M, Beckerman P, Mini S, Anand S, Garcia P, Kaghazchi A, Rangarajan S, Shin DS, Cherry G, Carlos CA, Hsu RK, Kisel A, Rashidi A, Kansal SK, Albert N, Carter K, Donley V, Young T, Cigoi H, Seigneux S, Koessler T, Ben EW, Shah CV, Eijgelsheim M, Mithani Z, Pagan JA, Coppock G, Hogan JJ, Abudayyeh A, Mamlouk O, Lin JS, Page V, Kitchlu A, Short SA, Renaghan AD, Gaughan EM, Bilal A, Soler MJ, García C, Bermejo S, Felip E, Muñoz E, Carreras MJ. J Immunother Cancer. 2021 Oct;9(10):e003467. IF: 13.751.

Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM). Gonzalez-Cao M, Puertolas T, Riveiro M, Muñoz-Couselo E, Ortiz C, Paredes R, Podzamczer D, Manzano JL, Molto J, Revollo B, Carrera C, Mateu L, Fancelli S, Espinosa E, Clotet B, Martinez-Picado J, Cerezuela P, Soria A, Marquez I, Mandala M, Berrocal A; Spanish Melanoma Group (GEM). J Immunother Cancer. 2021 Mar;9(3):e001664. IF: 13.751.

Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial. Sierra-Rodero B, Cruz-Bermúdez A, Nadal E, Garitaonaindía Y, Insa A, Mosquera J, Casal-Rubio J, Dómine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, De Castro Carpeño J, Cobo M, López Vivanco G, Del Barco E, Bernabé Caro R, Viñolas N, Barneto Aranda I, Viteri S, Massuti B, Laza-Briviesca R, Casarrubios M, García-Grande A, Romero A, Franco F, Provencio M. J Immunother Cancer. 2021 Aug;9(8):e002804. IF: 13.751.

First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas. Piha-Paul SA, Geva R, Tan TJ, Lim DW, Hierro C, Doi T, Rahma O, Lesokhin A, Luke JJ, Otero J, Nardi L, Singh A, Xyrafas A, Chen X, Mataraza J, Bedard PL. J Immunother Cancer. 2021 Aug;9(8):e002863. IF: 13.751.

Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. Pietrantonio F, Lonardi S, Corti F, Infante G, Elez ME, Fakih M, Jayachandran P, Shah AT, Salati M, Fenocchio E, Salvatore L, Curigliano G, Cremolini C, Ambrosini M, Ros J, Intini R, Nappo F, Damian S, Morano F, Fucà G, Overman M, Miceli R. J Immunother Cancer. 2021 Aug;9(8):e003370. IF: 13.751.

Safety and activity of the TGFß receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer. Melisi D, Oh DY, Hollebecque A, Calvo E, Varghese A, Borazanci E, Macarulla T, Merz V, Zecchetto C, Zhao Y, Gueorguieva I, Man M, Gandhi L, Estrem ST, Benhadji KA, Lanasa MC, Avsar E, Guba SC, Garcia-Carbonero R. J Immunother Cancer. 2021 Mar;9(3):e002068. IF: 13.751.

Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score. Dettorre GM, Dolly S, Loizidou A, Chester J, Jackson A, Mukherjee U, Zambelli A, Aguilar-Company J, Bower M, Sng CCT, Salazar R, Bertuzzi A, Brunet J, Mesia R, Sita-Lumsden A, Seguí E, Biello F, Generali D, Grisanti S, Seeva P, Rizzo G, Libertini M, Maconi A, Moss C, Russell B, Harbeck N, Vincenzi B, Bertulli R, Ottaviani D, Liñan R, Marrari A, Carmona-García MC, Chopra N, Tondini CA, Mirallas O, Tovazzi V, Fotia V, Cruz CA, Saoudi-Gonzalez N, Felip E, Roqué A, Lee AJX, Newsom-Davis T, García-Illescas D, Reyes R, Wong YNS, Ferrante D, Scotti L, Marco-Hernández J, Ruiz-Camps I, Patriarca A, Rimassa L, Chiudinelli L, Franchi M, Santoro A, Prat A, Gennari A, Van Hemelrijck M, Tabernero J, Diamantis N, Pinato DJ; OnCovid study group. J Immunother Cancer. 2021 Mar;9(3):e002277. IF: 13.751.

Association of Obesity with Breast Cancer Outcome in Relation to Cancer Subtypes: A Meta-Analysis. Lohmann AE, Soldera SV, Pimentel I, Ribnikar D, Ennis M, Amir E, Goodwin PJ. J Natl Cancer Inst. 2021 Nov 2;113(11):1465-1475. IF: 13.506.

EGFR Amplification in Metastatic Colorectal Cancer. Randon G, Yaeger R, Hechtman JF, Manca P, Fucà G, Walch H, Lee J, Élez E, Seligmann J, Mussolin B, Pagani F, Germani MM, Ambrosini M, Rossini D, Ratti M, Salvà F, Richman SD, Wood H, Nanjangud G, Gloghini A, Milione M, Bardelli A, de Braud F, Morano F, Cremolini C, Pietrantonio F. J Natl Cancer Inst. 2021 Nov 2;113(11):1561-1569. IF: 13.506.

The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32. Pimentel I, Chen BE, Lohmann AE, Ennis M, Ligibel J, Shepherd L, Hershman DL, Whelan T, Stambolic V, Mayer I, Hobday T, Lemieux J, Thompson A, Rastogi P, Gelmon K, Rea D, Rabaglio M, Ellard S, Mates M, Bedard P, Pitre L, Vandenberg T, Dowling RJO, Parulekar W, Goodwin PJ. J Natl Cancer Inst. 2021 Feb 1;113(2):192-198. IF: 13.506.

The Global Landscape of Treatment Standards for Breast Cancer. Trapani D, Douillard JY, Winer EP, Burstein H, Carey LA, Cortes J, Lopes G, Gralow JR, Gradishar WJ, Magrini N, Curigliano G, Ilbawi AM. The Global Landscape of Treatment Standards for Breast Cancer. J Natl Cancer Inst. 2021 Sep 4;113(9):1143-1155. IF: 13.506.

The Transcription Factor SLUG Uncouples Pancreatic Cancer Progression from the RAF-MEK1/2-ERK1/2 Pathway. Bilal F, Arenas EJ, Pedersen K, Martínez-Sabadell A, Nabet B, Guruceaga E, Vicent S, Tabernero J, Macarulla T, Arribas J. Cancer Res. 2021 Jul 15;81(14):3849-3861. IF: 12.701.

Widespread Repression of Gene Expression in Cancer by a Wnt/ß-Catenin/MAPK Pathway. Harmston N, Lim JYS, Arqués O, Palmer HG, Petretto E, Virshup DM, Madan B. Cancer Res. 2021 Jan 15;81(2):464-475. IF: 12.701.

Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer. Vathiotis IA, Moutafi MK, Divakar P, Aung TN, Qing T, Fernandez A, Yaghoobi V, El-Abed S, Wang Y, Guillaume S, Nuciforo P, Huober J, Di Cosimo S, Kim SB, Harbeck N, Gomez H, Shafi S, Syrigos KN, Fountzilas G, Sotiriou C, Pusztai L, Warren S, Rimm DL. Clin Cancer Res. 2021 Nov 15;27(22):6156-6163. IF: 12.531.

Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non-Hodgkin Lymphoma. Ribeiro ML, Reyes-Garau D, Vinyoles M, Profitós Pelejà N, Santos JC, Armengol M, Fernández-Serrano M, Sedó Mor A, Bech-Serra JJ, Blecua P, Musulen E, De La Torre C, Miskin H, Esteller M, Bosch F, Menéndez P, Normant E, Roué G. Clin Cancer Res. 2021 Dec 1;27(23):6591-6601. IF: 12.531.

Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer. Saura C, Matito J, Oliveira M, Wildiers H, Brufksy AM, Waters SH, Hurvitz SA, Moy B, Kim SB, Gradishar WJ, Queiroz GS, Cronemberger E, Wallweber GJ, Bebchuk J, Keyvanjah K, Lalani AS, Bryce R, Vivancos A, Eli LD, Delaloge S. Clin Cancer Res. 2021 Nov 1;27(21):5818-5827. IF: 12.531.

Characterizing CDK12-Mutated Prostate Cancers. Rescigno P, Gurel B, Pereira R, Crespo M, Rekowski J, Rediti M, Barrero M, Mateo J, Bianchini D, Messina C, Fenor de la Maza MD, Chandran K, Carmichael J, Guo C, Paschalis A, Sharp A, Seed G, Figueiredo I, Lambros M, Miranda S, Ferreira A, Bertan C, Riisnaes R, Porta N, Yuan W, Carreira S, de Bono JS. Clin Cancer Res. 2021 Jan 15;27(2):566-574. IF: 12.531.

Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study. Bauer S, Heinrich MC, George S, Zalcberg JR, Serrano C, Gelderblom H, Jones RL, Attia S, D’Amato G, Chi P, Reichardt P, Meade J, Su Y, Ruiz-Soto R, Blay JY, von Mehren M, Schöffski P. Clin Cancer Res. 2021 Dec 1;27(23):6333-6342. IF: 12.531.

Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD1402 Trial. Vidal J, Casadevall D, Bellosillo B, Pericay C, Garcia-Carbonero R, Losa F, Layos L, Alonso V, Capdevila J, Gallego J, Vera R, Salud A, Martin-Richard M, Nogué M, Cillán E, Maurel J, Faull I, Raymond V, Fernández-Martos C, Montagut C. Clin Cancer Res. 2021 May 15;27(10):2890-2898. IF: 12.531.

Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for RAS Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study. Kagawa Y, Elez E, García-Foncillas J, Bando H, Taniguchi H, Vivancos A, Akagi K, García A, Denda T, Ros J, Nishina T, Baraibar I, Komatsu Y, Ciardiello D, Oki E, Kudo T, Kato T, Yamanaka T, Tabernero J, Yoshino T. Clin Cancer Res. 2021 May 1;27(9):2515-2522. IF: 12.531.

Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial. Venet D, Rediti M, Maetens M, Fumagalli D, Brown DN, Majjaj S, Salgado R, Pusztai L, Harbeck N, El-Abed S, Wang Y, Saura C, Gomez H, Semiglazov VF, de Azambuja E, Huober J, Nuciforo P, Di Cosimo S, Piccart M, Loi S, Rothé F, Sotiriou C. Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial. Clin Cancer Res. 2021 Oct 15;27(20):5607-5618. IF: 12.531.

Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10. Wainberg ZA, Fuchs CS, Tabernero J, Shitara K, Muro K, Van Cutsem E, Bang YJ, Chung HC, Yamaguchi K, Varga E, Chen JS, Hochhauser D, Thuss-Patience P, Al-Batran SE, Garrido M, Kher U, Shih CS, Shah S, Bhagia P, Chao J. Clin Cancer Res. 2021 Apr 1;27(7):1923-1931. IF: 12.531.

In Memoriam: José Baselga’s Journey in Cancer Medicine. Kumar R, Hortobagy GN, Albanell J, Arribas J, Norton L. Clin Cancer Res. 2021 Jun 15;27(12):3499-3502. IF: 12.531.

Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy. Pascual T, Fernandez-Martinez A, Tanioka M, Dieci MV, Pernas S, Gavila J, Guarnieri V, Cortes J, Villagrasa P, Chic N, Vidal M, Adamo B, Muñoz M, Griguolo G, Llombart A, Conte P, Oliveira M, Conte B, Paré L, Galvan P, Carey LA, Perou CM, Prat A. Clin Cancer Res. 2021 Jun 1;27(11):3116-3125. IF: 12.531.

Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis. Pizzamiglio S, Ciniselli CM, Triulzi T, Gargiuli C, De Cecco L, de Azambuja E, Fumagalli D, Sotiriou C, Harbeck N, Izquierdo M, Nuciforo P, Huober J, Cappelletti V, Cinieri S, Piccart M, Daidone MG, Pruneri G, Colombo MP, Tagliabue E, Verderio P, Di Cosimo S. Clin Cancer Res. 2021 Dec 1;27(23):6307-6313. IF: 12.531.

Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma. Kiyokawa J, Kawamura Y, Ghouse SM, Acar S, Barçın E, Martínez-Quintanilla J, Martuza RL, Alemany R, Rabkin SD, Shah K, Wakimoto H. Clin Cancer Res. 2021 Feb 1;27(3):889-902. IF: 12.531.

Molecular Subtyping Combined with Biological Pathway Analyses to Study Regorafenib Response in Clinically Relevant Mouse Models of Colorectal Cancer. Lafferty A, O’Farrell AC, Migliardi G, Khemka N, Lindner AU, Sassi F, Zanella ER, Salvucci M, Vanderheyden E, Modave E, Boeckx B, Halang L, Betge J, Ebert MPA, Dicker P, Argilés G, Tabernero J, Dienstmann R, Medico E, Lambrechts D, Bertotti A, Isella C, Trusolino L, Prehn JHM, Byrne AT. Clin Cancer Res. 2021 Nov 1;27(21):5979-5992. IF: 12.531.

Motixafortide and pembrolizumab combined to nanoliposomal irinotecan, fluorouracil, and folinic acid in metastatic pancreatic cancer: The COMBAT/ KEYNOTE-202 trial. Bockorny B, Macarulla T, Semenisty V, Borazanci E, Feliu J, Ponz-Sarvise M, Abad DG, Oberstein P, Alistar A, Muñoz A, Geva R, Guillén-Ponce C, Fernandez MS, Peled A, Chaney M, Gliko-Kabir I, Shemesh-Darvish L, Ickowicz D, Sorani E, Kadosh S, Vainstein-Haras A, Hidalgo M. Clin Cancer Res. 2021 Sep 15;27(18):5020-5027. IF: 12.531.

Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study. Turner NC, Balmaña J, Poncet C, Goulioti T, Tryfonidis K, Honkoop AH, Zoppoli G, Razis E, Johannsson OT, Colleoni M, Tutt AN, Audeh W, Ignatiadis M, Mailliez A, Trédan O, Musolino A, Vuylsteke P, Juan-Fita MJ, Macpherson IRJ, Kaufman B, Manso L, Goldstein LJ, Ellard SL, Láng I, Jen KY, Adam V, Litière S, Erban J, Cameron DA; BRAVO Steering Committee and the BRAVO investigators. Clin Cancer Res. 2021 Oct 15;27(20):5482-5491. IF: 12.531.

OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors. Gutierrez M, Moreno V, Heinhuis KM, Olszanski AJ, Spreafico A, Ong M, Chu Q, Carvajal RD, Trigo J, Ochoa de Olza M, Provencio M, De Vos FY, De Braud F, Leong S, Lathers D, Wang R, Ravindran P, Feng Y, Aanur P, Melero I. Clin Cancer Res. 2021 Jan 15;27(2):460-472. IF: 12.531.

Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers. Jhaveri K, Chang MT, Juric D, Saura C, Gambardella V, Melnyk A, Patel MR, Ribrag V, Ma CX, Aljumaily R, Bedard PL, Sachdev JC, Dunn L, Won H, Bond J, Jones S, Savage HM, Scaltriti M, Wilson TR, Wei MC, Hyman DM. Clin Cancer Res. 2021 Jan 15;27(2):447-459. IF: 12.531.

Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma. Hollebecque A, Salvagni S, Plummer R, Isambert N, Niccoli P, Capdevila J, Curigliano G, Moreno V, Martin-Romano P, Baudin E, Arias M, Mora S, de Alvaro J, Di Martino J, Parra-Palau JL, Sánchez-Pérez T, Aronchik I, Filvaroff EH, Lamba M, Nikolova Z, de Bono JS. Clin Cancer Res. 2021 Jan 15;27(2):438-446. IF: 12.531.

Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer. Guardia C, Bianchini G, Arpí-LLucià O, Menendez S, Casadevall D, Galbardi B, Dugo M, Servitja S, Montero JC, Soria-Jiménez L, Sabbaghi M, Peña R, Madoz-Gúrpide J, Lloveras B, Lluch A, Eroles P, Arribas J, Pandiella A, Gianni L, Rojo F, Rovira A, Albanell J. Clin Cancer Res. 2021 Sep 15;27(18):5096-5108. IF: 12.531.

Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy. Casarrubios M, Cruz-Bermúdez A, Nadal E, Insa A, García Campelo MDR, Lázaro M, Dómine M, Majem M, Rodríguez-Abreu D, Martínez-Martí A, de Castro-Carpeño J, Cobo M, López-Vivanco G, Del Barco E, Bernabé Caro R, Viñolas N, Barneto Aranda I, Viteri S, Massuti B, Barquín M, Laza-Briviesca R, Sierra-Rodero B, Parra ER, Sanchez-Espiridion B, Rocha P, Kadara H, Wistuba II, Romero A, Calvo V, Provencio M. Clin Cancer Res. 2021 Nov 1;27(21):5878-5890. IF: 12.531.

Unmasking New Promises: Expanding the Antigen Landscape For Antibody-Drug Conjugates. Oberoi HK, Garralda E. Clin Cancer Res. 2021 Aug 15;27(16):4459-4461. IF: 12.531.

WORLD CANCER RESEARCH DAY: A Call to Action for a Coordinated International Research Effort to Prevent, Diagnose, and Treat Cancer. Puyol M, Seoane J, Aguilar E, Vozza LB, Orbe I, Crawford KH, Fernández A, Bray F, Johnson SE, Gopal S. Clin Cancer Res. 2021 Feb 15;27(4):963-966. IF: 12.531.

Neuron type-specific increase in lamin B1 contributes to nuclear dysfunction in Huntington’s disease. Alcalá-Vida R, Garcia-Forn M, Castany-Pladevall C, Creus-Muncunill J, Ito Y, Blanco E, Golbano A, Crespí-Vázquez K, Parry A, Slater G, Samarajiwa S, Peiró S, Di Croce L, Narita M, Pérez-Navarro E. EMBO Mol Med. 2021 Feb 5;13(2):e12105. IF: 12.137.

Checkpoint inhibitors in metastatic papillary renal cell carcinoma. de Vries-Brilland M, McDermott DF, Suárez C, Powles T, Gross-Goupil M, Ravaud A, Flippot R, Escudier B, Albigès L. Cancer Treat Rev. 2021 Sep;99:102228. IF: 12.111.

PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations. Vanacker H, Harter P, Labidi-Galy SI, Banerjee S, Oaknin A, Lorusso D, Ray-Coquard I. Cancer Treat Rev. 2021 Sep;99:102255. IF: 12.111.

Integrated requirement of non-specific and sequence-specific DNA binding in Myc-driven transcription. Pellanda P, Dalsass M, Filipuzzi M, Loffreda A, Verrecchia A, Castillo Cano V, Thabussot H, Doni M, Morelli MJ, Soucek L, Kress T, Mazza D, Mapelli M, Beaulieu ME, Amati B, Sabò A. EMBO J. 2021 May 17;40(10):e105464. IF: 11.598.

COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. Ljungman P, de la Camara R, Mikulska M, Tridello G, Aguado B, Zahrani MA, Apperley J, Berceanu A, Bofarull RM, Calbacho M, Ciceri F, Lopez-Corral L, Crippa C, Fox ML, Grassi A, Jimenez MJ, Demir SK, Kwon M, Llamas CV, Lorenzo JLL, Mielke S, Orchard K, Porras RP, Vallisa D, Xhaard A, Knelange NS, Cedillo A, Kröger N, Piñana JL, Styczynski J. Leukemia. 2021 Oct;35(10):2885-2894. IF: 11.528.

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Barbui T, Vannucchi AM, Alvarez-Larran A, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Ferrari A, Rossi G, Elli E, Andrade-Campos MM, Kabat MG, Kiladjian JJ, Palandri F, Benevolo G, Garcia-Gutierrez V, Fox ML, Foncillas MA, Morcillo CM, Rumi E, Osorio S, Papadopoulos P, Bonifacio M, Cervantes KSQ, Serrano MS, Carreno-Tarragona G, Sobas MA, Lunghi F, Patriarca A, Elorza BN, Angona A, Mazo EM, Koschmieder S, Ruggeri M, Cuevas B, Hernandez-Boluda JC, Abadia EL, Cirici BX, Guglielmelli P, Garrote M, Cattaneo D, Daffini R, Cavalca F, Bellosillo B, Benajiba L, Curto-Garcia N, Bellini M, Betti S, De Stefano V, Harrison C, Rambaldi A. Leukemia. 2021 Feb;35(2):485-493. IF: 11.528.

Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis. Cuenca I, Alameda D, Sanchez-Vega B, Gomez-Sanchez D, Alignani D, Lasa M, Onecha E, Lecumberri R, Prosper F, Ocio EM, González ME, García de Coca A, De La Rubia J, Gironella M, Palomera L, Oriol A, Casanova M, Cabañas V, Taboada F, Pérez-Montaña A, De Arriba F, Puig N, Carreño-Tarragona G, Barrio S, Enrique de la Puerta J, Ramirez-Payer A, Krsnik I, Bargay JJ, Lahuerta JJ, Mateos MV, San-Miguel JF, Paiva B, Martinez-Lopez J. Leukemia. 2021 Jan;35(1):245-249. IF: 11.528.

Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study. Visco C, Di Rocco A, Evangelista A, Quaglia FM, Tisi MC, Morello L, Zilioli VR, Rusconi C, Hohaus S, Sciarra R, Re A, Tecchio C, Chiappella A, Marin-Niebla A, McCulloch R, Gini G, Perrone T, Nassi L, Pennese E, Stefani PM, Cox MC, Bozzoli V, Fabbri A, Polli V, Ferrero S, Celis MIA, Sica A, Petrucci L, Arcaini L, Rule S, Krampera M, Vitolo U, Balzarotti M. Leukemia. 2021 Mar;35(3):787-795. IF: 11.528.

Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group. Spanjaart AM, Ljungman P, de La Camara R, Tridello G, Ortiz-Maldonado V, Urbano-Ispizua A, Barba P, Kwon M, Caballero D, Sesques P, Bachy E, Di Blasi R, Thieblemont C, Calkoen F, Mutsaers P, Maertens J, Giannoni L, Nicholson E, Collin M, Vaz CP, Metafuni E, Martinez-Lopez J, Dignan FL, Ribera JM, Nagler A, Folber F, Sanderson R, Bloor A, Ciceri F, Knelange N, Ayuk F, Kroger N, Kersten MJ, Mielke S. Leukemia. 2021 Dec;35(12):3585-3588. IF: 11.528.

Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. Wieduwilt MJ, Stock W, Advani A, Luger S, Larson RA, Tallman M, Appelbaum F, Zhang MJ, Bo-Subait K, Wang HL, Bhatt VR, Dholaria B, Eapen M, Hamadani M, Jamy O, Prestidge T, Pulsipher M, Ritchie D, Rizzieri D, Sharma A, Barba P, Sandmaier BM, de Lima M, Kebriaei P, Litzow M, Saber W, Weisdorf D. Leukemia. 2021 Jul;35(7):2076-2085. IF: 11.528.

COVID-19 in melanoma patients: Results of the Spanish Melanoma Group Registry, GRAVID study. Gonzalez-Cao M, Carrera C, Rodriguez Moreno JF, Rodríguez-Jiménez P, Basa MA, Ochoa RF, Puertolas T, Muñoz-Couselo E, Manzano JL, Marquez-Rodas I, Martín-Liberal J, Soria A, Criado PL, Garcia-Castaño A, Boada A, Ayala de Miguel P, Puig S, Crespo G, Fra PL, Zamora CA, Rodríguez MF, Valles L, Drozdowskyj A, Maldonado-Seral C, Gardeazabal J, Villalobos L, Rosell R, Fernandez-Morales LA, Rodrigo A, Viteri S, Provencio M, Berrocal A; Spanish Melanoma Group (GEM). J Am Acad Dermatol. 2021 May;84(5):1412-1415. IF: 11.527.

Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial. Laza-Briviesca R, Cruz-Bermúdez A, Nadal E, Insa A, García-Campelo MDR, Huidobro G, Dómine M, Majem M, Rodríguez-Abreu D, Martínez-Martí A, De Castro Carpeño J, Cobo M, López Vivanco G, Del Barco E, Bernabé Caro R, Viñolas N, Barneto Aranda I, Viteri S, Massuti B, Casarrubios M, Sierra-Rodero B, Tarín C, García-Grande A, Haymaker C, Wistuba II, Romero A, Franco F, Provencio M. Clin Transl Med. 2021 Jul;11(7):e491. IF: 11.492.

A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. Ligero M, Garcia-Ruiz A, Viaplana C, Villacampa G, Raciti MV, Landa J, Matos I, Martin-Liberal J, Ochoa-de-Olza M, Hierro C, Mateo J, Gonzalez M, Morales-Barrera R, Suarez C, Rodon J, Elez E, Braña I, Muñoz-Couselo E, Oaknin A, Fasani R, Nuciforo P, Gil D, Rubio-Perez C, Seoane J, Felip E, Escobar M, Tabernero J, Carles J, Dienstmann R, Garralda E, Perez-Lopez R. Radiology. 2021 Apr;299(1):109-119. IF: 11.105.

Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19. Barbui T, De Stefano V, Alvarez-Larran A, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Ferrari A, Cancelli V, Elli EM, Andrade-Campos MM, Kabat MG, Kiladjian JJ, Palandri F, Benevolo G, Garcia-Gutierrez V, Fox ML, Foncillas MA, Morcillo CM, Rumi E, Osorio S, Papadopoulos P, Bonifacio M, Cervantes KSQ, Serrano MS, Carreno-Tarragona G, Sobas MA, Lunghi F, Patriarca A, Elorza BN, Angona A, Mazo EM, Koschmieder S, Carli G, Cuevas B, Hernandez-Boluda JC, Abadia EL, Cirici BX, Guglielmelli P, Garrote M, Cattaneo D, Daffini R, Cavalca F, Bellosillo B, Benajiba L, Curto-Garcia N, Bellini M, Betti S, Harrison C, Rambaldi A, Vannucchi AM. Blood Cancer J. 2021 Feb 4;11(2):21. IF: 11.037.

Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial. Puig N, Hernández MT, Rosiñol L, González E, de Arriba F, Oriol A, González-Calle V, Escalante F, de la Rubia J, Gironella M, Ríos R, García-Sánchez R, Arguiñano JM, Alegre A, Martín J, Gutiérrez NC, Calasanz MJ, Martín ML, Couto MDC, Casanova M, Arnao M, Pérez-Persona E, Garzón S, González MS, Martín-Sánchez G, Ocio EM, Coleman M, Encinas C, Vale AM, Teruel AI, Cortés-Rodríguez M, Paiva B, Cedena MT, San-Miguel JF, Lahuerta JJ, Bladé J, Niesvizky R, Mateos MV. Blood Cancer J. 2021 May 21;11(5):101. IF: 11.037.

Long-term follow-up of recovered MPN patients with COVID-19. Barbui T, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Rossi G, Harrison C, Alvarez-Larran A, Elli EM, Kiladjian JJ, Gasior Kabat M, Marin Sanchez A, Palandri F, Andrade-Campos MM, Vannucchi AM, Carreno-Tarragona G, Papadopoulos P, Quiroz Cervantes K, Angeles Foncillas M, Fox ML, Sagues Serrano M, Rumi E, Osorio S, Benevolo G, Patriarca A, Navas Elorza B, Garcia-Gutierrez V, Magro Mazo E, Lunghi F, Bonifacio M, De Stefano V, Hernandez-Boluda JC, Lopez Abadia E, Angona A, Xicoy Cirici B, Ruggeri M, Koschmieder S, Sobas MA, Cuevas B, Cattaneo D, Daffini R, Bellini M, Curto-Garcia N, Garrote M, Cavalca F, Benajiba L, Bellosillo B, Guglielmelli P, Borsani O, Betti S, Salmoiraghi S, Rambaldi A. Blood Cancer J. 2021 Jun 16;11(6):115. IF: 11.037.

Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse. Bobillo S, Joffe E, Sermer D, Mondello P, Ghione P, Caron PC, Hamilton A, Hamlin PA, Horwitz SM, Kumar A, Matasar MJ, Batlevi CL, Moskowitz A, Noy A, Owens CN, Palomba ML, Straus D, von Keudell G, Dogan A, Zelenetz AD, Seshan VE, Younes A. Blood Cancer J. 2021 Jun 16;11(6):113. IF: 11.037.

Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora’s box. Tarantino P, Prat A, Cortes J, Cardoso F, Curigliano G. Biochim Biophys Acta Rev Cancer. 2021 Jan;1875(1):188487. IF: 10.680.

The long journey to bring a Myc inhibitor to the clinic. Whitfield JR, Soucek L. J Cell Biol. 2021 Aug 2;220(8):e202103090. IF: 10.539.

Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes. Garcia-Manero G, Diez-Campelo M, Vellenga E, Jacoby MA, Merchan B, Breems D, Cortelezzi A, Doronin V, Gomez V, Beckers M, Della Porta MG, Varsos H, Xiu L, DeAngelis N, Nnane I, Rose E, van Eygen K. Am J Hematol. 2021 Apr 1;96(4):E111-E114. IF: 10.047.

Natural gene therapy by reverse mosaicism leads to improved hematology in Fanconi anemia patients. Ramírez MJ, Pujol R, Trujillo-Quintero JP, Minguillón J, Bogliolo M, Río P, Navarro S, Casado JA, Badell I, Carrasco E, Balmaña J, Català A, Sevilla J, Beléndez C, Argilés B, López M, Díaz de Heredia C, Rao G, Nicoletti E, Schwartz JD, Bueren JA, Surrallés J. Natural gene therapy by reverse mosaicism leads to improved hematology in Fanconi anemia patients. Am J Hematol. 2021 Aug 1;96(8):989-999. IF: 10.047.

Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas. Bobillo S, Crespo M, Escudero L, Mayor R, Raheja P, Carpio C, Rubio-Perez C, Tazón-Vega B, Palacio C, Carabia J, Jiménez I, Nieto JC, Montoro J, Martínez-Ricarte F, Castellvi J, Simó M, Puigdefàbregas L, Abrisqueta P, Bosch F, Seoane J. Haematologica. 2021 Feb 1;106(2):513-521. IF: 9.941.

Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. Lazaryan A, Dolan M, Zhang MJ, Wang HL, Kharfan-Dabaja MA, Marks DI, Bejanyan N, Copelan E, Majhail NS, Waller EK, Chao N, Prestidge T, Nishihori T, Kebriaei P, Inamoto Y, Hamilton B, Hashmi SK, Kamble RT, Bacher U, Hildebrandt GC, Stiff PJ, McGuirk J, Aldoss I, Beitinjaneh AM, Muffly L, Vij R, Olsson RF, Byrne M, Schultz KR, Aljurf M, Seftel M, Savoie ML, Savani BN, Verdonck LF, Cairo MS, Hossain N, Bhatt VR, Frangoul HA, Abdel-Azim H, Al Malki M, Munker R, Rizzieri D, Khera N, Nakamura R, Ringdén O, Van der Poel M, Murthy HS, Liu H, Mori S, De Oliveira S, Bolaños-Meade J, Elsawy M, Barba P, et al. Haematologica. 2021 Aug 1;106(8):2295-2296. IF: 9.941.

Interleukin-1 receptor associated kinase 1/4 and bromodomain and extra-terminal inhibitions converge on NF-kB blockade and display synergistic antitumoral activity in activated B-cell subset of diffuse large B-cell lymphoma with MYD88 L265P mutation. Dlouhy I, Armengol M, Recasens-Zorzo C, Ribeiro ML, Pérez-Galán P, Bosch F, López-Guillermo A, Roué G. Haematologica. 2021 Oct 1;106(10):2749-2753. IF: 9.941.

Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Duell J, Maddocks KJ, González-Barca E, Jurczak W, Liberati AM, De Vos S, Nagy Z, Obr A, Gaidano G, Abrisqueta P, Kalakonda N, André M, Dreyling M, Menne T, Tournilhac O, Augustin M, Rosenwald A, Dirnberger-Hertweck M, Weirather J, Ambarkhane S, Salles G. Haematologica. 2021 Sep 1;106(9):2417-2426. IF: 9.941.

A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors. Di Giulio S, Colicchia V, Pastorino F, Pedretti F, Fabretti F, Nicolis di Robilant V, Ramponi V, Scafetta G, Moretti M, Licursi V, Belardinilli F, Peruzzi G, Infante P, Goffredo BM, Coppa A, Canettieri G, Bartolazzi A, Ponzoni M, Giannini G, Petroni M. Oncogene. 2021 Oct;40(43):6143-6152. IF: 9.867.

E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumor. García-Valverde A, Rosell J, Sayols S, Gómez-Peregrina D, Pilco-Janeta DF, Olivares-Rivas I, de Álava E, Maurel J, Rubió-Casadevall J, Esteve A, Gut M, Valverde C, Barretina J, Carles J, Demetri GD, Fletcher JA, Arribas J, Serrano C. Oncogene. 2021 Dec;40(48):6614-6626. IF: 9.867.